drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.69k
| drug2_id
int64 0
1.69k
| drug_pair
listlengths 2
2
| drug1_name
stringlengths 4
85
| drug2_name
stringlengths 4
85
| drug1_desc
stringlengths 27
1.09k
| drug2_desc
stringlengths 27
6.14k
| label
stringclasses 3
values | label_idx
int64 0
2
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
3.57k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB00342 | DB12130 | 1,181 | 1,017 | [
"DDInter1770",
"DDInter1094"
] | Terfenadine | Lorlatinib | In the U.S., Terfenadine was superseded by fexofenadine in the 1990s due to the risk of cardiac arrhythmia caused by QT interval prolongation. | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
1181,
24,
1017
]
],
[
[
1181,
24,
1612
],
[
1612,
23,
1017
]
],
[
[
1181,
63,
1101
],
[
1101,
23,
1017
]
],
[
[
1181,
24,
786
],
[
786,
24,
1017
]
],
[
[
1181,
25,
11
],
[
11,
24,
1017
]
],
[
[
1181,
63,
21
],
[
21,
24,
1017
]
],
[
[
1181,
23,
1387
],
[
1387,
24,
1017
]
],
[
[
1181,
64,
529
],
[
529,
24,
1017
]
],
[
[
1181,
24,
971
],
[
971,
63,
1017
]
],
[
[
1181,
25,
877
],
[
877,
63,
1017
]
]
] | [
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
]
] | Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Lorlatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may cause a minor interaction that can limit clinical effects when taken with Terbinafine and Terbinafine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may lead to a major life threatening interaction when taken with Fluvoxamine and Fluvoxamine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Terfenadine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib |
DB00277 | DB09278 | 1,031 | 852 | [
"DDInter1791",
"DDInter24"
] | Theophylline | Activated charcoal | A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD. | Activated charcoal, or activated carbon, is an amorphous form of carbon prepared from incomplete combustion of carbonaceous organic matter. It is activated by an oxidizing gas flow at high temperature passed over its surface to make a fine network of pores, producing a material with large surface area and high affinity for various substances. It is used as a gastric decontaminant and emergency medication to treat poisonings following excessive oral ingestion of certain medications or poisons by absorbing most drugs and toxins. However its effects is rendered poor on some compounds including strong acids or bases, methanol and substances with limited absorptive capacity (including iron, lithium, arsenic). It works by binding to the poison in the gastric contents in a reversible fashion thus may be adminstered together with a cathartic to reduce the small intestine transit time. The clinical applications of activated charcoal occured in the early 1800's. While this management for acute poisoning is considered fairly invasive, it is on the World Health Organization's List of Essential Medicines that includes the most important medications needed in a basic health system. | Moderate | 1 | [
[
[
1031,
24,
852
]
],
[
[
1031,
24,
1023
],
[
1023,
24,
852
]
],
[
[
1031,
1,
746
],
[
746,
24,
852
]
],
[
[
1031,
63,
964
],
[
964,
24,
852
]
],
[
[
1031,
25,
17
],
[
17,
24,
852
]
],
[
[
1031,
23,
1096
],
[
1096,
25,
852
]
],
[
[
1031,
24,
1023
],
[
1023,
1,
697
],
[
697,
24,
852
]
],
[
[
1031,
1,
746
],
[
746,
64,
17
],
[
17,
24,
852
]
],
[
[
1031,
24,
697
],
[
697,
40,
1023
],
[
1023,
24,
852
]
],
[
[
1031,
24,
1127
],
[
1127,
24,
1411
],
[
1411,
24,
852
]
]
] | [
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
],
[
"Dyphylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} (Compound) resembles {v} (Compound)",
"Dyphylline"
],
[
"Dyphylline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
],
[
[
"Theophylline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Activated charcoal"
]
]
] | Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline (Compound) resembles Dyphylline (Compound) and Dyphylline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Doxycycline and Doxycycline may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline may cause a minor interaction that can limit clinical effects when taken with Mycophenolic acid and Mycophenolic acid may lead to a major life threatening interaction when taken with Activated charcoal
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Pentobarbital and Pentobarbital (Compound) resembles Phenobarbital (Compound) and Phenobarbital may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline (Compound) resembles Dyphylline (Compound) and Dyphylline may lead to a major life threatening interaction when taken with Sotalol and Sotalol may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Phenobarbital and Phenobarbital (Compound) resembles Pentobarbital (Compound) and Pentobarbital may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal
Theophylline may cause a moderate interaction that could exacerbate diseases when taken with Nizatidine and Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide and Tolbutamide may cause a moderate interaction that could exacerbate diseases when taken with Activated charcoal |
DB00544 | DB06674 | 970 | 908 | [
"DDInter757",
"DDInter837"
] | Fluorouracil | Golimumab | A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid. | Golimumab is a human IgG1қ monoclonal antibody derived from immunizing genetically engineered mice with human TNFα. Golimumab binds and inhibits soluble and transmembrane human TNFα. Increased TNFα is associated with chronic inflammation. Thus golimumab is indicated for use in adults (i) as an adjunct to methotrexate treatment in patients with moderate to severe active rheumatoid arthritis (RA), (ii) alone or as an adjunct to methotrexate treatment in patients with active psoriatic arthritis (PsA), (iii) as a single agent in patients with active ankylosing spondylitis (AS), and (iv) as a single agent in patients with moderate to severe ulcerative colitis (UC) who require chronic steroids or have experienced intolerance or only a partial response to previous medications. In the U.S. and Canada, golimumab is marketed under the brand name Simponi®. The FDA label includes a black box warning of serious infections and malignancy. Additionally in children and adolescents taking golimumab, there have been lymphoma and other malignancies observed. | Major | 2 | [
[
[
970,
25,
908
]
],
[
[
970,
63,
1461
],
[
1461,
23,
908
]
],
[
[
970,
24,
651
],
[
651,
24,
908
]
],
[
[
970,
63,
208
],
[
208,
24,
908
]
],
[
[
970,
24,
200
],
[
200,
63,
908
]
],
[
[
970,
25,
126
],
[
126,
24,
908
]
],
[
[
970,
63,
450
],
[
450,
25,
908
]
],
[
[
970,
25,
334
],
[
334,
64,
908
]
],
[
[
970,
24,
1238
],
[
1238,
25,
908
]
],
[
[
970,
24,
385
],
[
385,
64,
908
]
]
] | [
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vitamin E"
],
[
"Vitamin E",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mephenytoin"
],
[
"Mephenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentostatin"
],
[
"Pentostatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
],
[
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isatuximab"
],
[
"Isatuximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Golimumab"
]
]
] | Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Vitamin E and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Mephenytoin and Mephenytoin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Fluorouracil may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Cyclophosphamide and Cyclophosphamide may lead to a major life threatening interaction when taken with Golimumab
Fluorouracil may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Pentostatin and Pentostatin may lead to a major life threatening interaction when taken with Golimumab
Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Isatuximab and Isatuximab may lead to a major life threatening interaction when taken with Golimumab |
DB01181 | DB08918 | 1,532 | 41 | [
"DDInter906",
"DDInter1059"
] | Ifosfamide | Levomilnacipran | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Levomilnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI), although it is a more potent inhibitor of norepinephrine reuptake than serotonin reuptake.[A261181, A38560] Levomilnacipran is the more active 1S,2R-enantiomer in the racemate [milnacipran].[A261181, L47956] Once administered, interconversion between levomilnacipran and its stereoisomer does not occur in humans. First approved by the FDA on July 25, 2013, levomilnacipran is used to treat major depressive disorder in adults. While levomilnacipran was previously investigated and proposed as a potential treatment for stroke in Europe, the EMA decided against this use. | Moderate | 1 | [
[
[
1532,
24,
41
]
],
[
[
1532,
24,
901
],
[
901,
40,
41
]
],
[
[
1532,
63,
1349
],
[
1349,
40,
41
]
],
[
[
1532,
6,
10215
],
[
10215,
45,
41
]
],
[
[
1532,
21,
28643
],
[
28643,
60,
41
]
],
[
[
1532,
63,
1314
],
[
1314,
24,
41
]
],
[
[
1532,
24,
1311
],
[
1311,
24,
41
]
],
[
[
1532,
63,
1264
],
[
1264,
25,
41
]
],
[
[
1532,
25,
497
],
[
497,
25,
41
]
],
[
[
1532,
24,
901
],
[
901,
1,
1349
],
[
1349,
40,
41
]
]
] | [
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
]
],
[
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
],
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
]
]
] | Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Levomilnacipran (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Levomilnacipran (Compound)
Ifosfamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Levomilnacipran (Compound)
Ifosfamide (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Levomilnacipran (Compound)
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Levomilnacipran
Ifosfamide may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Levomilnacipran
Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran and Milnacipran (Compound) resembles Meperidine (Compound) and Meperidine (Compound) resembles Levomilnacipran (Compound) |
DB09143 | DB11652 | 313 | 1,155 | [
"DDInter1701",
"DDInter1891"
] | Sonidegib | Tucatinib | Sonidegib is a Hedgehog signaling pathway inhibitor (via smoothened antagonism) developed as an anticancer agent by Novartis. It was FDA approved in 2015 for the treatment of basal cell carcinoma. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Major | 2 | [
[
[
313,
25,
1155
]
],
[
[
313,
63,
1101
],
[
1101,
23,
1155
]
],
[
[
313,
64,
609
],
[
609,
24,
1155
]
],
[
[
313,
63,
522
],
[
522,
24,
1155
]
],
[
[
313,
24,
1320
],
[
1320,
63,
1155
]
],
[
[
313,
25,
351
],
[
351,
64,
1155
]
],
[
[
313,
63,
951
],
[
951,
25,
1155
]
],
[
[
313,
64,
129
],
[
129,
25,
1155
]
],
[
[
313,
24,
159
],
[
159,
64,
1155
]
],
[
[
313,
63,
1101
],
[
1101,
24,
1424
],
[
1424,
24,
1155
]
]
] | [
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Zafirlukast"
],
[
"Zafirlukast",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Sonidegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
]
] | Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Sonidegib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Zafirlukast and Zafirlukast may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Sonidegib may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Tucatinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Palbociclib and Palbociclib may lead to a major life threatening interaction when taken with Tucatinib
Sonidegib may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Tucatinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may lead to a major life threatening interaction when taken with Tucatinib
Sonidegib may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib |
DB00881 | DB01285 | 954 | 708 | [
"DDInter1554",
"DDInter445"
] | Quinapril | Corticotropin | Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers. Quinapril was granted FDA approval on 19 November 1991. A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999. | Corticotropin (ACTH or adrenocorticotropic hormone) is a polypeptide hormone produced and secreted by the pituitary gland. It is an important player in the hypothalamic-pituitary-adrenal axis. | Moderate | 1 | [
[
[
954,
24,
708
]
],
[
[
954,
63,
245
],
[
245,
24,
708
]
],
[
[
954,
24,
123
],
[
123,
24,
708
]
],
[
[
954,
24,
1662
],
[
1662,
63,
708
]
],
[
[
954,
23,
286
],
[
286,
63,
708
]
],
[
[
954,
40,
743
],
[
743,
24,
708
]
],
[
[
954,
1,
1523
],
[
1523,
24,
708
]
],
[
[
954,
24,
593
],
[
593,
25,
708
]
],
[
[
954,
25,
1377
],
[
1377,
25,
708
]
],
[
[
954,
25,
1510
],
[
1510,
64,
708
]
]
] | [
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Exenatide"
],
[
"Exenatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Lisinopril"
],
[
"Lisinopril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
],
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
],
[
[
"Quinapril",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Corticotropin"
]
]
] | Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Exenatide and Exenatide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril (Compound) resembles Lisinopril (Compound) and Lisinopril may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril (Compound) resembles Labetalol (Compound) and Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Corticotropin
Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Corticotropin
Quinapril may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Corticotropin
Quinapril may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Corticotropin |
DB00281 | DB00598 | 608 | 1,523 | [
"DDInter1066",
"DDInter1013"
] | Lidocaine | Labetalol | Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | Moderate | 1 | [
[
[
608,
24,
1523
]
],
[
[
608,
25,
1188
],
[
1188,
1,
1523
]
],
[
[
608,
23,
371
],
[
371,
1,
1523
]
],
[
[
608,
6,
12523
],
[
12523,
45,
1523
]
],
[
[
608,
21,
28719
],
[
28719,
60,
1523
]
],
[
[
608,
24,
752
],
[
752,
24,
1523
]
],
[
[
608,
25,
497
],
[
497,
63,
1523
]
],
[
[
608,
23,
913
],
[
913,
63,
1523
]
],
[
[
608,
24,
1154
],
[
1154,
63,
1523
]
],
[
[
608,
63,
966
],
[
966,
24,
1523
]
]
] | [
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arbutamine"
],
[
"Arbutamine",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Propafenone"
],
[
"Propafenone",
"{u} (Compound) resembles {v} (Compound)",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pasireotide"
],
[
"Pasireotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
],
[
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Octreotide"
],
[
"Octreotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Labetalol"
]
]
] | Lidocaine may lead to a major life threatening interaction when taken with Arbutamine and Arbutamine (Compound) resembles Labetalol (Compound)
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Propafenone and Propafenone (Compound) resembles Labetalol (Compound)
Lidocaine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Labetalol (Compound)
Lidocaine (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Labetalol (Compound)
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Lidocaine may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Lidocaine may cause a minor interaction that can limit clinical effects when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Pasireotide and Pasireotide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol
Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Octreotide and Octreotide may cause a moderate interaction that could exacerbate diseases when taken with Labetalol |
DB01001 | DB01591 | 688 | 667 | [
"DDInter1632",
"DDInter1696"
] | Salbutamol | Solifenacin | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Solifenacin is a competitive muscarinic receptor antagonist indicated to treat an overactive bladder with urinary incontinence, urgency, and frequency. It has a long duration of action as it is usually taken once daily. Solifenacin was granted FDA approval on 19 November 2004. | Moderate | 1 | [
[
[
688,
24,
667
]
],
[
[
688,
6,
8374
],
[
8374,
45,
667
]
],
[
[
688,
21,
28743
],
[
28743,
60,
667
]
],
[
[
688,
62,
112
],
[
112,
23,
667
]
],
[
[
688,
24,
774
],
[
774,
63,
667
]
],
[
[
688,
63,
1324
],
[
1324,
24,
667
]
],
[
[
688,
24,
392
],
[
392,
24,
667
]
],
[
[
688,
23,
1220
],
[
1220,
24,
667
]
],
[
[
688,
63,
11
],
[
11,
25,
667
]
],
[
[
688,
24,
982
],
[
982,
64,
667
]
]
] | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} (Compound) causes {v} (Side Effect)",
"Atrial fibrillation"
],
[
"Atrial fibrillation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troglitazone"
],
[
"Troglitazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Solifenacin"
]
]
] | Salbutamol (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Solifenacin (Compound)
Salbutamol (Compound) causes Atrial fibrillation (Side Effect) and Atrial fibrillation (Side Effect) is caused by Solifenacin (Compound)
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Solifenacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Troglitazone and Troglitazone may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Salbutamol may cause a minor interaction that can limit clinical effects when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Solifenacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Solifenacin
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Solifenacin |
DB01278 | DB08912 | 1,021 | 1,040 | [
"DDInter1506",
"DDInter462"
] | Pramlintide | Dabrafenib | Pramlintide is a relatively new adjunct treatment for diabetes (both type 1 and 2), developed by Amylin Pharmaceuticals. It is derived from amylin, a hormone that is released into the bloodstream, in a similar pattern as insulin, after a meal. Like insulin, amylin is deficient in individuals with diabetes. | Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene. | Moderate | 1 | [
[
[
1021,
24,
1040
]
],
[
[
1021,
63,
168
],
[
168,
23,
1040
]
],
[
[
1021,
63,
870
],
[
870,
24,
1040
]
],
[
[
1021,
24,
192
],
[
192,
63,
1040
]
],
[
[
1021,
24,
651
],
[
651,
24,
1040
]
],
[
[
1021,
63,
1197
],
[
1197,
25,
1040
]
],
[
[
1021,
24,
1019
],
[
1019,
64,
1040
]
],
[
[
1021,
24,
879
],
[
879,
25,
1040
]
],
[
[
1021,
63,
168
],
[
168,
6,
3486
],
[
3486,
45,
1040
]
],
[
[
1021,
63,
870
],
[
870,
21,
31004
],
[
31004,
60,
1040
]
]
] | [
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esterified estrogens"
],
[
"Esterified estrogens",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lumateperone"
],
[
"Lumateperone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Dabrafenib"
]
],
[
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis acneiform"
],
[
"Dermatitis acneiform",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dabrafenib"
]
]
] | Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Esterified estrogens and Esterified estrogens may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Fosphenytoin and Fosphenytoin may cause a moderate interaction that could exacerbate diseases when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone may lead to a major life threatening interaction when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort and Deflazacort may lead to a major life threatening interaction when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Lumateperone and Lumateperone may lead to a major life threatening interaction when taken with Dabrafenib
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Dabrafenib (Compound)
Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Fludrocortisone and Fludrocortisone (Compound) causes Dermatitis acneiform (Side Effect) and Dermatitis acneiform (Side Effect) is caused by Dabrafenib (Compound) |
DB00480 | DB11828 | 1,668 | 1,406 | [
"DDInter1035",
"DDInter1281"
] | Lenalidomide | Neratinib | Lenalidomide (previously referred to as CC-5013) is an immunomodulatory drug with potent antineoplastic, anti-angiogenic, and anti-inflammatory properties. It is a 4-amino-glutamyl analogue of [thalidomide] and like thalidomide, lenalidomide exists as a racemic mixture of the active S(-) and R(+) forms. However, lenalidomide is much safer and potent than thalidomide, with fewer adverse effects and toxicities.[A714, A228543] Thalidomide and its analogues, including lenalidomide, are referred to as immunomodulatory imide drugs (also known as cereblon modulators), which are a class of immunomodulatory drugs that contain an imide group. Lenalidomide works through various mechanisms of actions that promote malignant cell death and enhance host immunity | Neratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib is currently under investigation for use in many other forms of cancer. | Moderate | 1 | [
[
[
1668,
24,
1406
]
],
[
[
1668,
63,
1252
],
[
1252,
24,
1406
]
],
[
[
1668,
25,
1510
],
[
1510,
24,
1406
]
],
[
[
1668,
24,
850
],
[
850,
24,
1406
]
],
[
[
1668,
24,
1155
],
[
1155,
25,
1406
]
],
[
[
1668,
63,
597
],
[
597,
25,
1406
]
],
[
[
1668,
24,
913
],
[
913,
64,
1406
]
],
[
[
1668,
63,
1252
],
[
1252,
25,
392
],
[
392,
24,
1406
]
],
[
[
1668,
25,
1510
],
[
1510,
64,
392
],
[
392,
24,
1406
]
],
[
[
1668,
24,
850
],
[
850,
63,
392
],
[
392,
24,
1406
]
]
] | [
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
],
[
"Tucatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chloramphenicol"
],
[
"Chloramphenicol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
],
[
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neratinib"
]
]
] | Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lenalidomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib and Tucatinib may lead to a major life threatening interaction when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Chloramphenicol and Chloramphenicol may lead to a major life threatening interaction when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lenalidomide may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib
Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Neratinib |
DB00850 | DB01166 | 1,630 | 477 | [
"DDInter1432",
"DDInter379"
] | Perphenazine | Cilostazol | An antipsychotic phenothiazine derivative with actions and uses similar to those of chlorpromazine. | Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reducing calcium-induced contractions. | Moderate | 1 | [
[
[
1630,
24,
477
]
],
[
[
1630,
6,
8374
],
[
8374,
45,
477
]
],
[
[
1630,
18,
16896
],
[
16896,
57,
477
]
],
[
[
1630,
21,
28892
],
[
28892,
60,
477
]
],
[
[
1630,
23,
112
],
[
112,
23,
477
]
],
[
[
1630,
1,
216
],
[
216,
24,
477
]
],
[
[
1630,
35,
820
],
[
820,
63,
477
]
],
[
[
1630,
63,
888
],
[
888,
24,
477
]
],
[
[
1630,
24,
603
],
[
603,
63,
477
]
],
[
[
1630,
24,
1133
],
[
1133,
24,
477
]
]
] | [
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} (Compound) downregulates {v} (Gene)",
"IARS2"
],
[
"IARS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} (Compound) causes {v} (Side Effect)",
"Cardiac arrest"
],
[
"Cardiac arrest",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium citrate"
],
[
"Magnesium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
],
[
[
"Perphenazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
]
]
] | Perphenazine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cilostazol (Compound)
Perphenazine (Compound) downregulates IARS2 (Gene) and IARS2 (Gene) is downregulated by Cilostazol (Compound)
Perphenazine (Compound) causes Cardiac arrest (Side Effect) and Cardiac arrest (Side Effect) is caused by Cilostazol (Compound)
Perphenazine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Cilostazol
Perphenazine (Compound) resembles Chlorpromazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Perphenazine (Compound) resembles Alimemazine (Compound) and Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium citrate and Magnesium citrate may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol
Perphenazine may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol |
DB00011 | DB08901 | 1,451 | 1,468 | [
"DDInter944",
"DDInter1492"
] | Interferon alfa-n1 | Ponatinib | Interferon alfa-n1 consists of purified, natural (n is for natural) alpha interferon subtypes, at least two of which are glycosylated. This differs from recombinant alpha interferons, which are individual non-glycosylated proteins produced from individual alpha interferon genes. | Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012. | Moderate | 1 | [
[
[
1451,
24,
1468
]
],
[
[
1451,
24,
589
],
[
589,
24,
1468
]
],
[
[
1451,
24,
384
],
[
384,
63,
1468
]
],
[
[
1451,
63,
491
],
[
491,
24,
1468
]
],
[
[
1451,
25,
1477
],
[
1477,
24,
1468
]
],
[
[
1451,
24,
1554
],
[
1554,
25,
1468
]
],
[
[
1451,
25,
1064
],
[
1064,
25,
1468
]
],
[
[
1451,
25,
1259
],
[
1259,
64,
1468
]
],
[
[
1451,
24,
375
],
[
375,
64,
1468
]
],
[
[
1451,
63,
1057
],
[
1057,
25,
1468
]
]
] | [
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cisplatin"
],
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Peginterferon alfa-2a"
],
[
"Peginterferon alfa-2a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Colchicine"
],
[
"Colchicine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Certolizumab pegol"
],
[
"Certolizumab pegol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
],
[
[
"Interferon alfa-n1",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
]
]
] | Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Cisplatin and Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Peginterferon alfa-2a and Peginterferon alfa-2a may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Telbivudine and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Colchicine and Colchicine may lead to a major life threatening interaction when taken with Ponatinib
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Ponatinib
Interferon alfa-n1 may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Ponatinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Certolizumab pegol and Certolizumab pegol may lead to a major life threatening interaction when taken with Ponatinib
Interferon alfa-n1 may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Ponatinib |
DB00934 | DB01181 | 413 | 1,532 | [
"DDInter1124",
"DDInter906"
] | Maprotiline | Ifosfamide | Maprotiline is a tetracyclic antidepressant with similar pharmacological properties to tricyclic antidepressants (TCAs). Similar to TCAs, maprotiline inhibits neuronal norepinephrine reuptake, possesses some anticholinergic activity, and does not affect monoamine oxidase activity. It differs from TCAs in that it does not appear to block serotonin reuptake. Maprotiline may be used to treat depressive affective disorders, including dysthymic disorder (depressive neurosis) and major depressive disorder. Maprotiline is effective at reducing symptoms of anxiety associated with depression. | Ifosfamide is a chemotherapeutic agent chemically related to the nitrogen mustards and a synthetic analog of cyclophosphamide. It is active as an alkylating agent and an immunosuppressive agent. | Moderate | 1 | [
[
[
413,
24,
1532
]
],
[
[
413,
21,
28956
],
[
28956,
60,
1532
]
],
[
[
413,
63,
1648
],
[
1648,
24,
1532
]
],
[
[
413,
25,
351
],
[
351,
63,
1532
]
],
[
[
413,
24,
401
],
[
401,
24,
1532
]
],
[
[
413,
25,
593
],
[
593,
24,
1532
]
],
[
[
413,
24,
849
],
[
849,
63,
1532
]
],
[
[
413,
1,
1302
],
[
1302,
24,
1532
]
],
[
[
413,
25,
497
],
[
497,
64,
1532
]
],
[
[
413,
24,
770
],
[
770,
25,
1532
]
]
] | [
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} (Compound) causes {v} (Side Effect)",
"Palpitations"
],
[
"Palpitations",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aldesleukin"
],
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mepyramine"
],
[
"Mepyramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} (Compound) resembles {v} (Compound)",
"Protriptyline"
],
[
"Protriptyline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
],
[
[
"Maprotiline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
]
]
] | Maprotiline (Compound) causes Palpitations (Side Effect) and Palpitations (Side Effect) is caused by Ifosfamide (Compound)
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Aldesleukin and Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Mepyramine and Mepyramine may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline (Compound) resembles Protriptyline (Compound) and Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide
Maprotiline may lead to a major life threatening interaction when taken with Iohexol and Iohexol may lead to a major life threatening interaction when taken with Ifosfamide
Maprotiline may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide may lead to a major life threatening interaction when taken with Ifosfamide |
DB01165 | DB14520 | 1,539 | 1,229 | [
"DDInter1325",
"DDInter1785"
] | Ofloxacin | Tetraferric tricitrate decahydrate | A synthetic fluoroquinolone (fluoroquinolones) antibacterial agent that inhibits the supercoiling activity of bacterial DNA gyrase, halting DNA replication. | Tetraferric tricitrate decahydrate is an iron containing phosphate binder used to treat hyperphosphatemia and iron deficiency anemia in adults with chronic kidney disease. Tetraferric tricitrate decahydrate was granted FDA approval on 5 September 2014. | Moderate | 1 | [
[
[
1539,
24,
1229
]
],
[
[
1539,
63,
1096
],
[
1096,
23,
1229
]
],
[
[
1539,
40,
246
],
[
246,
24,
1229
]
],
[
[
1539,
1,
945
],
[
945,
24,
1229
]
],
[
[
1539,
63,
1096
],
[
1096,
40,
955
],
[
955,
23,
1229
]
],
[
[
1539,
40,
246
],
[
246,
63,
1096
],
[
1096,
23,
1229
]
],
[
[
1539,
40,
1467
],
[
1467,
24,
1096
],
[
1096,
23,
1229
]
],
[
[
1539,
1,
945
],
[
945,
63,
1096
],
[
1096,
23,
1229
]
],
[
[
1539,
6,
5912
],
[
5912,
45,
955
],
[
955,
23,
1229
]
],
[
[
1539,
63,
1096
],
[
1096,
63,
954
],
[
954,
24,
1229
]
]
] | [
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} (Compound) resembles {v} (Compound)",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Enoxacin"
],
[
"Enoxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} (Compound) binds {v} (Gene)",
"ABCC2"
],
[
"ABCC2",
"{u} (Gene) is bound by {v} (Compound)",
"Mycophenolate mofetil"
],
[
"Mycophenolate mofetil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
],
[
[
"Ofloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mycophenolic acid"
],
[
"Mycophenolic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinapril"
],
[
"Quinapril",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetraferric tricitrate decahydrate"
]
]
] | Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid (Compound) resembles Mycophenolate mofetil (Compound) and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) resembles Gatifloxacin (Compound) and Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) resembles Enoxacin (Compound) and Enoxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) resembles Sparfloxacin (Compound) and Sparfloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin (Compound) binds ABCC2 (Gene) and ABCC2 (Gene) is bound by Mycophenolate mofetil (Compound) and Mycophenolate mofetil may cause a minor interaction that can limit clinical effects when taken with Tetraferric tricitrate decahydrate
Ofloxacin may cause a moderate interaction that could exacerbate diseases when taken with Mycophenolic acid and Mycophenolic acid may cause a moderate interaction that could exacerbate diseases when taken with Quinapril and Quinapril may cause a moderate interaction that could exacerbate diseases when taken with Tetraferric tricitrate decahydrate |
DB01020 | DB09038 | 1,107 | 1,450 | [
"DDInter990",
"DDInter636"
] | Isosorbide mononitrate | Empagliflozin | Isosorbide mononitrate is an organic nitrate with vasodilating properties. It is an anti-anginal agent that works by relaxing the smooth muscles of both arteries and veins, but but predominantly veins to reduce cardiac preload.[L11698, L11743] Isosorbide mononitrate is an active metabolite of [isosorbide dinitrate]. Like other organic nitrates, isosorbide mononitrate acts as a prodrug for its active metabolite, [nitric oxide], which mediates the therapeutic action of isosorbide mononitrate. Isosorbide mononitrate has a longer duration of action than [nitroglycerin] due to its slow onset of absorption and metabolism. First approved by the FDA in 1991, isosorbide mononitrate is used for the prevention and management of angina pectoris caused by coronary artery disease; however, the onset | Empagliflozin is an inhibitor of sodium-glucose co-transporter-2 (SGLT2), the transporters primarily responsible for the reabsorption of glucose in the kidney. It is used clinically as an adjunct to diet and exercise, often in combination with other drug therapies,[L13673,L13679,L11479] for the management of type 2 diabetes mellitus. The first known inhibitor of SGLTs, phlorizin, was isolated from the bark of apple trees in 1835 and researched extensively into the 20th century, but was ultimately deemed inappropriate for clinical use given its lack of specificity and significant gastrointestinal side effects. Attempts at overcoming these limitations first saw the development of O-glucoside analogs of phlorizin (e.g. [remogliflozin etabonate]), but these molecules proved relatively pharmacokinetically unstable. The development of C-glucoside phlorizin analogs remedied the issues observed in the previous generation, and led to the FDA approval of [canagliflozin] in 2013 and both [dapagliflozin] and empagliflozin in 2014. As the most recently approved of the "flozin" drugs, empagliflozin carries the highest selectivity for SGLT2 over SGLT1 (approximately 2700-fold). Empagliflozin was further approved by the EMA in March 2022 and Health Canada in April 2022, making it the first and only approved treatment in Europe and Canada for adults with symptomatic chronic heart failure regardless of ejection fraction.[L40783,L13916] | Moderate | 1 | [
[
[
1107,
24,
1450
]
],
[
[
1107,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1107,
24,
885
],
[
885,
24,
1450
]
],
[
[
1107,
25,
1455
],
[
1455,
63,
1450
]
],
[
[
1107,
1,
426
],
[
426,
24,
1450
]
],
[
[
1107,
63,
1061
],
[
1061,
63,
461
],
[
461,
24,
1450
]
],
[
[
1107,
24,
885
],
[
885,
63,
461
],
[
461,
24,
1450
]
],
[
[
1107,
25,
1455
],
[
1455,
63,
461
],
[
461,
24,
1450
]
],
[
[
1107,
1,
426
],
[
426,
63,
1061
],
[
1061,
24,
1450
]
],
[
[
1107,
21,
28719
],
[
28719,
60,
1103
],
[
1103,
23,
1450
]
]
] | [
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} (Compound) resembles {v} (Compound)",
"Isosorbide dinitrate"
],
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epoprostenol"
],
[
"Epoprostenol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nitrous acid"
],
[
"Nitrous acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} (Compound) resembles {v} (Compound)",
"Isosorbide dinitrate"
],
[
"Isosorbide dinitrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Treprostinil"
],
[
"Treprostinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
]
],
[
[
"Isosorbide mononitrate",
"{u} (Compound) causes {v} (Side Effect)",
"Pain"
],
[
"Pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amcinonide"
],
[
"Amcinonide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Empagliflozin"
]
]
] | Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate (Compound) resembles Isosorbide dinitrate (Compound) and Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate may cause a moderate interaction that could exacerbate diseases when taken with Epoprostenol and Epoprostenol may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate may lead to a major life threatening interaction when taken with Nitrous acid and Nitrous acid may cause a moderate interaction that could exacerbate diseases when taken with Timolol and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate (Compound) resembles Isosorbide dinitrate (Compound) and Isosorbide dinitrate may cause a moderate interaction that could exacerbate diseases when taken with Treprostinil and Treprostinil may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin
Isosorbide mononitrate (Compound) causes Pain (Side Effect) and Pain (Side Effect) is caused by Amcinonide (Compound) and Amcinonide may cause a minor interaction that can limit clinical effects when taken with Empagliflozin |
DB01044 | DB01362 | 246 | 497 | [
"DDInter809",
"DDInter960"
] | Gatifloxacin | Iohexol | Gatifloxacin is an antibiotic agent and a member of the fourth-generation fluoroquinolone family. It works by inhibiting the bacterial enzymes DNA gyrase and topoisomerase IV. It was first introduced by Bristol-Myers Squibb in 1999 under the brand name Tequin® for the treatment of respiratory tract infections. Gatifloxacin is available as tablets and in various aqueous solutions for intravenous therapy. It is also available as eye drops under the brand name Zymar® marketed by Allergan. The FDA withdrew its approval for the use of non-ophthalmic drug products containing gatifloxacin due to the high prevalence of gatifloxacin-associated dysglycemia adverse event reports and the high incidence of hyperglycemic and hypoglycemic episodes in patients taking gatifloxacin compared to those on macrolide antibiotics.[L43942,L44037] | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Major | 2 | [
[
[
246,
25,
497
]
],
[
[
246,
21,
28681
],
[
28681,
60,
497
]
],
[
[
246,
64,
891
],
[
891,
25,
497
]
],
[
[
246,
25,
1264
],
[
1264,
25,
497
]
],
[
[
246,
1,
956
],
[
956,
25,
497
]
],
[
[
246,
25,
129
],
[
129,
64,
497
]
],
[
[
246,
62,
372
],
[
372,
25,
497
]
],
[
[
246,
23,
1532
],
[
1532,
25,
497
]
],
[
[
246,
63,
1274
],
[
1274,
25,
497
]
],
[
[
246,
40,
739
],
[
739,
25,
497
]
]
] | [
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Norfloxacin"
],
[
"Norfloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clofarabine"
],
[
"Clofarabine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
],
[
[
"Gatifloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
]
]
] | Gatifloxacin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Iohexol (Compound)
Gatifloxacin may lead to a major life threatening interaction when taken with Prednisolone and Prednisolone may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin may lead to a major life threatening interaction when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin (Compound) resembles Norfloxacin (Compound) and Norfloxacin may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Clofarabine and Clofarabine may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin may cause a minor interaction that can limit clinical effects when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Iohexol
Gatifloxacin (Compound) resembles Lomefloxacin (Compound) and Lomefloxacin may lead to a major life threatening interaction when taken with Iohexol |
DB00001 | DB00176 | 1,578 | 529 | [
"DDInter1037",
"DDInter770"
] | Lepirudin | Fluvoxamine | Lepirudin is a recombinant hirudin formed by 65 amino acids that acts as a highly specific and direct thrombin inhibitor.[L41539,L41569] Natural hirudin is an endogenous anticoagulant found in _Hirudo medicinalis_ leeches. Lepirudin is produced in yeast cells and is identical to natural hirudin except for the absence of sulfate on the tyrosine residue at position 63 and the substitution of leucine for isoleucine at position 1 (N-terminal end). Lepirudin is used as an anticoagulant in patients with heparin-induced thrombocytopenia (HIT), an immune reaction associated with a high risk of thromboembolic complications.[A3, L41539] HIT is caused by the expression of immunoglobulin G (IgG) antibodies that bind to the complex formed by heparin and | Fluvoxamine is an antidepressant which functions pharmacologically as a selective serotonin reuptake inhibitor. Though it is in the same class as other SSRI drugs, it is most often used to treat obsessive-compulsive disorder. Fluvoxamine has been in use in clinical practice since 1983 and has a clinical trial database comprised of approximately 35,000 patients. It was launched in the US in December 1994 and in Japan in June 1999. As of the end of 1995, more than 10 million patients worldwide have been treated with fluvoxamine. | Moderate | 1 | [
[
[
1578,
24,
529
]
],
[
[
1578,
25,
20
],
[
20,
24,
529
]
],
[
[
1578,
24,
1274
],
[
1274,
63,
529
]
],
[
[
1578,
25,
1421
],
[
1421,
63,
529
]
],
[
[
1578,
24,
121
],
[
121,
64,
529
]
],
[
[
1578,
25,
1347
],
[
1347,
64,
529
]
],
[
[
1578,
25,
20
],
[
20,
24,
1274
],
[
1274,
63,
529
]
],
[
[
1578,
24,
1274
],
[
1274,
6,
6017
],
[
6017,
45,
529
]
],
[
[
1578,
25,
1172
],
[
1172,
64,
20
],
[
20,
24,
529
]
],
[
[
1578,
25,
1421
],
[
1421,
64,
1424
],
[
1424,
62,
529
]
]
] | [
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tenecteplase"
],
[
"Tenecteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluvoxamine"
]
],
[
[
"Lepirudin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluvoxamine"
]
]
] | Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Lepirudin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Fluvoxamine
Lepirudin may lead to a major life threatening interaction when taken with Clopidogrel and Clopidogrel may lead to a major life threatening interaction when taken with Fluvoxamine
Lepirudin may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Fluvoxamine (Compound)
Lepirudin may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may lead to a major life threatening interaction when taken with Tenecteplase and Tenecteplase may cause a moderate interaction that could exacerbate diseases when taken with Fluvoxamine
Lepirudin may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Quinine and Quinine may cause a minor interaction that can limit clinical effects when taken with Fluvoxamine |
DB01362 | DB01400 | 497 | 1,372 | [
"DDInter960",
"DDInter1279"
] | Iohexol | Neostigmine | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Major | 2 | [
[
[
497,
25,
1372
]
],
[
[
497,
21,
28681
],
[
28681,
60,
1372
]
],
[
[
497,
64,
1220
],
[
1220,
24,
1372
]
],
[
[
497,
64,
593
],
[
593,
25,
1372
]
],
[
[
497,
21,
28681
],
[
28681,
60,
751
],
[
751,
40,
1372
]
],
[
[
497,
21,
28778
],
[
28778,
60,
1511
],
[
1511,
63,
1372
]
],
[
[
497,
64,
1220
],
[
1220,
63,
751
],
[
751,
40,
1372
]
],
[
[
497,
64,
1503
],
[
1503,
21,
28787
],
[
28787,
60,
1372
]
],
[
[
497,
64,
251
],
[
251,
24,
751
],
[
751,
40,
1372
]
],
[
[
497,
21,
28792
],
[
28792,
60,
352
],
[
352,
24,
1372
]
]
] | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mepenzolate"
],
[
"Mepenzolate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lindane"
],
[
"Lindane",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trospium"
],
[
"Trospium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
]
] | Iohexol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Neostigmine (Compound)
Iohexol may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Iohexol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may lead to a major life threatening interaction when taken with Neostigmine
Iohexol (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Pyridostigmine (Compound) and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Iohexol (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Mepenzolate (Compound) and Mepenzolate may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Iohexol may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Iohexol may lead to a major life threatening interaction when taken with Lindane and Lindane (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Neostigmine (Compound)
Iohexol may lead to a major life threatening interaction when taken with Betamethasone and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Iohexol (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Trospium (Compound) and Trospium may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine |
DB00180 | DB00872 | 1,351 | 1,080 | [
"DDInter749",
"DDInter438"
] | Flunisolide | Conivaptan | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Conivaptan is a non-peptide inhibitor of antidiuretic hormone (vasopressin). It was approved in 2004 for hyponatremia (low blood sodium levels) caused by syndrome of inappropriate antidiuretic hormone (SIADH). Conivaptan inhibits both isotypes of the vasopressin receptor (V1a and V2). | Moderate | 1 | [
[
[
1351,
24,
1080
]
],
[
[
1351,
6,
8374
],
[
8374,
45,
1080
]
],
[
[
1351,
21,
28769
],
[
28769,
60,
1080
]
],
[
[
1351,
40,
1220
],
[
1220,
63,
1080
]
],
[
[
1351,
40,
891
],
[
891,
24,
1080
]
],
[
[
1351,
24,
86
],
[
86,
63,
1080
]
],
[
[
1351,
23,
659
],
[
659,
63,
1080
]
],
[
[
1351,
24,
283
],
[
283,
64,
1080
]
],
[
[
1351,
23,
455
],
[
455,
64,
1080
]
],
[
[
1351,
1,
617
],
[
617,
64,
1080
]
]
] | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} (Compound) causes {v} (Side Effect)",
"Feeling abnormal"
],
[
"Feeling abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Budesonide"
],
[
"Budesonide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Conivaptan"
]
]
] | Flunisolide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Conivaptan (Compound)
Flunisolide (Compound) causes Feeling abnormal (Side Effect) and Feeling abnormal (Side Effect) is caused by Conivaptan (Compound)
Flunisolide (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Flunisolide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Flunisolide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Conivaptan
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Conivaptan
Flunisolide may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Conivaptan
Flunisolide (Compound) resembles Budesonide (Compound) and Budesonide may lead to a major life threatening interaction when taken with Conivaptan |
DB06595 | DB06616 | 1,491 | 594 | [
"DDInter1214",
"DDInter224"
] | Midostaurin | Bosutinib | Midostaurin (as Rydapt) is a multitarget kinase inhibitor for the treatment for adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific genetic mutation called FLT3. It was initially characterized as a potential broad-spectrum antineoplastic agent, with activity toward diverse solid and hematopoietic tumors. It was approved on April 28, 2017 and has shown to increase the overall survival rate in patients with AML as an adjunct therapy along with chemotherapeutic agents. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
1491,
24,
594
]
],
[
[
1491,
62,
112
],
[
112,
23,
594
]
],
[
[
1491,
63,
1559
],
[
1559,
24,
594
]
],
[
[
1491,
24,
786
],
[
786,
63,
594
]
],
[
[
1491,
25,
1456
],
[
1456,
63,
594
]
],
[
[
1491,
64,
839
],
[
839,
24,
594
]
],
[
[
1491,
25,
334
],
[
334,
64,
594
]
],
[
[
1491,
64,
1493
],
[
1493,
25,
594
]
],
[
[
1491,
25,
39
],
[
39,
25,
594
]
],
[
[
1491,
24,
1017
],
[
1017,
64,
594
]
]
] | [
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rilpivirine"
],
[
"Rilpivirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Grepafloxacin"
],
[
"Grepafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mumps virus strain B level jeryl lynn live antigen"
],
[
"Mumps virus strain B level jeryl lynn live antigen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
]
] | Midostaurin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine and Rilpivirine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Midostaurin may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Midostaurin may lead to a major life threatening interaction when taken with Grepafloxacin and Grepafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Midostaurin may lead to a major life threatening interaction when taken with Mumps virus strain B level jeryl lynn live antigen and Mumps virus strain B level jeryl lynn live antigen may lead to a major life threatening interaction when taken with Bosutinib
Midostaurin may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Bosutinib
Midostaurin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Bosutinib
Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may lead to a major life threatening interaction when taken with Bosutinib |
DB00501 | DB01174 | 752 | 697 | [
"DDInter380",
"DDInter1442"
] | Cimetidine | Phenobarbital | A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions. It inhibits gastric acid secretion, as well as pepsin and gastrins output. It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. | A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations. | Minor | 0 | [
[
[
752,
23,
697
]
],
[
[
752,
23,
759
],
[
759,
1,
697
]
],
[
[
752,
64,
362
],
[
362,
1,
697
]
],
[
[
752,
62,
536
],
[
536,
40,
697
]
],
[
[
752,
62,
1023
],
[
1023,
1,
697
]
],
[
[
752,
6,
10083
],
[
10083,
45,
697
]
],
[
[
752,
21,
28864
],
[
28864,
60,
697
]
],
[
[
752,
25,
37
],
[
37,
62,
697
]
],
[
[
752,
63,
1018
],
[
1018,
23,
697
]
],
[
[
752,
23,
1512
],
[
1512,
23,
697
]
]
] | [
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Secobarbital"
],
[
"Secobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} (Compound) resembles {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} (Compound) binds {v} (Gene)",
"ABCB11"
],
[
"ABCB11",
"{u} (Gene) is bound by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} (Compound) causes {v} (Side Effect)",
"Erythema multiforme"
],
[
"Erythema multiforme",
"{u} (Side Effect) is caused by {v} (Compound)",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomustine"
],
[
"Lomustine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
],
[
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Phenobarbital"
]
]
] | Cimetidine may cause a minor interaction that can limit clinical effects when taken with Primidone and Primidone (Compound) resembles Phenobarbital (Compound)
Cimetidine may lead to a major life threatening interaction when taken with Phenytoin and Phenytoin (Compound) resembles Phenobarbital (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Secobarbital and Secobarbital (Compound) resembles Phenobarbital (Compound)
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Pentobarbital and Pentobarbital (Compound) resembles Phenobarbital (Compound)
Cimetidine (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Phenobarbital (Compound)
Cimetidine (Compound) causes Erythema multiforme (Side Effect) and Erythema multiforme (Side Effect) is caused by Phenobarbital (Compound)
Cimetidine may lead to a major life threatening interaction when taken with Lomustine and Lomustine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a minor interaction that can limit clinical effects when taken with Phenobarbital
Cimetidine may cause a minor interaction that can limit clinical effects when taken with Diclofenac and Diclofenac may cause a minor interaction that can limit clinical effects when taken with Phenobarbital |
DB00436 | DB09472 | 323 | 1,383 | [
"DDInter179",
"DDInter1693"
] | Bendroflumethiazide | Sodium sulfate | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. It has been used in the treatment of familial hyperkalemia, hypertension, edema, and urinary tract disorders. (From Martindale, The Extra Pharmacopoeia, 30th ed, p810) | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Moderate | 1 | [
[
[
323,
24,
1383
]
],
[
[
323,
40,
674
],
[
674,
24,
1383
]
],
[
[
323,
24,
1264
],
[
1264,
24,
1383
]
],
[
[
323,
63,
475
],
[
475,
24,
1383
]
],
[
[
323,
24,
407
],
[
407,
63,
1383
]
],
[
[
323,
25,
1166
],
[
1166,
25,
1383
]
],
[
[
323,
24,
11
],
[
11,
25,
1383
]
],
[
[
323,
40,
674
],
[
674,
24,
1264
],
[
1264,
24,
1383
]
],
[
[
323,
24,
1264
],
[
1264,
24,
609
],
[
609,
24,
1383
]
],
[
[
323,
24,
848
],
[
848,
63,
1252
],
[
1252,
23,
1383
]
]
] | [
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Morphine"
],
[
"Morphine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sodium sulfate"
]
],
[
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium sulfate"
]
]
] | Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Morphine and Morphine may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Toremifene and Toremifene may lead to a major life threatening interaction when taken with Sodium sulfate
Bendroflumethiazide (Compound) resembles Trichlormethiazide (Compound) and Trichlormethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Sodium sulfate
Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may cause a moderate interaction that could exacerbate diseases when taken with Digoxin and Digoxin may cause a minor interaction that can limit clinical effects when taken with Sodium sulfate |
DB01159 | DB12130 | 419 | 1,017 | [
"DDInter854",
"DDInter1094"
] | Halothane | Lorlatinib | A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178) | Lorlatinib is a third-generation ALK tyrosine kinase inhibitor (TKI) for patients with ALK-positive metastatic non-small cell lung cancer which was first approved by the US FDA in November of 2018. It was subsequently approved by the EMA in 2019 for the treatment of select patients with previously treated advanced ALK-positive non-small cell lung cancer, followed by an expanded approval in 2022 to include lorlatinib as a first-line treatment option in advanced ALK-positive NSCLC. | Moderate | 1 | [
[
[
419,
24,
1017
]
],
[
[
419,
24,
1491
],
[
1491,
24,
1017
]
],
[
[
419,
63,
888
],
[
888,
24,
1017
]
],
[
[
419,
64,
11
],
[
11,
24,
1017
]
],
[
[
419,
25,
1493
],
[
1493,
24,
1017
]
],
[
[
419,
24,
971
],
[
971,
63,
1017
]
],
[
[
419,
25,
877
],
[
877,
63,
1017
]
],
[
[
419,
24,
927
],
[
927,
25,
1017
]
],
[
[
419,
24,
1476
],
[
1476,
64,
1017
]
],
[
[
419,
24,
1491
],
[
1491,
24,
1612
],
[
1612,
23,
1017
]
]
] | [
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
],
[
"Gilteritinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brigatinib"
],
[
"Brigatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lorlatinib"
]
],
[
[
"Halothane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lorlatinib"
]
]
] | Halothane may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib and Gilteritinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may lead to a major life threatening interaction when taken with Lorlatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Brigatinib and Brigatinib may lead to a major life threatening interaction when taken with Lorlatinib
Halothane may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Lorlatinib |
DB04845 | DB12141 | 309 | 971 | [
"DDInter1001",
"DDInter817"
] | Ixabepilone | Gilteritinib | Ixabepilone is an epothilone B analog developed by Bristol-Myers Squibb as a cancer drug. It was FDA approved on October 16, 2007, for the treatment of unresponsive aggressive metastatic or locally advanced breast cancer. Ixabepilone is administered through injection, and will be marketed under the trade name Ixempra. Ixabepilone is a semisynthetic analogue of epothilone B. It has a lactone–lactam modification that minimizes susceptibility to esterase degradation. | Gilteritinib, also known as ASP2215, is a small molecule part of the FLT3 tyrosine kinase inhibitors that presented a greater selectivity and potency when compared with other agents from this group. It is a pyrazinecarboxamide derivative that showed high selectivity to FLT3 preventing the c-Kit -driven myelosuppression observed in other therapies. Gilteritinib was developed by Astellas Pharma and FDA approved on November 28, 2018. This drug was approved after being designed as an orphan drug with a fast track and priority review status. | Moderate | 1 | [
[
[
309,
24,
971
]
],
[
[
309,
63,
112
],
[
112,
23,
971
]
],
[
[
309,
24,
1097
],
[
1097,
24,
971
]
],
[
[
309,
63,
1335
],
[
1335,
24,
971
]
],
[
[
309,
25,
1339
],
[
1339,
63,
971
]
],
[
[
309,
24,
283
],
[
283,
63,
971
]
],
[
[
309,
64,
1064
],
[
1064,
24,
971
]
],
[
[
309,
62,
307
],
[
307,
24,
971
]
],
[
[
309,
24,
540
],
[
540,
25,
971
]
],
[
[
309,
24,
68
],
[
68,
64,
971
]
]
] | [
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lasmiditan"
],
[
"Lasmiditan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
],
[
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Troleandomycin"
],
[
"Troleandomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Gilteritinib"
]
]
] | Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Gilteritinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Lasmiditan and Lasmiditan may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Oxcarbazepine and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may lead to a major life threatening interaction when taken with Berotralstat and Berotralstat may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a moderate interaction that could exacerbate diseases when taken with Gilteritinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Gilteritinib
Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Troleandomycin and Troleandomycin may lead to a major life threatening interaction when taken with Gilteritinib |
DB01138 | DB09074 | 804 | 1,362 | [
"DDInter1726",
"DDInter1327"
] | Sulfinpyrazone | Olaparib | A uricosuric drug that is used to reduce the serum urate levels in gout therapy. It lacks anti-inflammatory, analgesic, and diuretic properties. | Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016. | Moderate | 1 | [
[
[
804,
24,
1362
]
],
[
[
804,
24,
1478
],
[
1478,
24,
1362
]
],
[
[
804,
63,
79
],
[
79,
24,
1362
]
],
[
[
804,
62,
168
],
[
168,
24,
1362
]
],
[
[
804,
24,
214
],
[
214,
63,
1362
]
],
[
[
804,
25,
1468
],
[
1468,
24,
1362
]
],
[
[
804,
40,
998
],
[
998,
24,
1362
]
],
[
[
804,
64,
1172
],
[
1172,
24,
1362
]
],
[
[
804,
25,
405
],
[
405,
63,
1362
]
],
[
[
804,
24,
760
],
[
760,
25,
1362
]
]
] | [
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} (Compound) resembles {v} (Compound)",
"Phenylbutazone"
],
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibritumomab tiuxetan"
],
[
"Ibritumomab tiuxetan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acalabrutinib"
],
[
"Acalabrutinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
]
],
[
[
"Sulfinpyrazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Olaparib"
]
]
] | Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may cause a minor interaction that can limit clinical effects when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Ponatinib and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone (Compound) resembles Phenylbutazone (Compound) and Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Ibritumomab tiuxetan and Ibritumomab tiuxetan may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may lead to a major life threatening interaction when taken with Acalabrutinib and Acalabrutinib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib
Sulfinpyrazone may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may lead to a major life threatening interaction when taken with Olaparib |
DB05541 | DB05812 | 801 | 1,374 | [
"DDInter239",
"DDInter8"
] | Brivaracetam | Abiraterone | Brivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam. It is available under the brand name Briviact made by UCB. Briviact received FDA approval on February 19, 2016. | Abiraterone is a potent, irreversible, and selective inhibitor of 17 αhydroxylase/C17,20-lyase (CYP17), an enzyme expressed in testicular, adrenal, and prostatic tumour tissues, to regulate androgen biosynthesis.[A3811, A260880, L40968] Abiraterone was first approved by the FDA and EMA on April, July, and September 2011, respectively. It is used to treat metastatic castration-resistant prostate cancer and hormone-sensitive high-risk metastatic prostate cancer.[L40968, L40193, L47740, L47745] As abiraterone has poor oral bioavailability and is susceptible to hydrolysis by esterases, abiraterone acetate was developed as an orally bioavailable prodrug with enhanced stability and absorption.[A3811, A260835] | Minor | 0 | [
[
[
801,
23,
1374
]
],
[
[
801,
63,
401
],
[
401,
24,
1374
]
],
[
[
801,
62,
600
],
[
600,
24,
1374
]
],
[
[
801,
63,
401
],
[
401,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
801,
63,
999
],
[
999,
24,
211
],
[
211,
23,
1374
]
],
[
[
801,
63,
1311
],
[
1311,
10,
11562
],
[
11562,
44,
1374
]
],
[
[
801,
62,
600
],
[
600,
24,
1561
],
[
1561,
1,
1374
]
],
[
[
801,
62,
477
],
[
477,
6,
12523
],
[
12523,
45,
1374
]
],
[
[
801,
63,
770
],
[
770,
21,
29113
],
[
29113,
60,
1374
]
],
[
[
801,
62,
101
],
[
101,
62,
1069
],
[
1069,
25,
1374
]
]
] | [
[
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} (Compound) palliates {v} (Disease)",
"prostate cancer"
],
[
"prostate cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Testosterone"
],
[
"Testosterone",
"{u} (Compound) resembles {v} (Compound)",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokalaemia"
],
[
"Hypokalaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Abiraterone"
]
],
[
[
"Brivaracetam",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dexlansoprazole"
],
[
"Dexlansoprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abiraterone"
]
]
] | Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone
Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Abiraterone
Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Metoclopramide and Metoclopramide (Compound) palliates prostate cancer (Disease) and prostate cancer (Disease) is treated by Abiraterone (Compound)
Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Testosterone and Testosterone (Compound) resembles Abiraterone (Compound)
Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Cilostazol and Cilostazol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Abiraterone (Compound)
Brivaracetam may cause a moderate interaction that could exacerbate diseases when taken with Thalidomide and Thalidomide (Compound) causes Hypokalaemia (Side Effect) and Hypokalaemia (Side Effect) is caused by Abiraterone (Compound)
Brivaracetam may cause a minor interaction that can limit clinical effects when taken with Dexlansoprazole and Dexlansoprazole may cause a minor interaction that can limit clinical effects when taken with Vandetanib and Vandetanib may lead to a major life threatening interaction when taken with Abiraterone |
DB00497 | DB09098 | 828 | 98 | [
"DDInter1366",
"DDInter1700"
] | Oxycodone | Somatrem | Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
828,
24,
98
]
],
[
[
828,
24,
159
],
[
159,
63,
98
]
],
[
[
828,
25,
609
],
[
609,
24,
98
]
],
[
[
828,
24,
222
],
[
222,
24,
98
]
],
[
[
828,
25,
283
],
[
283,
63,
98
]
],
[
[
828,
63,
530
],
[
530,
24,
98
]
],
[
[
828,
40,
1516
],
[
1516,
24,
98
]
],
[
[
828,
63,
1101
],
[
1101,
25,
98
]
],
[
[
828,
24,
159
],
[
159,
63,
608
],
[
608,
23,
98
]
],
[
[
828,
25,
609
],
[
609,
24,
1612
],
[
1612,
62,
98
]
]
] | [
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} (Compound) resembles {v} (Compound)",
"Galantamine"
],
[
"Galantamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Oxycodone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostemsavir"
],
[
"Fostemsavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
]
] | Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Dronabinol and Dronabinol may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone (Compound) resembles Galantamine (Compound) and Galantamine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Somatrem
Oxycodone may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Oxycodone may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Fostemsavir and Fostemsavir may cause a minor interaction that can limit clinical effects when taken with Somatrem |
DB00035 | DB04896 | 1,314 | 901 | [
"DDInter507",
"DDInter1220"
] | Desmopressin | Milnacipran | Desmopressin (dDAVP), a synthetic analogue of 8-arginine vasopressin (ADH), is an antidiuretic peptide drug modified by deamination of 1-cysteine and substitution of 8-L-arginine by 8-D-arginine. ADH is an endogenous pituitary hormone that has a crucial role in the control of the water content in the body. Upon release from the stimulation of increased plasma osmolarity or decreased circulating blood volume, ADH mainly acts on the cells of the distal part of the nephron and the collecting tubules in the kidney. The hormone interacts with V1, V2 or V3 receptors with differing signal cascade systems. Desmopressin displays enhanced antidiuretic potency, fewer pressor effects due to V2-selective actions, and a prolonged half-life and duration of action compared to endogenous ADH. It has been employed clinically since 1972 | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia , although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible proposal that noradrenaline plays an important role in the mitigation of pain signals in the descending inhibitory pain pathways in the brain and spinal cord [A175759, A175843, A175846]. Moreover, recent research has shown that the levorotatory enantiomer of milnacipran, levomilnacipran, may have the capacity to inhibit the activity of beta-site amyloid precursor protein cleaving enzyme-1 (BACE-1), which has investigationally been associated with β-amyloid plaque formation - making the agent a possible course of treatment for Alzheimer's disease . | Moderate | 1 | [
[
[
1314,
24,
901
]
],
[
[
1314,
24,
41
],
[
41,
1,
901
]
],
[
[
1314,
24,
1349
],
[
1349,
40,
901
]
],
[
[
1314,
21,
28723
],
[
28723,
60,
901
]
],
[
[
1314,
24,
1148
],
[
1148,
24,
901
]
],
[
[
1314,
23,
1479
],
[
1479,
24,
901
]
],
[
[
1314,
24,
1264
],
[
1264,
25,
901
]
],
[
[
1314,
24,
41
],
[
41,
1,
1349
],
[
1349,
40,
901
]
],
[
[
1314,
24,
1349
],
[
1349,
40,
41
],
[
41,
1,
901
]
],
[
[
1314,
21,
28723
],
[
28723,
60,
41
],
[
41,
1,
901
]
]
] | [
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Malnutrition"
],
[
"Malnutrition",
"{u} (Side Effect) is caused by {v} (Compound)",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Meperidine"
],
[
"Meperidine",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
],
[
[
"Desmopressin",
"{u} (Compound) causes {v} (Side Effect)",
"Malnutrition"
],
[
"Malnutrition",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Milnacipran"
]
]
] | Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Milnacipran (Compound)
Desmopressin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Milnacipran (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Desmopressin may cause a minor interaction that can limit clinical effects when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Milnacipran
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Milnacipran
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Levomilnacipran and Levomilnacipran (Compound) resembles Meperidine (Compound) and Meperidine (Compound) resembles Milnacipran (Compound)
Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Meperidine and Meperidine (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Milnacipran (Compound)
Desmopressin (Compound) causes Malnutrition (Side Effect) and Malnutrition (Side Effect) is caused by Levomilnacipran (Compound) and Levomilnacipran (Compound) resembles Milnacipran (Compound) |
DB00515 | DB06317 | 589 | 1,626 | [
"DDInter387",
"DDInter630"
] | Cisplatin | Elotuzumab | Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. | Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies. Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein. Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks. Elotuzumab is produced in NS0 cells by recombinant DNA technology. Elotuzumab has a theoretical mass of 148.1 kDa for the intact antibody. Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb. | Moderate | 1 | [
[
[
589,
24,
1626
]
],
[
[
589,
24,
973
],
[
973,
24,
1626
]
],
[
[
589,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
589,
24,
200
],
[
200,
63,
1626
]
],
[
[
589,
25,
869
],
[
869,
24,
1626
]
],
[
[
589,
25,
1011
],
[
1011,
64,
1626
]
],
[
[
589,
25,
507
],
[
507,
25,
1626
]
],
[
[
589,
64,
1057
],
[
1057,
25,
1626
]
],
[
[
589,
24,
973
],
[
973,
63,
1463
],
[
1463,
24,
1626
]
],
[
[
589,
63,
1463
],
[
1463,
24,
973
],
[
973,
24,
1626
]
]
] | [
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Candida albicans"
],
[
"Candida albicans",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
],
[
[
"Cisplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elotuzumab"
]
]
] | Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Candida albicans and Candida albicans may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Cisplatin may lead to a major life threatening interaction when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Cisplatin may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may lead to a major life threatening interaction when taken with Elotuzumab
Cisplatin may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Elotuzumab
Cisplatin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Elotuzumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab
Cisplatin may cause a moderate interaction that could exacerbate diseases when taken with Lovastatin and Lovastatin may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Elotuzumab |
DB00076 | DB00204 | 1,352 | 228 | [
"DDInter555",
"DDInter580"
] | Digoxin Immune Fab (Ovine) | Dofetilide | Digoxin Immune Fab is a sheep antibody (26-10) FAB fragment from sheep immunized with the digoxin derivative Digoxindicarboxymethylamine. It is used as an antidote for overdose of digoxin. | Dofetilide is a class III antiarrhythmic agent that is approved by the Food and Drug Administration (FDA) for the maintenance of sinus rhythm in individuals prone to the formation of atrial fibrillation and flutter, and for the chemical cardioversion to sinus rhythm from atrial fibrillation and flutter. | Major | 2 | [
[
[
1352,
25,
228
]
],
[
[
1352,
25,
540
],
[
540,
1,
228
]
],
[
[
1352,
25,
57
],
[
57,
64,
228
]
],
[
[
1352,
25,
540
],
[
540,
6,
3958
],
[
3958,
45,
228
]
],
[
[
1352,
24,
607
],
[
607,
21,
28714
],
[
28714,
60,
228
]
],
[
[
1352,
25,
57
],
[
57,
25,
540
],
[
540,
1,
228
]
],
[
[
1352,
24,
216
],
[
216,
6,
3958
],
[
3958,
45,
228
]
],
[
[
1352,
25,
57
],
[
57,
62,
112
],
[
112,
62,
228
]
],
[
[
1352,
25,
540
],
[
540,
21,
28810
],
[
28810,
60,
228
]
],
[
[
1352,
24,
508
],
[
508,
24,
1264
],
[
1264,
64,
228
]
]
] | [
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) binds {v} (Gene)",
"KCNH2"
],
[
"KCNH2",
"{u} (Gene) is bound by {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) resembles {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) binds {v} (Gene)",
"KCNH2"
],
[
"KCNH2",
"{u} (Gene) is bound by {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dofetilide"
]
],
[
[
"Digoxin Immune Fab (Ovine)",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
]
]
] | Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Dofetilide
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Amisulpride and Amisulpride (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) resembles Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Chlorpromazine and Chlorpromazine (Compound) binds KCNH2 (Gene) and KCNH2 (Gene) is bound by Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Arsenic trioxide and Arsenic trioxide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dofetilide
Digoxin Immune Fab (Ovine) may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Dofetilide (Compound)
Digoxin Immune Fab (Ovine) may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine may cause a moderate interaction that could exacerbate diseases when taken with Doxepin and Doxepin may lead to a major life threatening interaction when taken with Dofetilide |
DB01115 | DB11691 | 336 | 1,499 | [
"DDInter1291",
"DDInter1258"
] | Nifedipine | Naldemedine | Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981. | Naldemedine is an opioid receptor antagonist [FDA Label]. It is a modified form of to which a side chain has been added to increase molecular weight and polar surface area resulting in restricted transport across the blood brain barrier. Naldemedine was approved in 2017 in both the US and Japan for the treatment of Opioid-induced Constipation. | Moderate | 1 | [
[
[
336,
24,
1499
]
],
[
[
336,
63,
723
],
[
723,
24,
1499
]
],
[
[
336,
24,
1670
],
[
1670,
24,
1499
]
],
[
[
336,
23,
578
],
[
578,
24,
1499
]
],
[
[
336,
24,
124
],
[
124,
63,
1499
]
],
[
[
336,
40,
409
],
[
409,
24,
1499
]
],
[
[
336,
25,
1456
],
[
1456,
24,
1499
]
],
[
[
336,
25,
129
],
[
129,
25,
1499
]
],
[
[
336,
25,
913
],
[
913,
64,
1499
]
],
[
[
336,
63,
723
],
[
723,
23,
307
],
[
307,
23,
1499
]
]
] | [
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eliglustat"
],
[
"Eliglustat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} (Compound) resembles {v} (Compound)",
"Felodipine"
],
[
"Felodipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Venetoclax"
],
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Naldemedine"
]
],
[
[
"Nifedipine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Modafinil"
],
[
"Modafinil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naldemedine"
]
]
] | Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Eliglustat and Eliglustat may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine (Compound) resembles Felodipine (Compound) and Felodipine may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine may lead to a major life threatening interaction when taken with Venetoclax and Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine
Nifedipine may lead to a major life threatening interaction when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Naldemedine
Nifedipine may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Naldemedine
Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may cause a minor interaction that can limit clinical effects when taken with Modafinil and Modafinil may cause a minor interaction that can limit clinical effects when taken with Naldemedine |
DB00366 | DB00902 | 1,594 | 104 | [
"DDInter600",
"DDInter1168"
] | Doxylamine | Methdilazine | Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. | Methdilazine is a phenothiazine compound with antihistaminic activity. It is used in the treatment of various dermatoses to relieve pruritus. | Moderate | 1 | [
[
[
1594,
24,
104
]
],
[
[
1594,
24,
13
],
[
13,
24,
104
]
],
[
[
1594,
40,
11233
],
[
11233,
1,
104
]
],
[
[
1594,
24,
820
],
[
820,
1,
104
]
],
[
[
1594,
24,
537
],
[
537,
40,
104
]
],
[
[
1594,
1,
293
],
[
293,
40,
104
]
],
[
[
1594,
24,
401
],
[
401,
63,
104
]
],
[
[
1594,
6,
10104
],
[
10104,
45,
104
]
],
[
[
1594,
63,
1062
],
[
1062,
24,
104
]
],
[
[
1594,
25,
1053
],
[
1053,
63,
104
]
]
] | [
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Dimetacrine"
],
[
"Dimetacrine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclizine"
],
[
"Cyclizine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) resembles {v} (Compound)",
"Imipramine"
],
[
"Imipramine",
"{u} (Compound) resembles {v} (Compound)",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} (Compound) binds {v} (Gene)",
"HRH1"
],
[
"HRH1",
"{u} (Gene) is bound by {v} (Compound)",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
],
[
[
"Doxylamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methdilazine"
]
]
] | Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Doxylamine (Compound) resembles Dimetacrine (Compound) and Dimetacrine (Compound) resembles Methdilazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine (Compound) resembles Methdilazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Cyclizine and Cyclizine (Compound) resembles Methdilazine (Compound)
Doxylamine (Compound) resembles Imipramine (Compound) and Imipramine (Compound) resembles Methdilazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Doxylamine (Compound) binds HRH1 (Gene) and HRH1 (Gene) is bound by Methdilazine (Compound)
Doxylamine may cause a moderate interaction that could exacerbate diseases when taken with Tolcapone and Tolcapone may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine
Doxylamine may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may cause a moderate interaction that could exacerbate diseases when taken with Methdilazine |
DB00285 | DB01177 | 1,100 | 77 | [
"DDInter1927",
"DDInter904"
] | Venlafaxine | Idarubicin | Venlafaxine is an antidepressant and a serotonin and norepinephrine reuptake inhibitor (SNRI). Its active metabolite, [desvenlafaxine], works by blocking the reuptake of serotonin and norepinephrine, which are key neurotransmitters in mood regulation. Venlafaxine is officially approved to treat major depressive disorder (MDD), generalized anxiety disorder (GAD), social anxiety disorder, and panic disorder in adults. The immediate formulation of the drug, marketed as Effexor, was first approved by the FDA in 1993 and the extended-release formulation, Effexor XR, was later introduced in 1997. Venlafaxine has been used as a first-line treatment for MDD, GAD, social anxiety disorder, and panic disorder in Canada for many years. It was also considered a second-line treatment for obsessive-compulsive disorder (OCD).[A177226,A177235] Venl | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Moderate | 1 | [
[
[
1100,
24,
77
]
],
[
[
1100,
6,
6017
],
[
6017,
45,
77
]
],
[
[
1100,
21,
28931
],
[
28931,
60,
77
]
],
[
[
1100,
23,
112
],
[
112,
23,
77
]
],
[
[
1100,
24,
823
],
[
823,
63,
77
]
],
[
[
1100,
24,
543
],
[
543,
24,
77
]
],
[
[
1100,
40,
534
],
[
534,
24,
77
]
],
[
[
1100,
25,
1133
],
[
1133,
24,
77
]
],
[
[
1100,
63,
618
],
[
618,
24,
77
]
],
[
[
1100,
24,
351
],
[
351,
64,
77
]
]
] | [
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Loperamide"
],
[
"Loperamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} (Compound) resembles {v} (Compound)",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
]
],
[
[
"Venlafaxine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idarubicin"
]
]
] | Venlafaxine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Idarubicin (Compound)
Venlafaxine (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Idarubicin (Compound)
Venlafaxine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Idarubicin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Loperamide and Loperamide may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Venlafaxine (Compound) resembles Tramadol (Compound) and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Venlafaxine may lead to a major life threatening interaction when taken with Granisetron and Granisetron may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin
Venlafaxine may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Idarubicin |
DB04896 | DB09075 | 901 | 498 | [
"DDInter1220",
"DDInter621"
] | Milnacipran | Edoxaban | Milnacipran is a selective serotonin and norepinephrine reuptake inhibitor (SNRI) and like many agents in this category was originally developed for and continues to be approved and indicated for the treatment of depression [F3928, F3934, A175786, A175951]. Furthermore, in 2009 the US FDA approved milnacipran for the additional indication of treating fibromyalgia, although other regional regulatory authorities like the EMA, among others, have not yet approved the agent for such treatment, citing lack of robust evidence of efficacy, insufficient demonstration of maintenance of effect, and other concerns [F3928, F3934]. Nevertheless, milnacipran demonstrates a somewhat unique characteristic among SNRIs to elicit a relatively balanced reuptake inhibition of both serotonin and noradrenaline, with a somewhat increased preference for noradrenaline reuptake inhibition - which is potentially a point of interest given the plausible | Edoxaban is a member of the Novel Oral Anti-Coagulants (NOACs) class of drugs, and is a rapidly acting, oral, selective factor Xa inhibitor. By inhibiting factor Xa, a key protein in the coagulation cascade, edoxaban prevents the stepwise amplification of protein factors needed to form blood clots. It is indicated to reduce the risk of stroke and systemic embolism (SE) in patients with nonvalvular atrial fibrillation (NVAF) and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) following 5-10 days of initial therapy with a parenteral anticoagulant. Traditionally, warfarin, a vitamin K antagonist, was used for stroke prevention in these individuals but effective use of this drug is limited by it's delayed onset, narrow therapeutic window, need for regular monitoring and INR testing, and numerous drug-drug and drug-food interactions. This has prompted enthusiasm for newer agents such as dabigatran, apixaban, and rivaroxaban for effective clot prevention. In addition to once daily dosing, the benefits over warfarin also include significant reductions in hemorrhagic stroke and GI bleeding, and improved compliance, which is beneficial as many patients will be on lifelong therapy. | Moderate | 1 | [
[
[
901,
24,
498
]
],
[
[
901,
40,
41
],
[
41,
24,
498
]
],
[
[
901,
64,
222
],
[
222,
24,
498
]
],
[
[
901,
63,
305
],
[
305,
24,
498
]
],
[
[
901,
63,
582
],
[
582,
25,
498
]
],
[
[
901,
24,
397
],
[
397,
25,
498
]
],
[
[
901,
24,
1421
],
[
1421,
64,
498
]
],
[
[
901,
40,
41
],
[
41,
64,
222
],
[
222,
24,
498
]
],
[
[
901,
64,
222
],
[
222,
25,
41
],
[
41,
24,
498
]
],
[
[
901,
63,
305
],
[
305,
24,
109
],
[
109,
24,
498
]
]
] | [
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Reteplase"
],
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} (Compound) resembles {v} (Compound)",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
],
[
[
"Milnacipran",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edoxaban"
]
]
] | Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levo
Milnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Reteplase and Reteplase may lead to a major life threatening interaction when taken with Edoxaban
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Plicamycin and Plicamycin may lead to a major life threatening interaction when taken with Edoxaban
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Edoxaban
Milnacipran (Compound) resembles Levomilnacipran (Compound) and Levomilnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban
Milnacipran may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Levomilnacipran and Levo
Milnacipran may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Duloxetine and Duloxetine may cause a moderate interaction that could exacerbate diseases when taken with Edoxaban |
DB00214 | DB00712 | 1,028 | 1,274 | [
"DDInter1836",
"DDInter763"
] | Torasemide | Flurbiprofen | Torasemide is a high-ceiling loop diuretic. Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent. Torasemide was first approved for clinical use by the FDA in 1993. | Flurbiprofen, a propionic acid derivative, is a nonsteroidal anti-inflammatory agent (NSAIA) with antipyretic and analgesic activity. Oral formulations of flurbiprofen may be used for the symptomatic treatment of rheumatoid arthritis, osteoarthritis and anklylosing spondylitis. Flurbiprofen may also be used topically prior to ocular surgery to prevent or reduce intraoperative miosis. Flurbiprofen is structurally and pharmacologically related to fenoprofen, ibuprofen, and ketoprofen. | Moderate | 1 | [
[
[
1028,
24,
1274
]
],
[
[
1028,
6,
10522
],
[
10522,
45,
1274
]
],
[
[
1028,
18,
3439
],
[
3439,
57,
1274
]
],
[
[
1028,
21,
28989
],
[
28989,
60,
1274
]
],
[
[
1028,
24,
254
],
[
254,
24,
1274
]
],
[
[
1028,
24,
842
],
[
842,
63,
1274
]
],
[
[
1028,
64,
1314
],
[
1314,
24,
1274
]
],
[
[
1028,
23,
1347
],
[
1347,
63,
1274
]
],
[
[
1028,
25,
1448
],
[
1448,
63,
1274
]
],
[
[
1028,
24,
1552
],
[
1552,
64,
1274
]
]
] | [
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} (Compound) binds {v} (Gene)",
"PTGS1"
],
[
"PTGS1",
"{u} (Gene) is bound by {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} (Compound) downregulates {v} (Gene)",
"GRN"
],
[
"GRN",
"{u} (Gene) is downregulated by {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperuricaemia"
],
[
"Hyperuricaemia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyl aminolevulinate"
],
[
"Methyl aminolevulinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Desmopressin"
],
[
"Desmopressin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Streptomycin"
],
[
"Streptomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
]
],
[
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ioversol"
],
[
"Ioversol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Flurbiprofen"
]
]
] | Torasemide (Compound) binds PTGS1 (Gene) and PTGS1 (Gene) is bound by Flurbiprofen (Compound)
Torasemide (Compound) downregulates GRN (Gene) and GRN (Gene) is downregulated by Flurbiprofen (Compound)
Torasemide (Compound) causes Hyperuricaemia (Side Effect) and Hyperuricaemia (Side Effect) is caused by Flurbiprofen (Compound)
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Methyl aminolevulinate and Methyl aminolevulinate may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Torasemide may lead to a major life threatening interaction when taken with Desmopressin and Desmopressin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Torasemide may cause a minor interaction that can limit clinical effects when taken with Clopidogrel and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Torasemide may lead to a major life threatening interaction when taken with Streptomycin and Streptomycin may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen
Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Ioversol and Ioversol may lead to a major life threatening interaction when taken with Flurbiprofen |
DB00280 | DB06603 | 494 | 39 | [
"DDInter575",
"DDInter1387"
] | Disopyramide | Panobinostat | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
494,
25,
39
]
],
[
[
494,
23,
112
],
[
112,
23,
39
]
],
[
[
494,
40,
211
],
[
211,
23,
39
]
],
[
[
494,
24,
272
],
[
272,
24,
39
]
],
[
[
494,
63,
58
],
[
58,
24,
39
]
],
[
[
494,
24,
1478
],
[
1478,
63,
39
]
],
[
[
494,
25,
384
],
[
384,
63,
39
]
],
[
[
494,
23,
752
],
[
752,
24,
39
]
],
[
[
494,
25,
594
],
[
594,
64,
39
]
],
[
[
494,
25,
485
],
[
485,
25,
39
]
]
] | [
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Tolterodine"
],
[
"Tolterodine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Disopyramide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pentamidine"
],
[
"Pentamidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Disopyramide may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Disopyramide (Compound) resembles Tolterodine (Compound) and Tolterodine may cause a minor interaction that can limit clinical effects when taken with Panobinostat
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Disopyramide may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Disopyramide may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Disopyramide may lead to a major life threatening interaction when taken with Bosutinib and Bosutinib may lead to a major life threatening interaction when taken with Panobinostat
Disopyramide may lead to a major life threatening interaction when taken with Pentamidine and Pentamidine may lead to a major life threatening interaction when taken with Panobinostat |
DB06589 | DB11799 | 1,250 | 627 | [
"DDInter1400",
"DDInter205"
] | Pazopanib | Bictegravir | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Bictegravir is a recently approved investigational drug that has been used in trials studying the treatment of HIV-1 and HIV-2 infection. It has been approved for HIV-1 monotherapy combined with 2 other antiretrovirals in a single tablet. | Moderate | 1 | [
[
[
1250,
24,
627
]
],
[
[
1250,
24,
1362
],
[
1362,
24,
627
]
],
[
[
1250,
64,
478
],
[
478,
24,
627
]
],
[
[
1250,
63,
600
],
[
600,
24,
627
]
],
[
[
1250,
24,
466
],
[
466,
63,
627
]
],
[
[
1250,
25,
982
],
[
982,
63,
627
]
],
[
[
1250,
25,
985
],
[
985,
24,
627
]
],
[
[
1250,
24,
129
],
[
129,
25,
627
]
],
[
[
1250,
63,
1283
],
[
1283,
25,
627
]
],
[
[
1250,
24,
913
],
[
913,
64,
627
]
]
] | [
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
],
[
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bictegravir"
]
]
] | Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Bictegravir
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide and Enzalutamide may lead to a major life threatening interaction when taken with Bictegravir
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Magnesium oxide and Magnesium oxide may lead to a major life threatening interaction when taken with Bictegravir
Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Bictegravir |
DB00477 | DB01309 | 216 | 1,254 | [
"DDInter363",
"DDInter933"
] | Chlorpromazine | Insulin glulisine | The prototypical phenothiazine antipsychotic drug. Like the other drugs in this class, chlorpromazine's antipsychotic actions are thought to be due to long-term adaptation by the brain to blocking dopamine receptors. Chlorpromazine has several other actions and therapeutic uses, including as an antiemetic and in the treatment of intractable hiccup. | Insulin glulisine is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Insulin is typically prescribed for the management of diabetes mellitus to mimic the activity of endogenously produced human insulin, a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys the beta cells of the pancreas, resulting in the body not being able to produce or synthesize the insulin needed to manage circulating blood sugar levels. As a result, people with T1D rely primarily on exogenous forms of insulin, such as insulin glulisine, to lower glucose levels in the blood. Insulin is also used in the treatment of Type 2 Diabetes (T2D), another form of diabetes mellitus that is a slowly progressing metabolic disorder caused by a combination of genetic and lifestyle factors that promote chronically elevated blood sugar levels. Without treatment or improvement in non-pharmacological measures such as diet and exercise to lower blood glucose, high blood sugar eventually causes cellular resistance to endogenous insulin, and in the long term, damage to pancreatic islet cells. Insulin is typically prescribed later in the course of T2D, after trying several oral medications such as , , or have been tried, when sufficient damage has been caused to pancreatic cells that the body is no longer able to produce insulin on its own. Marketed as the brand name product Apidra, insulin glulisine begins to exert its effects within 15 minutes of subcutaneous administration, while peak levels occur 30 to 90 minutes after administration. Due to its duration of action of around 5 hours, Apidra is considered "bolus insulin" as it provides high levels of insulin in a short period of time to mimic the release of endogenous insulin from the pancreas after meals. Bolus insulin is often combined with once daily, long-acting "basal insulin" such as , , and to provide low concentrations of background insulin that can keep blood sugar stable between meals or overnight. Use of basal and bolus insulin together is intended to mimic the pancreas' production of endogenous insulin, with a goal of avoiding any periods of hypoglycemia. Insulin glulisine is a biosynthetic, rapid-acting human insulin analogue produced in a non-pathogenic laboratory strain of _Escherichia coli_ (K12). This recombinant hormone differs from native human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine at position B29 is replaced by glutamic acid. These structural modifications decrease hexamer formation, stabilize insulin glulisine monomers and increase the rate of absorption and onset of action compared to human insulin. Without an adequate supply of insulin to promote absorption of glucose from the bloodstream, blood sugar levels can climb to dangerously high levels and can result in symptoms such as fatigue, headache, blurred vision, and increased thirst. If left untreated, the body starts to break down fat, instead of glucose, for energy which results in a build-up of ketone acids in the blood and a syndrome called ketoacidosis, which is a life-threatening medical emergency. In the long term, elevated blood sugar levels increase the risk of heart attack, stroke, and diabetic neuropathy. | Moderate | 1 | [
[
[
216,
24,
1254
]
],
[
[
216,
25,
1621
],
[
1621,
23,
1254
]
],
[
[
216,
24,
274
],
[
274,
23,
1254
]
],
[
[
216,
63,
1424
],
[
1424,
24,
1254
]
],
[
[
216,
24,
167
],
[
167,
24,
1254
]
],
[
[
216,
35,
401
],
[
401,
24,
1254
]
],
[
[
216,
24,
1450
],
[
1450,
63,
1254
]
],
[
[
216,
1,
684
],
[
684,
24,
1254
]
],
[
[
216,
62,
417
],
[
417,
24,
1254
]
],
[
[
216,
25,
877
],
[
877,
63,
1254
]
]
] | [
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentolamine"
],
[
"Phentolamine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promethazine"
],
[
"Promethazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Empagliflozin"
],
[
"Empagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sucralfate"
],
[
"Sucralfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
],
[
[
"Chlorpromazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
],
[
"Macimorelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glulisine"
]
]
] | Chlorpromazine may lead to a major life threatening interaction when taken with Potassium chloride and Potassium chloride may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Phentolamine and Phentolamine may cause a minor interaction that can limit clinical effects when taken with Insulin glulisine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine (Compound) resembles Promethazine (Compound) and Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Promethazine and Promethazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine may cause a moderate interaction that could exacerbate diseases when taken with Empagliflozin and Empagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine (Compound) resembles Thioridazine (Compound) and Thioridazine may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine may cause a minor interaction that can limit clinical effects when taken with Sucralfate and Sucralfate may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine
Chlorpromazine may lead to a major life threatening interaction when taken with Macimorelin and Macimorelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin glulisine |
DB00394 | DB09082 | 218 | 659 | [
"DDInter168",
"DDInter1934"
] | Beclomethasone dipropionate | Vilanterol | Beclomethasone dipropionate is a second-generation synthetic corticosteroid and diester of beclomethasone, which is structurally similar to [dexamethasone]. It is a prodrug of an active metabolite beclomethasone 17-monopropionate (17-BMP) which acts on the glucocorticoid receptor to mediates its therapeutic action. Beclomethasone dipropionate itself posesses weak glucocorticoid receptor binding affinity and is rapidly converted into 17-BMP upon administration. Formulations for oral inhalation, intranasal, and topical use are available for beclomethasone dipropionate. Beclomethasone dipropionate became first available in a pressurized metered-dose inhaler in 1972 and later in a dry powder inhaler and an aqueous nasal spray. Due to its anti-inflammatory, antipruritic, and | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Minor | 0 | [
[
[
218,
23,
659
]
],
[
[
218,
1,
1220
],
[
1220,
23,
659
]
],
[
[
218,
24,
323
],
[
323,
24,
659
]
],
[
[
218,
23,
1674
],
[
1674,
24,
659
]
],
[
[
218,
23,
1032
],
[
1032,
63,
659
]
],
[
[
218,
25,
932
],
[
932,
24,
659
]
],
[
[
218,
63,
1028
],
[
1028,
24,
659
]
],
[
[
218,
1,
1220
],
[
1220,
1,
891
],
[
891,
23,
659
]
],
[
[
218,
1,
891
],
[
891,
40,
1220
],
[
1220,
23,
659
]
],
[
[
218,
24,
323
],
[
323,
24,
1220
],
[
1220,
23,
659
]
]
] | [
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
],
[
[
"Beclomethasone dipropionate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
]
]
] | Beclomethasone dipropionate (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Beclomethasone dipropionate may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol and Levosalbutamol may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Beclomethasone dipropionate may lead to a major life threatening interaction when taken with Mifepristone and Mifepristone may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Torasemide and Torasemide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Beclomethasone dipropionate (Compound) resembles Dexamethasone (Compound) and Dexamethasone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Beclomethasone dipropionate (Compound) resembles Prednisolone (Compound) and Prednisolone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol
Beclomethasone dipropionate may cause a moderate interaction that could exacerbate diseases when taken with Bendroflumethiazide and Bendroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Vilanterol |
DB00014 | DB00280 | 521 | 494 | [
"DDInter839",
"DDInter575"
] | Goserelin | Disopyramide | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties. | Major | 2 | [
[
[
521,
25,
494
]
],
[
[
521,
24,
675
],
[
675,
40,
494
]
],
[
[
521,
25,
1301
],
[
1301,
40,
494
]
],
[
[
521,
25,
576
],
[
576,
1,
494
]
],
[
[
521,
21,
28658
],
[
28658,
60,
494
]
],
[
[
521,
23,
112
],
[
112,
62,
494
]
],
[
[
521,
24,
286
],
[
286,
63,
494
]
],
[
[
521,
24,
1685
],
[
1685,
24,
494
]
],
[
[
521,
24,
484
],
[
484,
64,
494
]
],
[
[
521,
25,
478
],
[
478,
64,
494
]
]
] | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methadone"
],
[
"Methadone",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Disopyramide"
]
]
] | Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Disopyramide (Compound)
Goserelin may lead to a major life threatening interaction when taken with Levacetylmethadol and Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Goserelin may lead to a major life threatening interaction when taken with Methadone and Methadone (Compound) resembles Disopyramide (Compound)
Goserelin (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Disopyramide (Compound)
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Disopyramide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Disopyramide
Goserelin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Disopyramide |
DB00635 | DB06448 | 1,573 | 171 | [
"DDInter1515",
"DDInter1087"
] | Prednisone | Lonafarnib | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Hutchinson-Gilford progeria syndrome (HGPS) is a rare autosomal dominant disorder estimated to affect approximately one in 20 million individuals resulting in adverse symptoms associated with premature ageing: skeletal dysplasia, joint contractures, atherosclerosis, myocardial fibrosis/dysfunction, scleroderma-like cutaneous effects, lipoatrophy, alopecia, and a severe failure to thrive; HGPS is uniformly fatal.[A224379, A224384, A224389, A224394, A224399] Mechanistically, HGPS is underpinned by a single heterozygous C-to-T mutation at position 1824 of the _LMNA_ gene, which results in the accumulation of an aberrant farnesylated form of lamin A called progerin in the inner nuclear membrane.[A224379, A224394] Lonafarnib is a farnesyl transferase (FTase) inhibitor (FTI), which reduces the farnesylation of numerous cellular proteins, including progerin; as progerin farnesylation is important for localization to the nuclear membrane, lonafarnib inhibits progerin accumulation and improves symptoms in HGPS patients.[A224379, A224414, A224419, L23414] Merck originally developed Lonafarnib and subsequently licensed it to Eiger Biopharmaceuticals Inc., which currently markets it under the trademark ZOKINVY™.[L23414, L23544] Lonafarnib was granted FDA approval on November 20, 2020, and is the first FDA-approved treatment for HGPS and other related progeroid laminopathies.[L23414, L23549] | Moderate | 1 | [
[
[
1573,
24,
171
]
],
[
[
1573,
63,
254
],
[
254,
24,
171
]
],
[
[
1573,
1,
1351
],
[
1351,
24,
171
]
],
[
[
1573,
24,
473
],
[
473,
24,
171
]
],
[
[
1573,
24,
98
],
[
98,
63,
171
]
],
[
[
1573,
64,
1064
],
[
1064,
24,
171
]
],
[
[
1573,
25,
1377
],
[
1377,
24,
171
]
],
[
[
1573,
23,
659
],
[
659,
63,
171
]
],
[
[
1573,
40,
251
],
[
251,
24,
171
]
],
[
[
1573,
24,
723
],
[
723,
25,
171
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nitisinone"
],
[
"Nitisinone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Flunisolide"
],
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
],
[
"Betamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lonafarnib"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lonafarnib"
]
]
] | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Nitisinone and Nitisinone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone (Compound) resembles Flunisolide (Compound) and Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone (Compound) resembles Betamethasone (Compound) and Betamethasone may cause a moderate interaction that could exacerbate diseases when taken with Lonafarnib
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Lonafarnib |
DB00583 | DB00682 | 106 | 126 | [
"DDInter1052",
"DDInter1951"
] | Levocarnitine | Warfarin | Constituent of striated muscle and liver. It is used therapeutically to stimulate gastric and pancreatic secretions and in the treatment of hyperlipoproteinemias. | Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors. | Moderate | 1 | [
[
[
106,
24,
126
]
],
[
[
106,
1,
427
],
[
427,
25,
593
],
[
593,
63,
126
]
],
[
[
106,
40,
592
],
[
592,
64,
461
],
[
461,
23,
126
]
],
[
[
106,
6,
14172
],
[
14172,
39,
1829
],
[
1829,
45,
126
]
],
[
[
106,
6,
16560
],
[
16560,
45,
1453
],
[
1453,
63,
126
]
],
[
[
106,
6,
14172
],
[
14172,
46,
896
],
[
896,
63,
126
]
],
[
[
106,
6,
9752
],
[
9752,
45,
1424
],
[
1424,
24,
126
]
],
[
[
106,
6,
16560
],
[
16560,
45,
681
],
[
681,
23,
126
]
],
[
[
106,
6,
9375
],
[
9375,
45,
598
],
[
598,
25,
126
]
],
[
[
106,
6,
9752
],
[
9752,
45,
1539
],
[
1539,
64,
126
]
]
] | [
[
[
"Levocarnitine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) resembles {v} (Compound)",
"Bethanechol"
],
[
"Bethanechol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bupropion"
],
[
"Bupropion",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) resembles {v} (Compound)",
"Methacholine"
],
[
"Methacholine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Timolol"
],
[
"Timolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"CROT"
],
[
"CROT",
"{u} (Gene) interacts with {v} (Gene)",
"ALB"
],
[
"ALB",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
"Ceftriaxone"
],
[
"Ceftriaxone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"CROT"
],
[
"CROT",
"{u} (Gene) is upregulated by {v} (Compound)",
"Etoposide"
],
[
"Etoposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A4"
],
[
"SLC22A4",
"{u} (Gene) is bound by {v} (Compound)",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
"Pravastatin"
],
[
"Pravastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"MPO"
],
[
"MPO",
"{u} (Gene) is bound by {v} (Compound)",
"Nabumetone"
],
[
"Nabumetone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
],
[
[
"Levocarnitine",
"{u} (Compound) binds {v} (Gene)",
"SLC22A4"
],
[
"SLC22A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ofloxacin"
],
[
"Ofloxacin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
]
]
] | Levocarnitine (Compound) resembles Bethanechol (Compound) and Bethanechol may lead to a major life threatening interaction when taken with Bupropion and Bupropion may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Levocarnitine (Compound) resembles Methacholine (Compound) and Methacholine may lead to a major life threatening interaction when taken with Timolol and Timolol may cause a minor interaction that can limit clinical effects when taken with Warfarin
Levocarnitine (Compound) binds CROT (Gene) and CROT (Gene) interacts with ALB (Gene) and ALB (Gene) is bound by Warfarin (Compound)
Levocarnitine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Ceftriaxone (Compound) and Ceftriaxone may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Levocarnitine (Compound) binds CROT (Gene) and CROT (Gene) is upregulated by Etoposide (Compound) and Etoposide may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Levocarnitine (Compound) binds SLC22A4 (Gene) and SLC22A4 (Gene) is bound by Quinine (Compound) and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Warfarin
Levocarnitine (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Pravastatin (Compound) and Pravastatin may cause a minor interaction that can limit clinical effects when taken with Warfarin
Levocarnitine (Compound) binds MPO (Gene) and MPO (Gene) is bound by Nabumetone (Compound) and Nabumetone may lead to a major life threatening interaction when taken with Warfarin
Levocarnitine (Compound) binds SLC22A4 (Gene) and SLC22A4 (Gene) is bound by Ofloxacin (Compound) and Ofloxacin may lead to a major life threatening interaction when taken with Warfarin |
DB00264 | DB08881 | 88 | 868 | [
"DDInter1200",
"DDInter1925"
] | Metoprolol | Vemurafenib | Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978. | Vemurafenib is a competitive kinase inhibitor with activity against BRAF kinase with mutations like V600E. It exerts its function by binding to the ATP-binding domain of the mutant BRAF. Vemurafenib was co-developed by Roche and Plexxikon and it obtained its FDA approval on August 17, 2011, under the company Hoffmann La Roche. After approval, Roche in collaboration with Genentech launched a broad development program. | Moderate | 1 | [
[
[
88,
24,
868
]
],
[
[
88,
6,
12523
],
[
12523,
45,
868
]
],
[
[
88,
7,
4904
],
[
4904,
46,
868
]
],
[
[
88,
18,
3877
],
[
3877,
57,
868
]
],
[
[
88,
21,
28847
],
[
28847,
60,
868
]
],
[
[
88,
24,
608
],
[
608,
23,
868
]
],
[
[
88,
23,
578
],
[
578,
24,
868
]
],
[
[
88,
24,
480
],
[
480,
24,
868
]
],
[
[
88,
24,
760
],
[
760,
63,
868
]
],
[
[
88,
23,
286
],
[
286,
63,
868
]
]
] | [
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} (Compound) upregulates {v} (Gene)",
"CNOT4"
],
[
"CNOT4",
"{u} (Gene) is upregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} (Compound) downregulates {v} (Gene)",
"CAST"
],
[
"CAST",
"{u} (Gene) is downregulated by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
],
[
[
"Metoprolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vemurafenib"
]
]
] | Metoprolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Vemurafenib (Compound)
Metoprolol (Compound) upregulates CNOT4 (Gene) and CNOT4 (Gene) is upregulated by Vemurafenib (Compound)
Metoprolol (Compound) downregulates CAST (Gene) and CAST (Gene) is downregulated by Vemurafenib (Compound)
Metoprolol (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Vemurafenib (Compound)
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Vemurafenib
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Metoprolol may cause a moderate interaction that could exacerbate diseases when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib
Metoprolol may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Vemurafenib |
DB01142 | DB02959 | 1,264 | 871 | [
"DDInter593",
"DDInter1362"
] | Doxepin | Oxitriptan | Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter | 5-Hydroxytryptophan (5-HTP), also known as oxitriptan (INN), is a naturally occurring amino acid and metabolic intermediate in the synthesis of serotonin and melatonin. 5-HTP is sold over-the-counter in the United Kingdom, United States and Canada as a dietary supplement for use as an antidepressant, appetite suppressant, and sleep aid, and is also marketed in many European countries for the indication of major depression under trade names like Cincofarm, Levothym, Levotonine, Oxyfan, Telesol, Tript-OH, and Triptum. Several double-blind placebo-controlled clinical trials have demonstrated the effectiveness of 5-HTP in the treatment of depression, though a lack of high quality studies has been noted. More study is needed to determine efficacy in treating depression. | Major | 2 | [
[
[
1264,
25,
871
]
],
[
[
1264,
23,
1191
],
[
1191,
1,
871
]
],
[
[
1264,
63,
1152
],
[
1152,
1,
871
]
],
[
[
1264,
63,
13
],
[
13,
24,
871
]
],
[
[
1264,
24,
1532
],
[
1532,
24,
871
]
],
[
[
1264,
25,
1053
],
[
1053,
25,
871
]
],
[
[
1264,
63,
121
],
[
121,
25,
871
]
],
[
[
1264,
25,
1629
],
[
1629,
64,
871
]
],
[
[
1264,
64,
1166
],
[
1166,
25,
871
]
],
[
[
1264,
23,
1191
],
[
1191,
1,
11215
],
[
11215,
1,
871
]
]
] | [
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyproheptadine"
],
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Procarbazine"
],
[
"Procarbazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fenfluramine"
],
[
"Fenfluramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
],
[
"Methylene blue",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxitriptan"
]
],
[
[
"Doxepin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} (Compound) resembles {v} (Compound)",
"L-Phenylalanine"
],
[
"L-Phenylalanine",
"{u} (Compound) resembles {v} (Compound)",
"Oxitriptan"
]
]
] | Doxepin may cause a minor interaction that can limit clinical effects when taken with Levodopa and Levodopa (Compound) resembles Oxitriptan (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Liothyronine and Liothyronine (Compound) resembles Oxitriptan (Compound)
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Oxitriptan
Doxepin may lead to a major life threatening interaction when taken with Procarbazine and Procarbazine may lead to a major life threatening interaction when taken with Oxitriptan
Doxepin may cause a moderate interaction that could exacerbate diseases when taken with Fenfluramine and Fenfluramine may lead to a major life threatening interaction when taken with Oxitriptan
Doxepin may lead to a major life threatening interaction when taken with Methylene blue and Methylene blue may lead to a major life threatening interaction when taken with Oxitriptan
Doxepin may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Oxitriptan
Doxepin may cause a minor interaction that can limit clinical effects when taken with Levodopa and Levodopa (Compound) resembles L-Phenylalanine (Compound) and L-Phenylalanine (Compound) resembles Oxitriptan (Compound) |
DB00030 | DB00759 | 1,685 | 1,620 | [
"DDInter934",
"DDInter1783"
] | Insulin human | Tetracycline | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal subunit and may alter the cytoplasmic membrane causing intracellular components to leak from bacterial cells. The FDA withdrew its approval for the use of all liquid oral drug products formulated for pediatric use containing tetracycline in a concentration greater than 25 mg/ml. Other formulations of tetracycline continue to be used. | Moderate | 1 | [
[
[
1685,
24,
1620
]
],
[
[
1685,
24,
1572
],
[
1572,
40,
1620
]
],
[
[
1685,
24,
1326
],
[
1326,
62,
1620
]
],
[
[
1685,
24,
811
],
[
811,
23,
1620
]
],
[
[
1685,
24,
266
],
[
266,
63,
1620
]
],
[
[
1685,
63,
305
],
[
305,
24,
1620
]
],
[
[
1685,
24,
1560
],
[
1560,
24,
1620
]
],
[
[
1685,
24,
1572
],
[
1572,
1,
11377
],
[
11377,
40,
1620
]
],
[
[
1685,
24,
1669
],
[
1669,
40,
1572
],
[
1572,
40,
1620
]
],
[
[
1685,
24,
1326
],
[
1326,
62,
1572
],
[
1572,
40,
1620
]
]
] | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metolazone"
],
[
"Metolazone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bismuth subsalicylate"
],
[
"Bismuth subsalicylate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Escherichia coli"
],
[
"Asparaginase Escherichia coli",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Methacycline"
],
[
"Methacycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Minocycline"
],
[
"Minocycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} (Compound) resembles {v} (Compound)",
"Tetracycline"
]
]
] | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Metolazone and Metolazone may cause a minor interaction that can limit clinical effects when taken with Tetracycline
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Bismuth subsalicylate and Bismuth subsalicylate may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Escherichia coli and Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tetracycline
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Demeclocycline and Demeclocycline (Compound) resembles Methacycline (Compound) and Methacycline (Compound) resembles Tetracycline (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Minocycline and Minocycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline (Compound) resembles Tetracycline (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a minor interaction that can limit clinical effects when taken with Demeclocycline and Demeclocycline (Compound) resembles Tetracycline (Compound) |
DB00635 | DB11601 | 1,573 | 1,270 | [
"DDInter1515",
"DDInter1889"
] | Prednisone | Tuberculin purified protein derivative | A synthetic anti-inflammatory glucocorticoid derived from [cortisone]. It is biologically inert and converted to [prednisolone] in the liver. Prednisone was granted FDA approval on 21 February 1955. | Tuberculin Purified Protein Derivative (PPD) is a sterile aqueous solution of a purified protein fraction for intradermal administration as an aid in the diagnosis of tuberculosis. The diagnostic test is commonly referred to as the Mantoux test which serves to minimize the risk of transmission of infection with *Mycobacterium tuberculosis* through early diagnosis and appropriate therapeutic intervention. The purified protein fraction is isolated from culture media filtrates of a human strain of Mycobacterium tuberculosis. It is included in the World Health Organization's List of Essential Medicines. | Moderate | 1 | [
[
[
1573,
24,
1270
]
],
[
[
1573,
24,
1531
],
[
1531,
24,
1270
]
],
[
[
1573,
64,
1064
],
[
1064,
24,
1270
]
],
[
[
1573,
1,
1486
],
[
1486,
24,
1270
]
],
[
[
1573,
63,
599
],
[
599,
24,
1270
]
],
[
[
1573,
25,
1259
],
[
1259,
63,
1270
]
],
[
[
1573,
25,
976
],
[
976,
24,
1270
]
],
[
[
1573,
40,
870
],
[
870,
24,
1270
]
],
[
[
1573,
24,
1619
],
[
1619,
63,
1270
]
],
[
[
1573,
24,
1531
],
[
1531,
24,
350
],
[
350,
24,
1270
]
]
] | [
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
],
[
[
"Prednisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Canakinumab"
],
[
"Canakinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tuberculin purified protein derivative"
]
]
] | Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may lead to a major life threatening interaction when taken with Cladribine and Cladribine may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative
Prednisone may cause a moderate interaction that could exacerbate diseases when taken with Canakinumab and Canakinumab may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may cause a moderate interaction that could exacerbate diseases when taken with Tuberculin purified protein derivative |
DB00180 | DB11652 | 1,351 | 1,155 | [
"DDInter749",
"DDInter1891"
] | Flunisolide | Tucatinib | Flunisolide (marketed as AeroBid, Nasalide, Nasarel) is a corticosteroid with anti-inflammatory actions. It is often prescribed as treatment for allergic rhinitis and its principle mechanism of action involves activation of glucocorticoid receptors. | Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. It was developed by Seattle Genetics and approved by the FDA on April 17, 2020. Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens. | Moderate | 1 | [
[
[
1351,
24,
1155
]
],
[
[
1351,
23,
659
],
[
659,
24,
1155
]
],
[
[
1351,
24,
609
],
[
609,
24,
1155
]
],
[
[
1351,
40,
891
],
[
891,
24,
1155
]
],
[
[
1351,
24,
283
],
[
283,
64,
1155
]
],
[
[
1351,
23,
455
],
[
455,
25,
1155
]
],
[
[
1351,
1,
1486
],
[
1486,
25,
1155
]
],
[
[
1351,
23,
659
],
[
659,
63,
222
],
[
222,
23,
1155
]
],
[
[
1351,
24,
609
],
[
609,
62,
222
],
[
222,
23,
1155
]
],
[
[
1351,
40,
891
],
[
891,
63,
1101
],
[
1101,
23,
1155
]
]
] | [
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
],
[
[
"Flunisolide",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tucatinib"
]
]
] | Flunisolide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Flunisolide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Tucatinib
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Fedratinib and Fedratinib may lead to a major life threatening interaction when taken with Tucatinib
Flunisolide may cause a minor interaction that can limit clinical effects when taken with Salmeterol and Salmeterol may lead to a major life threatening interaction when taken with Tucatinib
Flunisolide (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may lead to a major life threatening interaction when taken with Tucatinib
Flunisolide may cause a minor interaction that can limit clinical effects when taken with Vilanterol and Vilanterol may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Flunisolide may cause a moderate interaction that could exacerbate diseases when taken with Clarithromycin and Clarithromycin may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Tucatinib
Flunisolide (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may cause a minor interaction that can limit clinical effects when taken with Tucatinib |
DB11581 | DB12457 | 1,456 | 1,180 | [
"DDInter1926",
"DDInter1598"
] | Venetoclax | Rimegepant | Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 [FDA label]. Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process,. Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma [FDA label]. CLL is the most prevalent leukemia diagnosed in Western countries. Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax. Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells. A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have | Rimegepant is an oral antagonist of the CGRP receptor developed by Biohaven Pharmaceuticals. It received FDA approval on February 27, 2020 for the acute treatment migraine headache, and was subsequently approved by the European Commission in April 2022 for both the treatment and prevention of migraines. While several parenteral antagonists of CGRP and its receptor have been approved for migraine therapy (e.g. [erenumab], [fremanezumab], [galcanezumab]), rimegepant and [ubrogepant] were the only CGRP antagonists that possessed oral bioavailability until the approval of [atogepant] in 2021. The current standard of migraine therapy involves abortive treatment with "triptans", such as [sumatriptan], but these medications are contraindicated in patients with pre-existing cerebrovascular and cardiovascular disease due to their vasoconstrictive properties. Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore safer for use in patients with contraindications to standard therapy.[A189330,A189207] | Moderate | 1 | [
[
[
1456,
24,
1180
]
],
[
[
1456,
64,
741
],
[
741,
24,
1180
]
],
[
[
1456,
24,
1501
],
[
1501,
63,
1180
]
],
[
[
1456,
25,
351
],
[
351,
24,
1180
]
],
[
[
1456,
25,
283
],
[
283,
63,
1180
]
],
[
[
1456,
63,
26
],
[
26,
24,
1180
]
],
[
[
1456,
24,
927
],
[
927,
24,
1180
]
],
[
[
1456,
64,
1220
],
[
1220,
25,
1180
]
],
[
[
1456,
25,
913
],
[
913,
25,
1180
]
],
[
[
1456,
64,
741
],
[
741,
63,
26
],
[
26,
24,
1180
]
]
] | [
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enasidenib"
],
[
"Enasidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fedratinib"
],
[
"Fedratinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rimegepant"
]
],
[
[
"Venetoclax",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rolapitant"
],
[
"Rolapitant",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Afatinib"
],
[
"Afatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rimegepant"
]
]
] | Venetoclax may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Enasidenib and Enasidenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may lead to a major life threatening interaction when taken with Fedratinib and Fedratinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant
Venetoclax may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may lead to a major life threatening interaction when taken with Rimegepant
Venetoclax may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Rimegepant
Venetoclax may lead to a major life threatening interaction when taken with Rolapitant and Rolapitant may cause a moderate interaction that could exacerbate diseases when taken with Afatinib and Afatinib may cause a moderate interaction that could exacerbate diseases when taken with Rimegepant |
DB00215 | DB09082 | 1,230 | 659 | [
"DDInter388",
"DDInter1934"
] | Citalopram | Vilanterol | Citalopram is an antidepressant belonging to the class of selective _serotonin-reuptake inhibitors_ (SSRIs) widely used to treat the symptoms of depression. It is a racemic bicyclic phthalate derivate and is the only compound with a tertiary amine and 2 nitrogen-containing metabolites among all SSRIs.[A261316,A14720] Citalopram enhances serotonergic transmission through the inhibition of serotonin reuptake, and among all the SSRIs, citalopram appears to be the most selective toward serotonin reuptake inhibition.[A261316,A14720] Specifically, it has a very minimal effect on dopamine and norepinephrine transportation and virtually no affinity for muscarinic, histaminergic, or GABAergic receptors. Citalopram was approved by the FDA in 1998 for the treatment of depression in adults 18 years or older. | Vilanterol is a selective long-acting β2-adrenergic agonist (LABA) with inherent 24-hour activity for the once-daily treatment of COPD and asthma. This is in response to the need for longer-acting β2-adrenergic agonists to overcome poor patient compliance (due to the frequency of dosing regimens or complexities of drug administration). Vilanterol was designed based on the salmeterol molecular scaffold, particularly as a antedrug analog of salmeterol modification by modifying the salmeterol molecule to create homochiral compounds with the (R)-configuration. Vilanterol is 1000 and 400 fold more selective for β2 than β1 and β3 adrenoceptors, respectively, with a faster onset of action than salmeterol. Additionally, vilanterol demonstrated a significantly longer duration of action than salmeterol, with the bronchodilator effect still apparent at 22h. Vilanterol's pharmacological effect is attributable to stimulation of intracellular adenylyl cyclase which catalyzes the conversion of adenosine triphosphate (ATP) to cyclic-3',5'-adenosine monophosphate (cAMP). Increases in cyclic AMP are associated with the relaxation of bronchial smooth muscle and inhibition of the release of hypersensitivity mediators from mast cells in the lungs.[A7738,A259961] Vilanterol is approved for use in several combination products such as with [fluticasone furoate] under the tradename BREO ELLIPTA, with [umeclidinium bromide] as ANORO ELLIPTA, and with both [fluticasone furoate] and [umeclidinium bromide] under the trade name TRELEGY ELLIPTA.[L46481,L44461,L44456] BREO ELLIPTA is the first vilanterol-containing product to be approved by the FDA in May 2013, followed by ANORO ELLIPTA in December 2013 and TRELEGY ELLIPTA in September 2020.[L46876,L46881,L46886] Although all 3 products are approved for the maintenance treatment of chronic obstructive pulmonary disease (COPD), only TRELEGY ELLIPTA and BREO ELLIPTA are approved for maintenance treatments of asthma in patients aged 18 years and older and 5 years and older respectively.[L46481,L44461,L44456] | Moderate | 1 | [
[
[
1230,
24,
659
]
],
[
[
1230,
24,
1296
],
[
1296,
63,
659
]
],
[
[
1230,
25,
927
],
[
927,
63,
659
]
],
[
[
1230,
25,
1069
],
[
1069,
24,
659
]
],
[
[
1230,
24,
959
],
[
959,
24,
659
]
],
[
[
1230,
23,
159
],
[
159,
63,
659
]
],
[
[
1230,
63,
176
],
[
176,
24,
659
]
],
[
[
1230,
23,
384
],
[
384,
24,
659
]
],
[
[
1230,
64,
618
],
[
618,
24,
659
]
],
[
[
1230,
1,
318
],
[
318,
24,
659
]
]
] | [
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Vandetanib"
],
[
"Vandetanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin glargine"
],
[
"Insulin glargine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Abarelix"
],
[
"Abarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
],
[
[
"Citalopram",
"{u} (Compound) resembles {v} (Compound)",
"Escitalopram"
],
[
"Escitalopram",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
]
]
] | Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may lead to a major life threatening interaction when taken with Vandetanib and Vandetanib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may cause a minor interaction that can limit clinical effects when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may cause a moderate interaction that could exacerbate diseases when taken with Insulin glargine and Insulin glargine may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may cause a minor interaction that can limit clinical effects when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram may lead to a major life threatening interaction when taken with Abarelix and Abarelix may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol
Citalopram (Compound) resembles Escitalopram (Compound) and Es |
DB05239 | DB06636 | 866 | 1,623 | [
"DDInter425",
"DDInter980"
] | Cobimetinib | Isavuconazonium | Cobimetinib is an orally active, potent and highly selective small molecule inhibiting mitogen-activated protein kinase kinase 1 (MAP2K1 or MEK1), and central components of the RAS/RAF/MEK/ERK signal transduction pathway. It has been approved in Switzerland and the US, in combination with vemurafenib for the treatment of patients with unresectable or metastatic BRAF V600 mutation-positive melanoma. | Isavuconazonium is a second-generation triazole antifungal approved on March 6, 2015 by the FDA and July 2015 by the EMA for the treatment of adults with invasive aspergillosis and invasive mucormycosis, marketed by Astellas under the brand Cresemba. It is the prodrug form of isavuconazole, the active moiety, and it is available in oral and parenteral formulations. Due to low solubility in water of isavuconazole on its own, the isovuconazonium formulation is favorable as it has high solubility in water and allows for intravenous administration. This formulation also avoids the use of a cyclodextrin vehicle for solubilization required for intravenous administration of other antifungals such as voriconazole and posaconazole, eliminating concerns of nephrotoxicity associated with cyclodextrin. Isovuconazonium has excellent oral bioavailability, predictable pharmacokinetics, and a good safety profile, making it a reasonable alternative to its few other competitors on the market.[A6913,A6914,A262706] On December 08, 2023, the FDA approved the expanded use of isovuconazonium in pediatric patients for the same indications. | Major | 2 | [
[
[
866,
25,
1623
]
],
[
[
866,
64,
1419
],
[
1419,
24,
1623
]
],
[
[
866,
63,
1213
],
[
1213,
24,
1623
]
],
[
[
866,
25,
1593
],
[
1593,
63,
1623
]
],
[
[
866,
24,
1250
],
[
1250,
24,
1623
]
],
[
[
866,
24,
214
],
[
214,
63,
1623
]
],
[
[
866,
25,
913
],
[
913,
64,
1623
]
],
[
[
866,
24,
484
],
[
484,
64,
1623
]
],
[
[
866,
64,
609
],
[
609,
25,
1623
]
],
[
[
866,
64,
1419
],
[
1419,
24,
466
],
[
466,
62,
1623
]
]
] | [
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
],
[
"Pazopanib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Entrectinib"
],
[
"Entrectinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isavuconazonium"
]
],
[
[
"Cobimetinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Darolutamide"
],
[
"Darolutamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Isavuconazonium"
]
]
] | Cobimetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Dasatinib and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cobimetinib may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Isavuconazonium
Cobimetinib may lead to a major life threatening interaction when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Isavuconazonium
Cobimetinib may cause a moderate interaction that could exacerbate diseases when taken with Entrectinib and Entrectinib may lead to a major life threatening interaction when taken with Isavuconazonium
Cobimetinib may lead to a major life threatening interaction when taken with Clarithromycin and Clarithromycin may lead to a major life threatening interaction when taken with Isavuconazonium
Cobimetinib may lead to a major life threatening interaction when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Darolutamide and Darolutamide may cause a minor interaction that can limit clinical effects when taken with Isavuconazonium |
DB00812 | DB11921 | 998 | 1,019 | [
"DDInter1451",
"DDInter492"
] | Phenylbutazone | Deflazacort | A drug that has anti-inflammatory, antipyretic, and analgesic activities. It is especially effective in the treatment of ankylosing spondylitis. It also is useful in rheumatoid arthritis and Reiter's syndrome (investigational indication). Although phenylbutazone is effective in gouty arthritis, risk/benefit considerations indicate that this drug should not be employed for this disease. (From AMA Drug Evaluations Annual, 1994, p1822) | Deflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA.[L6694,FDA label] Duchenne Muscular Dystrophy is an inherited disorder resulting from mutations of the dystrophin gene, which is important for muscle function. This disease can cause serious muscle weakness and progressive breathing and cardiovascular disability, severely impacting patient quality of life and survival.[A179446,A179449,L6697] This disease usually manifests by muscle weakness in early childhood followed by loss of the ability to walk (ambulation) as early as age 7. Deflazacort delays the onset of muscle related complications resulting from DMD, prolonging the lives of children diagnosed with this disease and exerting less harmful effects on the bone health and weight than other steroid medications.[A179452,A25340] | Moderate | 1 | [
[
[
998,
24,
1019
]
],
[
[
998,
24,
959
],
[
959,
24,
1019
]
],
[
[
998,
24,
270
],
[
270,
63,
1019
]
],
[
[
998,
25,
629
],
[
629,
24,
1019
]
],
[
[
998,
64,
126
],
[
126,
24,
1019
]
],
[
[
998,
63,
1512
],
[
1512,
24,
1019
]
],
[
[
998,
1,
97
],
[
97,
24,
1019
]
],
[
[
998,
63,
723
],
[
723,
25,
1019
]
],
[
[
998,
40,
362
],
[
362,
25,
1019
]
],
[
[
998,
1,
651
],
[
651,
25,
1019
]
]
] | [
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Oxaprozin"
],
[
"Oxaprozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Phenytoin"
],
[
"Phenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
],
[
[
"Phenylbutazone",
"{u} (Compound) resembles {v} (Compound)",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
]
]
] | Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone may lead to a major life threatening interaction when taken with Sirolimus and Sirolimus may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone may lead to a major life threatening interaction when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone (Compound) resembles Oxaprozin (Compound) and Oxaprozin may cause a moderate interaction that could exacerbate diseases when taken with Deflazacort
Phenylbutazone may cause a moderate interaction that could exacerbate diseases when taken with Aprepitant and Aprepitant may lead to a major life threatening interaction when taken with Deflazacort
Phenylbutazone (Compound) resembles Phenytoin (Compound) and Phenytoin may lead to a major life threatening interaction when taken with Deflazacort
Phenylbutazone (Compound) resembles Fosphenytoin (Compound) and Fosphenytoin may lead to a major life threatening interaction when taken with Deflazacort |
DB01076 | DB06589 | 700 | 1,250 | [
"DDInter133",
"DDInter1400"
] | Atorvastatin | Pazopanib | Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid. This conversion is a critical metabolic reaction involved in the production of several compounds involved in lipid metabolism and transport, including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very-low-density lipoprotein (VLDL). Prescribing statins is considered standard practice for patients following any cardiovascular event, and for people who are at moderate to high risk of developing cardiovascular disease. The evidence supporting statin use, coupled with minimal | Pazopanib is a small molecule inhibitor of multiple protein tyrosine kinases with potential antineoplastic activity. It is developed by GlaxoSmithKline and was FDA approved on October 19, 2009. | Moderate | 1 | [
[
[
700,
24,
1250
]
],
[
[
700,
6,
15333
],
[
15333,
45,
1250
]
],
[
[
700,
7,
7827
],
[
7827,
46,
1250
]
],
[
[
700,
63,
112
],
[
112,
23,
1250
]
],
[
[
700,
24,
14
],
[
14,
24,
1250
]
],
[
[
700,
63,
1419
],
[
1419,
24,
1250
]
],
[
[
700,
24,
214
],
[
214,
63,
1250
]
],
[
[
700,
64,
600
],
[
600,
24,
1250
]
],
[
[
700,
40,
671
],
[
671,
24,
1250
]
],
[
[
700,
23,
286
],
[
286,
63,
1250
]
]
] | [
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} (Compound) binds {v} (Gene)",
"SLCO1B1"
],
[
"SLCO1B1",
"{u} (Gene) is bound by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"CYTH1"
],
[
"CYTH1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rosuvastatin"
],
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fostamatinib"
],
[
"Fostamatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} (Compound) resembles {v} (Compound)",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
],
[
[
"Atorvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pazopanib"
]
]
] | Atorvastatin (Compound) binds SLCO1B1 (Gene) and SLCO1B1 (Gene) is bound by Pazopanib (Compound)
Atorvastatin (Compound) upregulates CYTH1 (Gene) and CYTH1 (Gene) is upregulated by Pazopanib (Compound)
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Pazopanib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Atorvastatin may cause a moderate interaction that could exacerbate diseases when taken with Fostamatinib and Fostamatinib may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Atorvastatin may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Atorvastatin (Compound) resembles Fluvastatin (Compound) and Fluvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib
Atorvastatin may cause a minor interaction that can limit clinical effects when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Pazopanib |
DB00791 | DB09054 | 132 | 384 | [
"DDInter1902",
"DDInter905"
] | Uracil mustard | Idelalisib | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
132,
24,
384
]
],
[
[
132,
63,
58
],
[
58,
24,
384
]
],
[
[
132,
24,
287
],
[
287,
63,
384
]
],
[
[
132,
24,
713
],
[
713,
24,
384
]
],
[
[
132,
62,
1299
],
[
1299,
24,
384
]
],
[
[
132,
1,
970
],
[
970,
24,
384
]
],
[
[
132,
25,
1259
],
[
1259,
64,
384
]
],
[
[
132,
64,
1066
],
[
1066,
25,
384
]
],
[
[
132,
25,
1510
],
[
1510,
25,
384
]
],
[
[
132,
24,
1362
],
[
1362,
64,
384
]
]
] | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
],
[
"Dimethyl fumarate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} (Compound) resembles {v} (Compound)",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Baricitinib"
],
[
"Baricitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Natalizumab"
],
[
"Natalizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
]
]
] | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate and Dimethyl fumarate may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Uracil mustard may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Uracil mustard (Compound) resembles Fluorouracil (Compound) and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Uracil mustard may lead to a major life threatening interaction when taken with Baricitinib and Baricitinib may lead to a major life threatening interaction when taken with Idelalisib
Uracil mustard may lead to a major life threatening interaction when taken with Natalizumab and Natalizumab may lead to a major life threatening interaction when taken with Idelalisib
Uracil mustard may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Idelalisib
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may lead to a major life threatening interaction when taken with Idelalisib |
DB00552 | DB00773 | 1,238 | 896 | [
"DDInter1425",
"DDInter702"
] | Pentostatin | Etoposide | A potent inhibitor of adenosine deaminase. The drug is effective in the treatment of many lymphoproliferative malignancies, particularly hairy-cell leukemia. It is also synergistic with some other antineoplastic agents and has immunosuppressive activity. | A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle. | Moderate | 1 | [
[
[
1238,
24,
896
]
],
[
[
1238,
5,
11555
],
[
11555,
44,
896
]
],
[
[
1238,
21,
28681
],
[
28681,
60,
896
]
],
[
[
1238,
23,
945
],
[
945,
62,
896
]
],
[
[
1238,
23,
1299
],
[
1299,
23,
896
]
],
[
[
1238,
62,
1176
],
[
1176,
23,
896
]
],
[
[
1238,
24,
147
],
[
147,
23,
896
]
],
[
[
1238,
63,
58
],
[
58,
24,
896
]
],
[
[
1238,
24,
1362
],
[
1362,
63,
896
]
],
[
[
1238,
1,
1477
],
[
1477,
63,
896
]
]
] | [
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} (Compound) treats {v} (Disease)",
"hematologic cancer"
],
[
"hematologic cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sparfloxacin"
],
[
"Sparfloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Trovafloxacin"
],
[
"Trovafloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Moxifloxacin"
],
[
"Moxifloxacin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alefacept"
],
[
"Alefacept",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
],
[
[
"Pentostatin",
"{u} (Compound) resembles {v} (Compound)",
"Telbivudine"
],
[
"Telbivudine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etoposide"
]
]
] | Pentostatin (Compound) treats hematologic cancer (Disease) and hematologic cancer (Disease) is treated by Etoposide (Compound)
Pentostatin (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Etoposide (Compound)
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Sparfloxacin and Sparfloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Trovafloxacin and Trovafloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Pentostatin may cause a minor interaction that can limit clinical effects when taken with Moxifloxacin and Moxifloxacin may cause a minor interaction that can limit clinical effects when taken with Etoposide
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a minor interaction that can limit clinical effects when taken with Etoposide
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Alefacept and Alefacept may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Pentostatin may cause a moderate interaction that could exacerbate diseases when taken with Olaparib and Olaparib may cause a moderate interaction that could exacerbate diseases when taken with Etoposide
Pentostatin (Compound) resembles Telbivudine (Compound) and Telbivudine may cause a moderate interaction that could exacerbate diseases when taken with Etoposide |
DB00819 | DB01284 | 471 | 1,042 | [
"DDInter15",
"DDInter1782"
] | Acetazolamide | Tetracosactide | One of the carbonic anhydrase inhibitors that is sometimes effective against absence seizures. It is sometimes useful also as an adjunct in the treatment of tonic-clonic, myoclonic, and atonic seizures, particularly in women whose seizures occur or are exacerbated at specific times in the menstrual cycle. However, its usefulness is transient often because of rapid development of tolerance. Its antiepileptic effect may be due to its inhibitory effect on brain carbonic anhydrase, which leads to an increased transneuronal chloride gradient, increased chloride current, and increased inhibition. (From Smith and Reynard, Textbook of Pharmacology, 1991, p337) | Tetracosactide (also known as Cosyntropin) is a synthetic peptide that is identical to the 24-amino acid segment (sequence: SYSMEHFRWGKPVGKKRRPVKVYP) at the N-terminal of adrenocorticotropic hormone. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of corticosteroids in the adrenal cortex. Tetracosactide exhibits the same activity as natural ACTH with regard to all its biological activities. The complex results in a product whose absorption in man is effected over a longer period of time as compared to corticotropin. Therefore, therapy may be maintained with less frequent administration. | Moderate | 1 | [
[
[
471,
24,
1042
]
],
[
[
471,
24,
455
],
[
455,
23,
1042
]
],
[
[
471,
24,
659
],
[
659,
62,
1042
]
],
[
[
471,
63,
1674
],
[
1674,
23,
1042
]
],
[
[
471,
24,
761
],
[
761,
63,
1042
]
],
[
[
471,
63,
1144
],
[
1144,
24,
1042
]
],
[
[
471,
24,
1021
],
[
1021,
24,
1042
]
],
[
[
471,
1,
997
],
[
997,
24,
1042
]
],
[
[
471,
64,
1645
],
[
1645,
24,
1042
]
],
[
[
471,
24,
455
],
[
455,
24,
209
],
[
209,
62,
1042
]
]
] | [
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vilanterol"
],
[
"Vilanterol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pramlintide"
],
[
"Pramlintide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} (Compound) resembles {v} (Compound)",
"Methazolamide"
],
[
"Methazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetracosactide"
]
],
[
[
"Acetazolamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Salmeterol"
],
[
"Salmeterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Racepinephrine"
],
[
"Racepinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tetracosactide"
]
]
] | Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Vilanterol and Vilanterol may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Orciprenaline and Orciprenaline may cause a minor interaction that can limit clinical effects when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Pramlintide and Pramlintide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetazolamide (Compound) resembles Methazolamide (Compound) and Methazolamide may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetazolamide may lead to a major life threatening interaction when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Tetracosactide
Acetazolamide may cause a moderate interaction that could exacerbate diseases when taken with Salmeterol and Salmeterol may cause a moderate interaction that could exacerbate diseases when taken with Racepinephrine and Racepinephrine may cause a minor interaction that can limit clinical effects when taken with Tetracosactide |
DB00414 | DB14509 | 590 | 1,399 | [
"DDInter16",
"DDInter1081"
] | Acetohexamide | Lithium carbonate | A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market. | Lithium has been used to treat manic episodes since the 19th century. Though it is widely used, its mechanism of action is still unknown[FDA Label][A14585,A176642,A176651,L5843]. Lithium carbonate has a narrow therapeutic range and so careful monitoring is required to avoid adverse effects[FDA Label]. | Moderate | 1 | [
[
[
590,
24,
1399
]
],
[
[
590,
24,
874
],
[
874,
23,
1399
]
],
[
[
590,
63,
1636
],
[
1636,
23,
1399
]
],
[
[
590,
24,
1385
],
[
1385,
24,
1399
]
],
[
[
590,
63,
1645
],
[
1645,
24,
1399
]
],
[
[
590,
23,
1475
],
[
1475,
24,
1399
]
],
[
[
590,
64,
600
],
[
600,
24,
1399
]
],
[
[
590,
24,
1512
],
[
1512,
25,
1399
]
],
[
[
590,
24,
874
],
[
874,
40,
1636
],
[
1636,
23,
1399
]
],
[
[
590,
63,
1636
],
[
1636,
1,
874
],
[
874,
23,
1399
]
]
] | [
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Semaglutide"
],
[
"Semaglutide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metformin"
],
[
"Metformin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sodium citrate"
],
[
"Sodium citrate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epinephrine"
],
[
"Epinephrine",
"{u} (Compound) resembles {v} (Compound)",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
],
[
[
"Acetohexamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} (Compound) resembles {v} (Compound)",
"Epinephrine"
],
[
"Epinephrine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lithium carbonate"
]
]
] | Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Semaglutide and Semaglutide may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Metformin and Metformin may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Acetohexamide may cause a minor interaction that can limit clinical effects when taken with Sodium citrate and Sodium citrate may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Acetohexamide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Epinephrine and Epinephrine (Compound) resembles Phenylephrine (Compound) and Phenylephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate
Acetohexamide may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine (Compound) resembles Epinephrine (Compound) and Epinephrine may cause a minor interaction that can limit clinical effects when taken with Lithium carbonate |
DB00563 | DB01004 | 663 | 563 | [
"DDInter1174",
"DDInter806"
] | Methotrexate | Ganciclovir | Methotrexate is a folate derivative that inhibits several enzymes responsible for nucleotide synthesis. This inhibition leads to suppression of inflammation as well as prevention of cell division. Because of these effects, methotrexate is often used to treat inflammation caused by arthritis or to control cell division in neoplastic diseases such as breast cancer and non-Hodgkin's lymphoma.[A180322,L7144,L7147,L7150,L7180] Due to the toxic effects of methotrexate, it is indicated for treatment of some forms of arthritis and severe psoriasis only if first line treatment has failed or patients are intolerant of those treatments. Methotrexate was granted FDA approval on 7 December 1953. | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Moderate | 1 | [
[
[
663,
24,
563
]
],
[
[
663,
24,
1295
],
[
1295,
1,
563
]
],
[
[
663,
24,
248
],
[
248,
40,
563
]
],
[
[
663,
6,
16560
],
[
16560,
45,
563
]
],
[
[
663,
18,
1917
],
[
1917,
57,
563
]
],
[
[
663,
21,
29169
],
[
29169,
60,
563
]
],
[
[
663,
63,
552
],
[
552,
24,
563
]
],
[
[
663,
25,
770
],
[
770,
63,
563
]
],
[
[
663,
24,
869
],
[
869,
63,
563
]
],
[
[
663,
24,
147
],
[
147,
24,
563
]
]
] | [
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valaciclovir"
],
[
"Valaciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} (Compound) binds {v} (Gene)",
"SLC22A8"
],
[
"SLC22A8",
"{u} (Gene) is bound by {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} (Compound) downregulates {v} (Gene)",
"CDC25B"
],
[
"CDC25B",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} (Compound) causes {v} (Side Effect)",
"Tinnitus"
],
[
"Tinnitus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Topotecan"
],
[
"Topotecan",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
],
[
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinblastine"
],
[
"Vinblastine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ganciclovir"
]
]
] | Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Valaciclovir and Valaciclovir (Compound) resembles Ganciclovir (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir (Compound) resembles Ganciclovir (Compound)
Methotrexate (Compound) binds SLC22A8 (Gene) and SLC22A8 (Gene) is bound by Ganciclovir (Compound)
Methotrexate (Compound) downregulates CDC25B (Gene) and CDC25B (Gene) is downregulated by Ganciclovir (Compound)
Methotrexate (Compound) causes Tinnitus (Side Effect) and Tinnitus (Side Effect) is caused by Ganciclovir (Compound)
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Methotrexate may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Topotecan and Topotecan may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir
Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Vinblastine and Vinblastine may cause a moderate interaction that could exacerbate diseases when taken with Ganciclovir |
DB01067 | DB01238 | 959 | 673 | [
"DDInter826",
"DDInter118"
] | Glipizide | Aripiprazole | Glipizide is an oral hypoglycemic agent in the second-generation sulfonylurea drug class that is used to control blood sugar levels in patients with type 2 diabetes mellitus. It was first introduced in 1984 and is available in various countries including Canada and the U.S. According to the 2018 Clinical Practice Guidelines by Diabetes Canada, sulfonylurea drugs are considered a second-line glucose-lowering therapy following metformin. Because sulfonylureas require functional pancreatic beta cells for their therapeutic effectiveness, sulfonylureas are more commonly used for early-stage type 2 diabetes when there is no progressed pancreatic failure. Compared to the first-generation sulfonylureas, such as [tolbutamide] and [chlorpropamide], second-generation sulfonylureas contain a more non-polar side chain in their chemical structure, which enhances their hypoglycemic potency. Compared to other members of the sulfonyl | Aripiprazole is an atypical antipsychotic orally indicated for the treatment of schizophrenia, bipolar I, major depressive disorder, irritability associated with autism, and Tourette's. It is also indicated as an injection for agitation associated with schizophrenia or bipolar mania. Aripiprazole exerts its effects through agonism of dopaminergic and 5-HT1A receptors and antagonism of alpha-adrenergic and 5-HT2A receptors.[L45859,A4393] Aripiprazole was given FDA approval on November 15, 2002. | Moderate | 1 | [
[
[
959,
24,
673
]
],
[
[
959,
63,
1630
],
[
1630,
1,
673
]
],
[
[
959,
6,
8374
],
[
8374,
45,
673
]
],
[
[
959,
18,
1918
],
[
1918,
57,
673
]
],
[
[
959,
21,
28792
],
[
28792,
60,
673
]
],
[
[
959,
64,
600
],
[
600,
24,
673
]
],
[
[
959,
24,
1039
],
[
1039,
24,
673
]
],
[
[
959,
63,
1424
],
[
1424,
24,
673
]
],
[
[
959,
24,
761
],
[
761,
63,
673
]
],
[
[
959,
62,
1051
],
[
1051,
24,
673
]
]
] | [
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} (Compound) downregulates {v} (Gene)",
"PCNA"
],
[
"PCNA",
"{u} (Gene) is downregulated by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal disorder"
],
[
"Gastrointestinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Quinine"
],
[
"Quinine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Saxagliptin"
],
[
"Saxagliptin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
],
[
[
"Glipizide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Aminoglutethimide"
],
[
"Aminoglutethimide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
]
]
] | Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Perphenazine and Perphenazine (Compound) resembles Aripiprazole (Compound)
Glipizide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Aripiprazole (Compound)
Glipizide (Compound) downregulates PCNA (Gene) and PCNA (Gene) is downregulated by Aripiprazole (Compound)
Glipizide (Compound) causes Gastrointestinal disorder (Side Effect) and Gastrointestinal disorder (Side Effect) is caused by Aripiprazole (Compound)
Glipizide may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Quinine and Quinine may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Saxagliptin and Saxagliptin may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole
Glipizide may cause a minor interaction that can limit clinical effects when taken with Aminoglutethimide and Aminoglutethimide may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole |
DB00434 | DB01173 | 13 | 358 | [
"DDInter459",
"DDInter1349"
] | Cyproheptadine | Orphenadrine | Cyproheptadine is a potent competitive antagonist of both serotonin and histamine receptors. It is used primarily to treat allergic symptoms, though it is perhaps more notable for its use in appetite stimulation and its off-label use in the treatment of serotonin syndrome. | A muscarinic antagonist used to treat drug-induced parkinsonism and to relieve pain from muscle spasm. | Moderate | 1 | [
[
[
13,
24,
358
]
],
[
[
13,
24,
211
],
[
211,
1,
358
]
],
[
[
13,
24,
272
],
[
272,
24,
358
]
],
[
[
13,
24,
820
],
[
820,
63,
358
]
],
[
[
13,
24,
758
],
[
758,
40,
358
]
],
[
[
13,
63,
508
],
[
508,
1,
358
]
],
[
[
13,
35,
1405
],
[
1405,
40,
358
]
],
[
[
13,
25,
675
],
[
675,
40,
358
]
],
[
[
13,
74,
21
],
[
21,
1,
358
]
],
[
[
13,
40,
11286
],
[
11286,
1,
358
]
]
] | [
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Chlorpheniramine"
],
[
"Chlorpheniramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
],
[
[
"Cyproheptadine",
"{u} (Compound) resembles {v} (Compound)",
"Diphenylpyraline"
],
[
"Diphenylpyraline",
"{u} (Compound) resembles {v} (Compound)",
"Orphenadrine"
]
]
] | Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Tolterodine and Tolterodine (Compound) resembles Orphenadrine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Chlorpheniramine and Chlorpheniramine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Orphenadrine
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Fluoxetine and Fluoxetine (Compound) resembles Orphenadrine (Compound)
Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Promazine and Promazine (Compound) resembles Orphenadrine (Compound)
Cyproheptadine (Compound) resembles Cyclobenzaprine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Orphenadrine (Compound)
Cyproheptadine may lead to a major life threatening interaction when taken with Dextropropoxyphene and Dextropropoxyphene (Compound) resembles Orphenadrine (Compound)
Cyproheptadine (Compound) resembles Amitriptyline (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Amitriptyline and Amitriptyline (Compound) resembles Orphenadrine (Compound)
Cyproheptadine (Compound) resembles Diphenylpyraline (Compound) and Diphenylpyraline (Compound) resembles Orphenadrine (Compound) |
DB00358 | DB04855 | 1,010 | 540 | [
"DDInter1140",
"DDInter602"
] | Mefloquine | Dronedarone | Malaria is a protozoan disease that places an enormous burden on human health in endemic areas around the world. The 2020 World Health Organization malaria report indicates a 60% decrease in the global malaria fatality rate between 2000 to 2019. Despite this, malaria remains a significant cause of morbidity and mortality; 90% of deaths from malaria occur in Africa. Individuals at the highest risk for malaria are those in disease naïve populations, children under age 5, refugees in Central and Eastern Africa, nonimmune civilian and military travelers, pregnant women, and immigrants traveling to their place of origin. Mefloquine, commonly known as Lariam, is an antimalarial drug used for the prevention and treatment of malaria caused by infection with Plasmodium vivax and Plasmodium falciparum. The drug was initially discovered by the Walter Reed Army Institute of Research (WRAIR) during a malaria drug discovery program between 196 | Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally, the methyl sulfonyl group in its structure renders dronedarone to be more lipophilic with a shorter half-life than amiodarone. This ultimately leads to reduced tissue accumulation of the drug and decreased risk for organ toxicities, such as thyroid and pulmonary toxicities. Commonly marketed as Multaq®, dronedarone was approved by the FDA in July 2009 and Health Canada in August 2009. A safety concern for the risk of drug-induced hepatocellular injury has been issued following marketing of dronedarone. | Major | 2 | [
[
[
1010,
25,
540
]
],
[
[
1010,
64,
347
],
[
347,
40,
540
]
],
[
[
1010,
25,
33
],
[
33,
40,
540
]
],
[
[
1010,
6,
8374
],
[
8374,
45,
540
]
],
[
[
1010,
21,
28883
],
[
28883,
60,
540
]
],
[
[
1010,
23,
112
],
[
112,
23,
540
]
],
[
[
1010,
24,
28
],
[
28,
63,
540
]
],
[
[
1010,
63,
608
],
[
608,
24,
540
]
],
[
[
1010,
24,
1220
],
[
1220,
24,
540
]
],
[
[
1010,
23,
1311
],
[
1311,
24,
540
]
]
] | [
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ibutilide"
],
[
"Ibutilide",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} (Compound) resembles {v} (Compound)",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bisacodyl"
],
[
"Bisacodyl",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
],
[
[
"Mefloquine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dronedarone"
]
]
] | Mefloquine may lead to a major life threatening interaction when taken with Ibutilide and Ibutilide (Compound) resembles Dronedarone (Compound)
Mefloquine may lead to a major life threatening interaction when taken with Amiodarone and Amiodarone (Compound) resembles Dronedarone (Compound)
Mefloquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dronedarone (Compound)
Mefloquine (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Dronedarone (Compound)
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Dronedarone
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Bisacodyl and Bisacodyl may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone
Mefloquine may cause a minor interaction that can limit clinical effects when taken with Metoclopramide and Metoclopramide may cause a moderate interaction that could exacerbate diseases when taken with Dronedarone |
DB00530 | DB11757 | 1,195 | 960 | [
"DDInter667",
"DDInter994"
] | Erlotinib | Istradefylline | Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloprolifer | Istradefylline, or KW6002, was developed by Kyowa Hakko Kirin in Japan for the treatment of Parkinson's disease as an adjunct to standard therapy. Unlike standard dopaminergic therapies for Parkinson's, Istradefylline targets adenosine A<sub>2A</sub> receptors in the basal ganglia. This region of the brain is highly involved in motor control. Istradefylline is indicated as an adjunct treatment to [levodopa] and [carbidopa] for Parkinson's disease. This drug was first approved in Japan on 25 March 2013. Istradefylline was granted FDA approval on 27 August 2019. | Moderate | 1 | [
[
[
1195,
24,
960
]
],
[
[
1195,
24,
86
],
[
86,
24,
960
]
],
[
[
1195,
63,
752
],
[
752,
24,
960
]
],
[
[
1195,
24,
1017
],
[
1017,
63,
960
]
],
[
[
1195,
24,
913
],
[
913,
64,
960
]
],
[
[
1195,
24,
384
],
[
384,
25,
960
]
],
[
[
1195,
24,
86
],
[
86,
24,
1499
],
[
1499,
24,
960
]
],
[
[
1195,
24,
850
],
[
850,
63,
134
],
[
134,
24,
960
]
],
[
[
1195,
24,
98
],
[
98,
63,
1135
],
[
1135,
23,
960
]
],
[
[
1195,
63,
752
],
[
752,
23,
1135
],
[
1135,
23,
960
]
]
] | [
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lorlatinib"
],
[
"Lorlatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Miconazole"
],
[
"Miconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
],
[
"Somatrem",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Istradefylline"
]
],
[
[
"Erlotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Naloxegol"
],
[
"Naloxegol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Istradefylline"
]
]
] | Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Lorlatinib and Lorlatinib may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may lead to a major life threatening interaction when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Miconazole and Miconazole may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem and Somatrem may cause a moderate interaction that could exacerbate diseases when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline
Erlotinib may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Naloxegol and Naloxegol may cause a minor interaction that can limit clinical effects when taken with Istradefylline |
DB00598 | DB06704 | 1,523 | 247 | [
"DDInter1013",
"DDInter951"
] | Labetalol | Iobenguane (I-123) | Labetalol is a racemic mixture of 2 diastereoisomers where dilevalol, the R,R' stereoisomer, makes up 25% of the mixture. Labetalol is formulated as an injection or tablets to treat hypertension.[L7727,L7730] Labetalol was granted FDA approval on 1 August 1984. | 2-[(3-iodophenyl)methyl]guanidine is an organoiodine compound. | Moderate | 1 | [
[
[
1523,
37,
247
]
],
[
[
1523,
21,
28787
],
[
28787,
60,
247
]
],
[
[
1523,
24,
820
],
[
820,
24,
247
]
],
[
[
1523,
63,
999
],
[
999,
24,
247
]
],
[
[
1523,
24,
1527
],
[
1527,
64,
247
]
],
[
[
1523,
24,
258
],
[
258,
25,
247
]
],
[
[
1523,
24,
1445
],
[
1445,
37,
247
]
],
[
[
1523,
40,
633
],
[
633,
37,
247
]
],
[
[
1523,
63,
1636
],
[
1636,
37,
247
]
],
[
[
1523,
21,
28787
],
[
28787,
60,
563
],
[
563,
24,
247
]
]
] | [
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alimemazine"
],
[
"Alimemazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Thiethylperazine"
],
[
"Thiethylperazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iothalamic acid"
],
[
"Iothalamic acid",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodixanol"
],
[
"Iodixanol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pseudoephedrine"
],
[
"Pseudoephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} (Compound) resembles {v} (Compound)",
"Lisdexamfetamine"
],
[
"Lisdexamfetamine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phenylephrine"
],
[
"Phenylephrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
]
],
[
[
"Labetalol",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ganciclovir"
],
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iobenguane"
]
]
] | Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Labetalol may lead to a major life threatening interaction when taken with Iobenguane
Labetalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Iobenguane (Compound)
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Alimemazine and Alimemazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Thiethylperazine and Thiethylperazine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iothalamic acid and Iothalamic acid may lead to a major life threatening interaction when taken with Iobenguane
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Iodixanol and Iodixanol may lead to a major life threatening interaction when taken with Iobenguane
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Pseudoephedrine and Pseudoephedrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Pseudoephedrine may lead to a major life threatening interaction when taken with Iobenguane
Labetalol (Compound) resembles Lisdexamfetamine (Compound) and Lisdexamfetamine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Lisdexamfetamine may lead to a major life threatening interaction when taken with Iobenguane
Labetalol may cause a moderate interaction that could exacerbate diseases when taken with Phenylephrine and Phenylephrine may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane and Phenylephrine may lead to a major life threatening interaction when taken with Iobenguane
Labetalol (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ganciclovir (Compound) and Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Iobenguane |
DB00115 | DB00213 | 227 | 837 | [
"DDInter451",
"DDInter1388"
] | Cyanocobalamin | Pantoprazole | Cyanocobalamin (commonly known as Vitamin B12) is a highly complex, essential vitamin, owing its name to the fact that it contains the mineral, cobalt. This vitamin is produced naturally by bacteria, and is necessary for DNA synthesis and cellular energy production. Vitamin B12 has many forms, including the cyano-, methyl-, deoxyadenosyl- and hydroxy-cobalamin forms. The _cyano_ form, is the most widely used form in supplements and prescription drugs, [FDA label]. Several pharmaceutical forms of cyanocobalamin have been developed, including the tablet, injection, and nasal spray forms [FDA label],,. This drug was initially approved by the FDA in 1942 [FDA label]. | Pantoprazole is a first-generation proton pump inhibitor (PPI) used for the management of gastroesophageal reflux disease (GERD), for gastric protection to prevent recurrence of stomach ulcers or gastric damage from chronic use of NSAIDs, and for the treatment of pathological hypersecretory conditions including Zollinger-Ellison (ZE) Syndrome. It can also be found in quadruple regimens for the treatment of _H. pylori_ infections along with other antibiotics including [amoxicillin], [clarithromycin], and [metronidazole], for example. Its efficacy is considered similar to other medications within the PPI class including [omeprazole], [esomeprazole], [lansoprazole], [dexlansoprazole], and [rabeprazole]. Pantoprazole exerts its stomach acid-suppressing effects by preventing the final step in gastric acid production by covalently binding to sulfhydryl groups of cysteines found on the (H+, K+)-ATPase enzyme at the secretory surface of gastric parietal cell. This effect leads to inhibition of both basal and stimulated gastric acid secretion, irrespective of the stimulus. As the binding of pantoprazole to the (H+, K+)-ATPase enzyme is irreversible and new enzyme needs to be expressed in order to resume acid secretion, pantoprazole's duration of antisecretory effect persists longer than 24 hours.[FDA Label] Due to their good safety profile and as several PPIs are available over the counter without a prescription, their current use in North America is widespread. Long term use of PPIs such as pantoprazole have been associated with possible adverse effects, however, including increased susceptibility to bacterial infections (including gastrointestinal _C. difficile_), reduced absorption of micronutrients including iron and B12, and an increased risk of developing hypomagnesemia and hypocalcemia which may contribute to osteoporosis and bone fractures later in life. PPIs such as pantoprazole have also been shown to inhibit the activity of dimethylarginine dimethylaminohydrolase (DDAH), an enzyme necessary for cardiovascular health. DDAH inhibition causes a consequent accumulation of the nitric oxide synthase inhibitor asymmetric dimethylarginie (ADMA), which is thought to cause the association of PPIs with increased risk of cardiovascular events in patients with unstable coronary syndromes.[A177577, A177580] Pantoprazole doses should be slowly lowered, or tapered, before discontinuing as rapid discontinuation of PPIs such as pantoprazole may cause a rebound effect and a short term increase in hypersecretion. | Minor | 0 | [
[
[
227,
23,
837
]
],
[
[
227,
23,
1215
],
[
1215,
40,
837
]
],
[
[
227,
23,
1215
],
[
1215,
40,
117
],
[
117,
40,
837
]
],
[
[
227,
1,
204
],
[
204,
21,
28741
],
[
28741,
60,
837
]
],
[
[
227,
23,
379
],
[
379,
1,
1215
],
[
1215,
40,
837
]
],
[
[
227,
6,
5805
],
[
5805,
17,
3877
],
[
3877,
57,
837
]
],
[
[
227,
6,
8300
],
[
8300,
45,
663
],
[
663,
64,
837
]
],
[
[
227,
23,
1215
],
[
1215,
6,
7065
],
[
7065,
45,
837
]
],
[
[
227,
6,
4182
],
[
4182,
46,
1213
],
[
1213,
64,
837
]
],
[
[
227,
23,
1621
],
[
1621,
21,
28809
],
[
28809,
60,
837
]
]
] | [
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Omeprazole"
],
[
"Omeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) resembles {v} (Compound)",
"Hydroxocobalamin"
],
[
"Hydroxocobalamin",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rabeprazole"
],
[
"Rabeprazole",
"{u} (Compound) resembles {v} (Compound)",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) resembles {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) binds {v} (Gene)",
"MTRR"
],
[
"MTRR",
"{u} (Gene) regulates {v} (Gene)",
"CAST"
],
[
"CAST",
"{u} (Gene) is downregulated by {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) binds {v} (Gene)",
"MTHFR"
],
[
"MTHFR",
"{u} (Gene) is bound by {v} (Compound)",
"Methotrexate"
],
[
"Methotrexate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lansoprazole"
],
[
"Lansoprazole",
"{u} (Compound) binds {v} (Gene)",
"ATP4B"
],
[
"ATP4B",
"{u} (Gene) is bound by {v} (Compound)",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} (Compound) binds {v} (Gene)",
"CASP9"
],
[
"CASP9",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
],
[
"Dasatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Pantoprazole"
]
],
[
[
"Cyanocobalamin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Potassium chloride"
],
[
"Potassium chloride",
"{u} (Compound) causes {v} (Side Effect)",
"Diarrhoea"
],
[
"Diarrhoea",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pantoprazole"
]
]
] | Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Pantoprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) resembles Omeprazole (Compound) and Omeprazole (Compound) resembles Pantoprazole (Compound)
Cyanocobalamin (Compound) resembles Hydroxocobalamin (Compound) and Hydroxocobalamin (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Pantoprazole (Compound)
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Rabeprazole and Rabeprazole (Compound) resembles Lansoprazole (Compound) and Lansoprazole (Compound) resembles Pantoprazole (Compound)
Cyanocobalamin (Compound) binds MTRR (Gene) and MTRR (Gene) regulates CAST (Gene) and CAST (Gene) is downregulated by Pantoprazole (Compound)
Cyanocobalamin (Compound) binds MTHFR (Gene) and MTHFR (Gene) is bound by Methotrexate (Compound) and Methotrexate may lead to a major life threatening interaction when taken with Pantoprazole
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Lansoprazole and Lansoprazole (Compound) binds ATP4B (Gene) and ATP4B (Gene) is bound by Pantoprazole (Compound)
Cyanocobalamin (Compound) binds CASP9 (Gene) and CASP9 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may lead to a major life threatening interaction when taken with Pantoprazole
Cyanocobalamin may cause a minor interaction that can limit clinical effects when taken with Potassium chloride and Potassium chloride (Compound) causes Diarrhoea (Side Effect) and Diarrhoea (Side Effect) is caused by Pantoprazole (Compound) |
DB00220 | DB09098 | 798 | 98 | [
"DDInter1276",
"DDInter1700"
] | Nelfinavir | Somatrem | Nelfinavir is a potent HIV-1 protease inhibitor. It is used in combination with other antiviral drugs in the treatment of HIV in both adults and children. Nelfinavir inhibits the HIV viral proteinase enzyme which prevents cleavage of the gag-pol polyprotein, resulting in noninfectious, immature viral particles. | Despite the ability of almost all contemporary recombinant growth hormones to cause definite and demonstrable increases in growth rate in patients who are administered the drug, the use of these agents continues to be mired in persistent bioethical debate . Such discussion revolves around whether patients' natural disposition of short stature should be considered a medical condition justifying medical treatment with such hormone therapy - especially when these hormone agents have been proven effective at increasing the height of children with or without growth hormone deficiency . | Moderate | 1 | [
[
[
798,
24,
98
]
],
[
[
798,
24,
608
],
[
608,
23,
98
]
],
[
[
798,
63,
168
],
[
168,
23,
98
]
],
[
[
798,
24,
284
],
[
284,
24,
98
]
],
[
[
798,
25,
159
],
[
159,
63,
98
]
],
[
[
798,
25,
11
],
[
11,
24,
98
]
],
[
[
798,
23,
222
],
[
222,
24,
98
]
],
[
[
798,
63,
1179
],
[
1179,
24,
98
]
],
[
[
798,
24,
1499
],
[
1499,
63,
98
]
],
[
[
798,
40,
1327
],
[
1327,
24,
98
]
]
] | [
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Finasteride"
],
[
"Finasteride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Toremifene"
],
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin lispro"
],
[
"Insulin lispro",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Naldemedine"
],
[
"Naldemedine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
],
[
[
"Nelfinavir",
"{u} (Compound) resembles {v} (Compound)",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Somatrem"
]
]
] | Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Somatrem
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a minor interaction that can limit clinical effects when taken with Somatrem
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Finasteride and Finasteride may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir may lead to a major life threatening interaction when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir may lead to a major life threatening interaction when taken with Toremifene and Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Insulin lispro and Insulin lispro may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir may cause a moderate interaction that could exacerbate diseases when taken with Naldemedine and Naldemedine may cause a moderate interaction that could exacerbate diseases when taken with Somatrem
Nelfinavir (Compound) resembles Saquinavir (Compound) and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Somatrem |
DB01098 | DB09054 | 14 | 384 | [
"DDInter1622",
"DDInter905"
] | Rosuvastatin | Idelalisib | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 | Idelalisib is a phosphoinositide 3-kinase inhibitor indicated in the treatment of chronic lymphocytic leukemia (CLL), relapsed follicular B-cell non-Hodgkin lymphoma (FL), and relapsed small lymphocytic lymphoma (SLL). For the treatment of relapsed CLL, it is currently indicated as a second-line agent in combination with rituximab in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities, while in the treatment of FL and SLL it is intended to be used in patients who have received at least two prior systemic therapies. More specifically, idelalisib targets P110δ, the delta isoform of the enzyme phosphatidylinositol-4,5-bisphosphate 3-kinase, also known as PI-3K. The PI-3Ks are a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival and intracellular trafficking, which in turn are involved in cancer. In contrast to the other class IA PI3Ks p110α and p110β, p110δ is principally expressed in leukocytes (white blood cells) and is important for the function of T cells, B cell, mast cells and neutrophils. By inhibiting this enzyme, idelalisib induces apoptosis of malignant cells and inhibits several cell signaling pathways, including B-cell receptor (BCR) signaling and C-X-C chemokine receptors type 5 and type 4 signalling, which are involved in trafficking and homing of B-cells to the lymph nodes and bone marrow. Treatment of lymphoma cells with idelalisib has been shown to result in inhibition of chemotaxis and adhesion, and reduced cell viability. | Moderate | 1 | [
[
[
14,
24,
384
]
],
[
[
14,
24,
1627
],
[
1627,
62,
384
]
],
[
[
14,
24,
72
],
[
72,
24,
384
]
],
[
[
14,
63,
289
],
[
289,
24,
384
]
],
[
[
14,
35,
788
],
[
788,
24,
384
]
],
[
[
14,
24,
242
],
[
242,
63,
384
]
],
[
[
14,
62,
600
],
[
600,
24,
384
]
],
[
[
14,
64,
1668
],
[
1668,
24,
384
]
],
[
[
14,
25,
1519
],
[
1519,
63,
384
]
],
[
[
14,
25,
1327
],
[
1327,
24,
384
]
]
] | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cannabidiol"
],
[
"Cannabidiol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eltrombopag"
],
[
"Eltrombopag",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cerivastatin"
],
[
"Cerivastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Remdesivir"
],
[
"Remdesivir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lenalidomide"
],
[
"Lenalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Velpatasvir"
],
[
"Velpatasvir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
]
]
] | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cannabidiol and Cannabidiol may cause a minor interaction that can limit clinical effects when taken with Idelalisib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Eltrombopag and Eltrombopag may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cerivastatin and Cerivastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin (Compound) resembles Pitavastatin (Compound) and Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Pitavastatin and Pitavastatin may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Remdesivir and Remdesivir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may lead to a major life threatening interaction when taken with Lenalidomide and Lenalidomide may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may lead to a major life threatening interaction when taken with Velpatasvir and Velpatasvir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib
Rosuvastatin may lead to a major life threatening interaction when taken with Saquinavir and Saquinavir may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib |
DB01098 | DB01229 | 14 | 973 | [
"DDInter1622",
"DDInter1377"
] | Rosuvastatin | Paclitaxel | Rosuvastatin, also known as the brand name product Crestor, is a lipid-lowering drug that belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage elevated lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered standard practice following any cardiovascular events and for people with a moderate to high risk of development of CVD, such as those with Type 2 | Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane. | Moderate | 1 | [
[
[
14,
24,
973
]
],
[
[
14,
24,
310
],
[
310,
63,
973
]
],
[
[
14,
6,
7524
],
[
7524,
45,
973
]
],
[
[
14,
18,
2183
],
[
2183,
46,
973
]
],
[
[
14,
7,
2473
],
[
2473,
57,
973
]
],
[
[
14,
18,
1870
],
[
1870,
57,
973
]
],
[
[
14,
21,
28643
],
[
28643,
60,
973
]
],
[
[
14,
63,
134
],
[
134,
24,
973
]
],
[
[
14,
25,
990
],
[
990,
63,
973
]
],
[
[
14,
24,
33
],
[
33,
24,
973
]
]
] | [
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A5"
],
[
"CYP3A5",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) upregulates {v} (Gene)",
"RHOA"
],
[
"RHOA",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) downregulates {v} (Gene)",
"MYC"
],
[
"MYC",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} (Compound) causes {v} (Side Effect)",
"Infection"
],
[
"Infection",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vinorelbine"
],
[
"Vinorelbine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lomitapide"
],
[
"Lomitapide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
],
[
[
"Rosuvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Paclitaxel"
]
]
] | Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rosuvastatin (Compound) binds CYP3A5 (Gene) and CYP3A5 (Gene) is bound by Paclitaxel (Compound)
Rosuvastatin (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Paclitaxel (Compound)
Rosuvastatin (Compound) upregulates RHOA (Gene) and RHOA (Gene) is downregulated by Paclitaxel (Compound)
Rosuvastatin (Compound) downregulates MYC (Gene) and MYC (Gene) is downregulated by Paclitaxel (Compound)
Rosuvastatin (Compound) causes Infection (Side Effect) and Infection (Side Effect) is caused by Paclitaxel (Compound)
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Vinorelbine and Vinorelbine may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rosuvastatin may lead to a major life threatening interaction when taken with Lomitapide and Lomitapide may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel
Rosuvastatin may cause a moderate interaction that could exacerbate diseases when taken with Amiodarone and Amiodarone may cause a moderate interaction that could exacerbate diseases when taken with Paclitaxel |
DB00015 | DB00465 | 582 | 886 | [
"DDInter1585",
"DDInter1010"
] | Reteplase | Ketorolac | Human tissue plasminogen activator, purified, glycosylated, 355 residues purified from CHO cells. Retavase is considered a "third-generation" thrombolytic agent, genetically engineered to retain and delete certain portions of human tPA. Retavase is a deletion mutein of human tPA formed by deleting various amino acids present in endogenous human tPA. Retavase contains 355 of the 527 amino acids of native human tPA (amino acids 1-3 and 176-527), and retains the activity-related kringle-2 and serine protease domains of human tPA. Three domains are deleted from retavase - kringle-1, finger, and epidermal growth factor (EGF). | Ketorolac is a Non-steroidal anti-inflammatory drug (NSAID) and is commercially available as an oral tablet, injectable, nasal spray and as an ophthalmic solution. It's analgesic properties make it a useful pain management tool across many settings including postoperative pain, rheumatoid arthritis, osteoarthritis, menstrual disorders, headaches, spinal and soft tissue pain, and ankylosing spondylitis. Impressively, ketorolac has a similar efficacy to standard doses of morphine and meperidine making it a useful opioid sparing agent. | Moderate | 1 | [
[
[
582,
24,
886
]
],
[
[
582,
24,
24
],
[
24,
40,
886
]
],
[
[
582,
64,
1578
],
[
1578,
24,
886
]
],
[
[
582,
25,
1564
],
[
1564,
63,
886
]
],
[
[
582,
24,
1039
],
[
1039,
63,
886
]
],
[
[
582,
25,
366
],
[
366,
24,
886
]
],
[
[
582,
24,
1018
],
[
1018,
24,
886
]
],
[
[
582,
25,
256
],
[
256,
64,
886
]
],
[
[
582,
25,
834
],
[
834,
25,
886
]
],
[
[
582,
24,
1274
],
[
1274,
64,
886
]
]
] | [
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolmetin"
],
[
"Tolmetin",
"{u} (Compound) resembles {v} (Compound)",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lepirudin"
],
[
"Lepirudin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Defibrotide"
],
[
"Defibrotide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexfenfluramine"
],
[
"Dexfenfluramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Eptifibatide"
],
[
"Eptifibatide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Prasugrel"
],
[
"Prasugrel",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Drotrecogin alfa"
],
[
"Drotrecogin alfa",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
]
],
[
[
"Reteplase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ketorolac"
]
]
] | Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Tolmetin and Tolmetin (Compound) resembles Ketorolac (Compound)
Reteplase may lead to a major life threatening interaction when taken with Lepirudin and Lepirudin may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac
Reteplase may lead to a major life threatening interaction when taken with Defibrotide and Defibrotide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Dexfenfluramine and Dexfenfluramine may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac
Reteplase may lead to a major life threatening interaction when taken with Eptifibatide and Eptifibatide may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Ticlopidine and Ticlopidine may cause a moderate interaction that could exacerbate diseases when taken with Ketorolac
Reteplase may lead to a major life threatening interaction when taken with Prasugrel and Prasugrel may lead to a major life threatening interaction when taken with Ketorolac
Reteplase may lead to a major life threatening interaction when taken with Drotrecogin alfa and Drotrecogin alfa may lead to a major life threatening interaction when taken with Ketorolac
Reteplase may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may lead to a major life threatening interaction when taken with Ketorolac |
DB01203 | DB11348 | 699 | 1,065 | [
"DDInter1255",
"DDInter279"
] | Nadolol | Calcium Phosphate | Nadolol is a nonselective beta adrenal receptor blocker that is used to lower blood pressure.[L7922,L7925] Nonselective beta adrenal receptor blockers may no longer be first line in the treatment of hypertension as newer generations of beta adrenal receptor blockers have higher selectivity and offer better rates of adverse effects. Nadolol was granted FDA approval on 10 December 1979. | Calcium phosphate is typically available as an over the counter supplement, antacid, or as an added ingredient in some toothpastes [FDA Label] . | Moderate | 1 | [
[
[
699,
24,
1065
]
],
[
[
699,
62,
1152
],
[
1152,
24,
1065
]
],
[
[
699,
40,
729
],
[
729,
24,
1065
]
],
[
[
699,
62,
1152
],
[
1152,
23,
819
],
[
819,
24,
1065
]
],
[
[
699,
40,
729
],
[
729,
40,
461
],
[
461,
24,
1065
]
],
[
[
699,
40,
887
],
[
887,
1,
819
],
[
819,
24,
1065
]
],
[
[
699,
24,
1606
],
[
1606,
24,
943
],
[
943,
63,
1065
]
],
[
[
699,
40,
729
],
[
729,
62,
1152
],
[
1152,
24,
1065
]
],
[
[
699,
23,
1054
],
[
1054,
24,
943
],
[
943,
63,
1065
]
],
[
[
699,
24,
1606
],
[
1606,
63,
819
],
[
819,
24,
1065
]
]
] | [
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} (Compound) resembles {v} (Compound)",
"Timolol"
],
[
"Timolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Pindolol"
],
[
"Pindolol",
"{u} (Compound) resembles {v} (Compound)",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} (Compound) resembles {v} (Compound)",
"Penbutolol"
],
[
"Penbutolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Liothyronine"
],
[
"Liothyronine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Kaolin"
],
[
"Kaolin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sarecycline"
],
[
"Sarecycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
],
[
[
"Nadolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lanthanum carbonate"
],
[
"Lanthanum carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calcium Phosphate"
]
]
] | Nadolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a minor interaction that can limit clinical effects when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol (Compound) resembles Penbutolol (Compound) and Penbutolol (Compound) resembles Timolol (Compound) and Timolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol (Compound) resembles Pindolol (Compound) and Pindolol (Compound) resembles Acebutolol (Compound) and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol (Compound) resembles Penbutolol (Compound) and Penbutolol may cause a minor interaction that can limit clinical effects when taken with Liothyronine and Liothyronine may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol may cause a minor interaction that can limit clinical effects when taken with Kaolin and Kaolin may cause a moderate interaction that could exacerbate diseases when taken with Sarecycline and Sarecycline may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate
Nadolol may cause a moderate interaction that could exacerbate diseases when taken with Lanthanum carbonate and Lanthanum carbonate may cause a moderate interaction that could exacerbate diseases when taken with Acebutolol and Acebutolol may cause a moderate interaction that could exacerbate diseases when taken with Calcium Phosphate |
DB00539 | DB00867 | 11 | 1,052 | [
"DDInter1837",
"DDInter1606"
] | Toremifene | Ritodrine | Toremifene is a selective estrogen receptor modulator (SERM) and a nonsteroidal antiestrogen used to treat estrogen receptor positive breast cancer. Like [tamoxifen], toremifene is part of the first-generation triphenylethylene derivative chemical class of SERMs. Toremifene possesses tissue-specific actions: it has estrogenic (agonist) activity on the cardiovascular system and on bone tissue and it has weak estrogenic effects on uterine tissue, however, it also has antiestrogenic (estrogen-antagonist) activity on breast tissue. | Adrenergic beta-agonist used to control premature labor. | Major | 2 | [
[
[
11,
25,
1052
]
],
[
[
11,
18,
2183
],
[
2183,
57,
1052
]
],
[
[
11,
25,
1220
],
[
1220,
62,
1052
]
],
[
[
11,
25,
1148
],
[
1148,
63,
1052
]
],
[
[
11,
24,
1559
],
[
1559,
63,
1052
]
],
[
[
11,
64,
600
],
[
600,
24,
1052
]
],
[
[
11,
24,
1144
],
[
1144,
24,
1052
]
],
[
[
11,
25,
1674
],
[
1674,
24,
1052
]
],
[
[
11,
36,
888
],
[
888,
24,
1052
]
],
[
[
11,
25,
982
],
[
982,
64,
1052
]
]
] | [
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nateglinide"
],
[
"Nateglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} (Compound) resembles {v} (Compound) and {u} may lead to a major life threatening interaction when taken with {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
]
],
[
[
"Toremifene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ritodrine"
]
]
] | Toremifene (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is downregulated by Ritodrine (Compound)
Toremifene may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Ritodrine
Toremifene may lead to a major life threatening interaction when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene may cause a moderate interaction that could exacerbate diseases when taken with Nateglinide and Nateglinide may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene may lead to a major life threatening interaction when taken with Orciprenaline and Orciprenaline may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene (Compound) resembles Tamoxifen (Compound) and Toremifene may lead to a major life threatening interaction when taken with Tamoxifen and Tamoxifen may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine
Toremifene may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Ritodrine |
DB00741 | DB11113 | 167 | 657 | [
"DDInter885",
"DDInter307"
] | Hydrocortisone | Castor oil | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | Castor oil is a vegetable oil obtained by pressing the seeds of the castor oil plant (_Ricinus communis_ L.) mainly cultivated in India, South America, Africa, and China. Castor oil is a rich source of , which represents up to 90% of the total castor oil content. It also consists up to 4% linoleic, 3% oleic, 1% stearic, and less than 1% linolenic fatty acids . has a hydroxyl group that provides a functional group location for various chemical reactions, making it a favourable substance in industrial applications . Castor oil does not contain ricin, which is a natural poison found in the castor oil plant; the toxic lectin remains in the bean pulp following oil isolation . Due to its renewability and high versatility in addition to being the only commercial source of a hydroxylated fatty acid , castor oil has been used as a vital raw material for the chemical industry . Castor oil was mainly used in the manufacturing of soaps, lubricants, and coatings . It is an FDA-approved food additive directly added to food products for human consumption. It can also be found in hard candies as a release agent and anti-sticking agent, or supplementary vitamins and mineral oral tablets as an ingredient for protective coatings. Castor oil is found in over-the-counter oral liquids as a stimulant laxative, and is also added in commercial cosmetic, hair, and skincare products. | Moderate | 1 | [
[
[
167,
24,
657
]
],
[
[
167,
25,
540
],
[
540,
24,
657
]
],
[
[
167,
24,
1326
],
[
1326,
24,
657
]
],
[
[
167,
1,
891
],
[
891,
24,
657
]
],
[
[
167,
64,
228
],
[
228,
24,
657
]
],
[
[
167,
63,
789
],
[
789,
24,
657
]
],
[
[
167,
24,
351
],
[
351,
63,
657
]
],
[
[
167,
40,
870
],
[
870,
24,
657
]
],
[
[
167,
23,
688
],
[
688,
24,
657
]
],
[
[
167,
25,
540
],
[
540,
25,
927
],
[
927,
63,
657
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Prednisolone"
],
[
"Prednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Salbutamol"
],
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Encorafenib"
],
[
"Encorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Castor oil"
]
]
] | Hydrocortisone may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Diclofenamide and Diclofenamide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone (Compound) resembles Prednisolone (Compound) and Prednisolone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may lead to a major life threatening interaction when taken with Dofetilide and Dofetilide may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may cause a minor interaction that can limit clinical effects when taken with Salbutamol and Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Castor oil
Hydrocortisone may lead to a major life threatening interaction when taken with Dronedarone and Dronedarone may lead to a major life threatening interaction when taken with Encorafenib and Encorafenib may cause a moderate interaction that could exacerbate diseases when taken with Castor oil |
DB09280 | DB13074 | 1,604 | 877 | [
"DDInter1101",
"DDInter1110"
] | Lumacaftor | Macimorelin | Lumacaftor is a drug used in combination with as the fixed dose combination product Orkambi for the management of Cystic Fibrosis (CF) in patients aged 6 years and older. Cystic Fibrosis is an autosomal recessive disorder caused by one of several different mutations in the gene for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein, a transmembrane ion channel involved in the transport of chloride and sodium ions across cell membranes of the lungs, pancreas, and other organs. Mutations in the CFTR gene result in altered production, misfolding, or function of the CFTR protein and consequently abnormal fluid and ion transport across cell membranes.[A20298, A20299] As a result, CF patients produce thick, sticky mucus that clogs the ducts of organs where it is produced making patients more susceptible to infections, lung damage, pancreatic insufficiency, and malnutrition. Lum | Macimorelin, a novel and orally active ghrelin mimetic that stimulates GH secretion, is used in the diagnosis of adult GH deficiency (AGHD). More specifically, macimorelin is a peptidomimetic growth hormone secretagogue (GHS) that acts as an agonist of GH secretagogue receptor, or ghrelin receptor (GHS-R1a) to dose-dependently increase GH levels . Growth hormone secretagogues (GHS) represent a new class of pharmacological agents which have the potential to be used in numerous clinical applications. They include treatment for growth retardation in children and cachexia associated with chronic disease such as AIDS and cancer. Growth hormone (GH) is classically linked with linear growth during childhood. In deficiency of this hormone, AGHD is commonly associated with increased fat mass (particularly in the abdominal region), decreased lean body mass, osteopenia, dyslipidemia, insulin resistance, and/or glucose intolerance overtime. In addition, individuals with may be susceptible to cardiovascular complications from altered structures and function . Risk factors of AGHD include a history of childhood-onset GH deficiency or with hypothalamic/pituitary disease, surgery, or irradiation to these areas, head trauma, or evidence of other pituitary hormone deficiencies . While there are various therapies available such as GH replacement therapy, the absence of panhypopituitarism and low serum IGF-I levels with nonspecific clinical symptoms pose challenges to the detection and diagnosis of AGHD. The diagnosis of AGHD requires biochemical confirmation with at least 1 GH stimulation test . Macimorelin is clinically useful since it displays good stability and oral bioavailability with comparable affinity to ghrelin receptor as its endogenous ligand. In clinical studies involving healthy subjects, macimorelin stimulated GH release in a dose-dependent manner with good tolerability . Macimorelin, developed by Aeterna Zentaris, was approved by the FDA in December 2017 under the market name Macrilen for oral solution. | Moderate | 1 | [
[
[
1604,
24,
877
]
],
[
[
1604,
63,
673
],
[
673,
24,
877
]
],
[
[
1604,
25,
1019
],
[
1019,
24,
877
]
],
[
[
1604,
64,
655
],
[
655,
24,
877
]
],
[
[
1604,
64,
478
],
[
478,
25,
877
]
],
[
[
1604,
25,
1375
],
[
1375,
25,
877
]
],
[
[
1604,
63,
477
],
[
477,
25,
877
]
],
[
[
1604,
25,
982
],
[
982,
64,
877
]
],
[
[
1604,
63,
673
],
[
673,
62,
112
],
[
112,
23,
877
]
],
[
[
1604,
63,
479
],
[
479,
24,
112
],
[
112,
23,
877
]
]
] | [
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deflazacort"
],
[
"Deflazacort",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etravirine"
],
[
"Etravirine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lefamulin"
],
[
"Lefamulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cilostazol"
],
[
"Cilostazol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
],
[
[
"Lumacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Macimorelin"
]
]
] | Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Lumacaftor may lead to a major life threatening interaction when taken with Deflazacort and Deflazacort may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Lumacaftor may lead to a major life threatening interaction when taken with Etravirine and Etravirine may cause a moderate interaction that could exacerbate diseases when taken with Macimorelin
Lumacaftor may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Macimorelin
Lumacaftor may lead to a major life threatening interaction when taken with Lefamulin and Lefamulin may lead to a major life threatening interaction when taken with Macimorelin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Cilostazol and Cilostazol may lead to a major life threatening interaction when taken with Macimorelin
Lumacaftor may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Macimorelin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Aripiprazole and Aripiprazole may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin
Lumacaftor may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Macimorelin |
DB00059 | DB00621 | 1,560 | 1,026 | [
"DDInter1404",
"DDInter1357"
] | Pegaspargase | Oxandrolone | Pegaspargase is a conjugate of monomethoxypolyethylene glycol (mPEG) and L-asparaginase (L-asparagine amidohydrolase), an asparagine-specific enzyme that converts L-asparagine into aspartic acid and ammonia. Asparagine is an amino acid that is vital for cell survival. In humans, most normal tissues can produce asparagine through the action of asparagine synthetase. However, leukemia cells have low levels of this enzyme and depend on exogenous sources. Therefore, the use of pegaspargase results in leukemic cell death.[A103,A255912,L44667] Pegaspargase has the same mechanism of action as [L-asparaginase] derived from _Escherichia coli_, a previously developed enzyme used for the treatment of acute lymphoblastic leukemia (ALL). However, using L-asparaginase derived from _Escherich | A synthetic hormone with anabolic and androgenic properties. | Moderate | 1 | [
[
[
1560,
24,
1026
]
],
[
[
1560,
24,
1546
],
[
1546,
1,
1026
]
],
[
[
1560,
24,
473
],
[
473,
63,
1026
]
],
[
[
1560,
24,
482
],
[
482,
24,
1026
]
],
[
[
1560,
63,
1685
],
[
1685,
24,
1026
]
],
[
[
1560,
25,
1510
],
[
1510,
64,
1026
]
],
[
[
1560,
24,
350
],
[
350,
64,
1026
]
],
[
[
1560,
24,
1546
],
[
1546,
40,
11326
],
[
11326,
1,
1026
]
],
[
[
1560,
24,
1197
],
[
1197,
1,
11326
],
[
11326,
1,
1026
]
],
[
[
1560,
24,
473
],
[
473,
24,
1546
],
[
1546,
1,
1026
]
]
] | [
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin human"
],
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carfilzomib"
],
[
"Carfilzomib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Allylestrenol"
],
[
"Allylestrenol",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Norethisterone"
],
[
"Norethisterone",
"{u} (Compound) resembles {v} (Compound)",
"Allylestrenol"
],
[
"Allylestrenol",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
],
[
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methyltestosterone"
],
[
"Methyltestosterone",
"{u} (Compound) resembles {v} (Compound)",
"Oxandrolone"
]
]
] | Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Oxandrolone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Insulin human and Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Oxandrolone
Pegaspargase may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may lead to a major life threatening interaction when taken with Oxandrolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Carfilzomib and Carfilzomib may lead to a major life threatening interaction when taken with Oxandrolone
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Allylestrenol (Compound) and Allylestrenol (Compound) resembles Oxandrolone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Norethisterone and Norethisterone (Compound) resembles Allylestrenol (Compound) and Allylestrenol (Compound) resembles Oxandrolone (Compound)
Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Methyltestosterone and Methyltestosterone (Compound) resembles Oxandrolone (Compound) |
DB00290 | DB08908 | 329 | 713 | [
"DDInter219",
"DDInter564"
] | Bleomycin | Dimethyl fumarate | A complex of related glycopeptide antibiotics from <i>Streptomyces verticillus</i> consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin. | Dimethyl fumarate is an agent indicated for the treatment of relapsing forms of multiple sclerosis.[A253942,L43752] The mechanism of action of dimethyl fumarate in multiple sclerosis is not well understood. It is thought to involve dimethyl fumarate degradation to its active metabolite monomethyl fumarate (MMF) then MMF up-regulates the Nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway that is activated in response to oxidative stress. Dimethyl fumarate is marketed under the brand name Tecfidera, and it was the third oral disease-modifying agent for multiple sclerosis approved by the FDA, following [fingolimod] and [teriflunomide]. Prior to its FDA approval, dimethyl fumarate had been used in Germany for treatment of psoriasis. | Moderate | 1 | [
[
[
329,
24,
713
]
],
[
[
329,
24,
4
],
[
4,
24,
713
]
],
[
[
329,
63,
552
],
[
552,
24,
713
]
],
[
[
329,
24,
270
],
[
270,
63,
713
]
],
[
[
329,
25,
770
],
[
770,
24,
713
]
],
[
[
329,
25,
976
],
[
976,
25,
713
]
],
[
[
329,
25,
779
],
[
779,
64,
713
]
],
[
[
329,
64,
1057
],
[
1057,
25,
713
]
],
[
[
329,
24,
287
],
[
287,
64,
713
]
],
[
[
329,
24,
4
],
[
4,
63,
1083
],
[
1083,
24,
713
]
]
] | [
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Carmustine"
],
[
"Carmustine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tofacitinib"
],
[
"Tofacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Smallpox (Vaccinia) Vaccine, Live"
],
[
"Smallpox (Vaccinia) Vaccine, Live",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diroximel fumarate"
],
[
"Diroximel fumarate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dimethyl fumarate"
]
],
[
[
"Bleomycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trifluridine"
],
[
"Trifluridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dimethyl fumarate"
]
]
] | Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Carmustine and Carmustine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bleomycin may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate
Bleomycin may lead to a major life threatening interaction when taken with Tofacitinib and Tofacitinib may lead to a major life threatening interaction when taken with Dimethyl fumarate
Bleomycin may lead to a major life threatening interaction when taken with Smallpox (Vaccinia) Vaccine, Live and Smallpox (Vaccinia) Vaccine, Live may lead to a major life threatening interaction when taken with Dimethyl fumarate
Bleomycin may lead to a major life threatening interaction when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Dimethyl fumarate
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Diroximel fumarate and Diroximel fumarate may lead to a major life threatening interaction when taken with Dimethyl fumarate
Bleomycin may cause a moderate interaction that could exacerbate diseases when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Trifluridine and Trifluridine may cause a moderate interaction that could exacerbate diseases when taken with Dimethyl fumarate |
DB00795 | DB01125 | 50 | 279 | [
"DDInter1725",
"DDInter98"
] | Sulfasalazine | Anisindione | Sulfasalazine is an anti-inflammatory drug structurally related to salicylates and other non-steroidal anti-inflammatory drugs. It is indicated for managing inflammatory diseases such as ulcerative colitis and rheumatoid arthritis (RA).[L39065, A255582] Metabolized by intestinal bacteria, sulfasalazine is broken down into [mesalazine] and [sulfapyridine], 2 compounds that carry out the main pharmacological activity of sulfasalazine. Sulfasalazine was first used in 1940 for rheumatic polyarthritis, and has been firmly established itself as one fo the most useful disease-modifying antirheumatic drug (DMARD). Compared to the first line treatment of RA like methotrexate, sulfasalazine is almost as efficacious as methotrexate although with slightly less tolerability. However, sulfasalazine has less teratogenic side effects and faster onset of action compared to conventional DMARD. Sulf | Anisindione is a synthetic anticoagulant and an indanedione derivative. Its anticoagulant action is mediated through the inhibition of the vitamin K-mediated gamma-carboxylation of precursor proteins that are critical in forming the formation of active procoagulation factors II, VII, IX, and X, as well as the anticoagulant proteins C and S, in the liver. | Major | 2 | [
[
[
50,
25,
279
]
],
[
[
50,
40,
712
],
[
712,
62,
279
]
],
[
[
50,
24,
913
],
[
913,
63,
279
]
],
[
[
50,
24,
328
],
[
328,
24,
279
]
],
[
[
50,
63,
912
],
[
912,
24,
279
]
],
[
[
50,
25,
1510
],
[
1510,
63,
279
]
],
[
[
50,
25,
1377
],
[
1377,
24,
279
]
],
[
[
50,
24,
848
],
[
848,
25,
279
]
],
[
[
50,
63,
1512
],
[
1512,
25,
279
]
],
[
[
50,
63,
1274
],
[
1274,
37,
279
]
]
] | [
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} (Compound) resembles {v} (Compound)",
"Olsalazine"
],
[
"Olsalazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mercaptopurine"
],
[
"Mercaptopurine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Interferon beta-1a"
],
[
"Interferon beta-1a",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Teriflunomide"
],
[
"Teriflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Diclofenac"
],
[
"Diclofenac",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
],
[
[
"Sulfasalazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Anisindione"
]
]
] | Sulfasalazine (Compound) resembles Olsalazine (Compound) and Olsalazine may cause a minor interaction that can limit clinical effects when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Mercaptopurine and Mercaptopurine may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Interferon beta-1a and Interferon beta-1a may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sulfasalazine may lead to a major life threatening interaction when taken with Teriflunomide and Teriflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sulfasalazine may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may cause a moderate interaction that could exacerbate diseases when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Ibuprofen and Ibuprofen may lead to a major life threatening interaction when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Diclofenac and Diclofenac may lead to a major life threatening interaction when taken with Anisindione
Sulfasalazine may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Anisindione and Flurbiprofen may lead to a major life threatening interaction when taken with Anisindione |
DB00014 | DB08865 | 521 | 1,593 | [
"DDInter839",
"DDInter448"
] | Goserelin | Crizotinib | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements. | Major | 2 | [
[
[
521,
25,
1593
]
],
[
[
521,
21,
29093
],
[
29093,
60,
1593
]
],
[
[
521,
24,
479
],
[
479,
23,
1593
]
],
[
[
521,
23,
1247
],
[
1247,
23,
1593
]
],
[
[
521,
24,
286
],
[
286,
63,
1593
]
],
[
[
521,
24,
898
],
[
898,
24,
1593
]
],
[
[
521,
23,
112
],
[
112,
24,
1593
]
],
[
[
521,
24,
1181
],
[
1181,
25,
1593
]
],
[
[
521,
25,
684
],
[
684,
25,
1593
]
],
[
[
521,
24,
36
],
[
36,
64,
1593
]
]
] | [
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Donepezil"
],
[
"Donepezil",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sulfamethoxazole"
],
[
"Sulfamethoxazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Propofol"
],
[
"Propofol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Eribulin"
],
[
"Eribulin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
]
]
] | Goserelin (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Crizotinib (Compound)
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Donepezil and Donepezil may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Goserelin may cause a minor interaction that can limit clinical effects when taken with Sulfamethoxazole and Sulfamethoxazole may cause a minor interaction that can limit clinical effects when taken with Crizotinib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Propofol and Propofol may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Goserelin may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Terfenadine and Terfenadine may lead to a major life threatening interaction when taken with Crizotinib
Goserelin may lead to a major life threatening interaction when taken with Thioridazine and Thioridazine may lead to a major life threatening interaction when taken with Crizotinib
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Eribulin and Eribulin may lead to a major life threatening interaction when taken with Crizotinib |
DB08816 | DB08886 | 578 | 637 | [
"DDInter1802",
"DDInter126"
] | Ticagrelor | Asparaginase Erwinia chrysanthemi | Ticagrelor, or AZD6140, was first described in the literature in 2003.[A204170,A2903] Ticagrelor is an ADP derivative developed for its P2Y<sub>12</sub> receptor antagonism. Unlike [clopidogrel], ticagrelor is not a prodrug. It is marketed by Astra Zeneca as Brilinta in the US and Brilique or Possia in the EU,. Ticagrelor was granted EMA approval on 3 December 2010. Ticagrelor was granted FDA approval on 20 July 2011. | Asparaginase _Erwinia chrysanthemi_ is an asparaginase-specific enzyme derived from _Erwinia_ _chrysanthemi_ used as an anticancer agent. It works by depleting the stores of an important amino acid called asparagine, which is involved in DNA synthesis and cell survival of malignant cells, leading to cell death. L-asparaginase was first identified in 1963, and there are different formulations of L-asparaginase, including [Asparaginase Escherichia coli] and a pegylated form of this enzyme, [Pegaspargase]. Asparaginase _Erwinia chrysanthemi_ and [Asparaginase Escherichia coli] differ in their pharmacokinetic and immunogenic profiles; thus, those who are allergic to [Asparaginase Escherichia coli] do not cross-react to Asparaginase _Erwinia chrysanthemi_. Studies show that substitution of _Erwinia_ asparaginase for _E. coli_-derived asparaginase following an allergic reaction has been safe and effective. Asparaginase _Erwinia chrysanthemi_ was first approved by the FDA in November 2011 to treat patients with acute lymphoblastic leukemia (ALL) who are allergic to _E. coli_-derived asparaginase: it has been used as part of multi-agent chemotherapy. In June 2021, the recombinant form of asparaginase _Erwinia chrysanthemi_ was approved by the FDA as a component of a chemotherapy regimen to treat acute lymphoblastic leukemia and lymphoblastic lymphoma in adult and pediatric patients who are allergic to the _E. coli_-derived asparaginase. | Moderate | 1 | [
[
[
578,
24,
637
]
],
[
[
578,
63,
1479
],
[
1479,
24,
637
]
],
[
[
578,
25,
1421
],
[
1421,
63,
637
]
],
[
[
578,
24,
159
],
[
159,
63,
637
]
],
[
[
578,
64,
1047
],
[
1047,
24,
637
]
],
[
[
578,
24,
1593
],
[
1593,
24,
637
]
],
[
[
578,
63,
1101
],
[
1101,
25,
637
]
],
[
[
578,
63,
1479
],
[
1479,
63,
167
],
[
167,
24,
637
]
],
[
[
578,
63,
1274
],
[
1274,
24,
167
],
[
167,
24,
637
]
],
[
[
578,
25,
1421
],
[
1421,
64,
392
],
[
392,
24,
637
]
]
] | [
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
],
[
"Trastuzumab emtansine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Acetylsalicylic acid"
],
[
"Acetylsalicylic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
],
[
[
"Ticagrelor",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Betrixaban"
],
[
"Betrixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lapatinib"
],
[
"Lapatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Asparaginase Erwinia chrysanthemi"
]
]
] | Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may lead to a major life threatening interaction when taken with Trastuzumab emtansine and Trastuzumab emtansine may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Bexarotene and Bexarotene may lead to a major life threatening interaction when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Acetylsalicylic acid and Acetylsalicylic acid may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi
Ticagrelor may lead to a major life threatening interaction when taken with Betrixaban and Betrixaban may lead to a major life threatening interaction when taken with Lapatinib and Lapatinib may cause a moderate interaction that could exacerbate diseases when taken with Asparaginase Erwinia chrysanthemi |
DB01319 | DB06176 | 34 | 1,342 | [
"DDInter777",
"DDInter1616"
] | Fosamprenavir | Romidepsin | Fosamprenavir is a prodrug of amprenavir, an inhibitor of human immunodeficiency virus (HIV) protease. | Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) in patients who have received at least one prior systemic therapy. | Moderate | 1 | [
[
[
34,
24,
1342
]
],
[
[
34,
24,
1491
],
[
1491,
63,
1342
]
],
[
[
34,
25,
1478
],
[
1478,
63,
1342
]
],
[
[
34,
64,
1557
],
[
1557,
24,
1342
]
],
[
[
34,
63,
1559
],
[
1559,
24,
1342
]
],
[
[
34,
1,
1091
],
[
1091,
24,
1342
]
],
[
[
34,
62,
609
],
[
609,
24,
1342
]
],
[
[
34,
23,
1374
],
[
1374,
24,
1342
]
],
[
[
34,
64,
1493
],
[
1493,
25,
1342
]
],
[
[
34,
25,
985
],
[
985,
64,
1342
]
]
] | [
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Midostaurin"
],
[
"Midostaurin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivacaftor"
],
[
"Ivacaftor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Astemizole"
],
[
"Astemizole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} (Compound) resembles {v} (Compound)",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
],
[
[
"Fosamprenavir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Romidepsin"
]
]
] | Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Midostaurin and Midostaurin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may lead to a major life threatening interaction when taken with Ivacaftor and Ivacaftor may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may lead to a major life threatening interaction when taken with Astemizole and Astemizole may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir (Compound) resembles Amprenavir (Compound) and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Clarithromycin and Clarithromycin may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may cause a minor interaction that can limit clinical effects when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin
Fosamprenavir may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Romidepsin
Fosamprenavir may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Romidepsin |
DB00911 | DB12332 | 458 | 1,619 | [
"DDInter1811",
"DDInter1626"
] | Tinidazole | Rucaparib | A nitroimidazole antitrichomonal agent effective against _Trichomonas vaginalis_, _Entamoeba histolytica_, and _Giardia lamblia_ infections. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
458,
24,
1619
]
],
[
[
458,
40,
112
],
[
112,
23,
1619
]
],
[
[
458,
24,
309
],
[
309,
24,
1619
]
],
[
[
458,
63,
1438
],
[
1438,
24,
1619
]
],
[
[
458,
24,
159
],
[
159,
63,
1619
]
],
[
[
458,
64,
1091
],
[
1091,
24,
1619
]
],
[
[
458,
24,
1593
],
[
1593,
25,
1619
]
],
[
[
458,
24,
1339
],
[
1339,
64,
1619
]
],
[
[
458,
63,
581
],
[
581,
25,
1619
]
],
[
[
458,
40,
112
],
[
112,
62,
87
],
[
87,
24,
1619
]
]
] | [
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ixabepilone"
],
[
"Ixabepilone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Estradiol"
],
[
"Estradiol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Larotrectinib"
],
[
"Larotrectinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Amprenavir"
],
[
"Amprenavir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Berotralstat"
],
[
"Berotralstat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Tinidazole",
"{u} (Compound) resembles {v} (Compound)",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
]
] | Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Ixabepilone and Ixabepilone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Estradiol and Estradiol may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Larotrectinib and Larotrectinib may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Tinidazole may lead to a major life threatening interaction when taken with Amprenavir and Amprenavir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib and Crizotinib may lead to a major life threatening interaction when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Berotralstat and Berotralstat may lead to a major life threatening interaction when taken with Rucaparib
Tinidazole may cause a moderate interaction that could exacerbate diseases when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Rucaparib
Tinidazole (Compound) resembles Metronidazole (Compound) and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Amoxapine and Amoxapine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib |
DB00615 | DB08899 | 690 | 129 | [
"DDInter1589",
"DDInter649"
] | Rifabutin | Enzalutamide | A broad-spectrum antibiotic that is being used as prophylaxis against disseminated Mycobacterium avium complex infection in HIV-positive patients. | Enzalutamide is an androgen receptor (AR) inhibitor for the treatment of castration-resistant prostate cancer (CRPC), both metastatic and non-metastatic. It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.[L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant prostate cancer. Until recently, docetaxel is the only treatment available for metastatic CRPC; however, AR inhibitors have been developed for more targeted therapy, although first-generation AR inhibitors like bicalutamide did not substantially increase the survival rate. Second-generation such as enzalutamide is more efficacious due to a higher affinity to AR and no partial agonist activity compared to bicalutamide.[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. Compared to the average time of 10 to 15 years for a drug to go from pre-clinical to clinical studies, enzalutamide was developed relatively rapidly. | Moderate | 1 | [
[
[
690,
24,
129
]
],
[
[
690,
6,
8374
],
[
8374,
45,
129
]
],
[
[
690,
21,
28703
],
[
28703,
60,
129
]
],
[
[
690,
24,
112
],
[
112,
23,
129
]
],
[
[
690,
62,
608
],
[
608,
23,
129
]
],
[
[
690,
63,
79
],
[
79,
24,
129
]
],
[
[
690,
24,
1320
],
[
1320,
63,
129
]
],
[
[
690,
24,
959
],
[
959,
24,
129
]
],
[
[
690,
62,
1101
],
[
1101,
24,
129
]
],
[
[
690,
1,
1088
],
[
1088,
24,
129
]
]
] | [
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sorafenib"
],
[
"Sorafenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Elagolix"
],
[
"Elagolix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bexarotene"
],
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
],
[
[
"Rifabutin",
"{u} (Compound) resembles {v} (Compound)",
"Rifaximin"
],
[
"Rifaximin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Enzalutamide"
]
]
] | Rifabutin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Enzalutamide (Compound)
Rifabutin (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Enzalutamide (Compound)
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Lidocaine and Lidocaine may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Sorafenib and Sorafenib may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Elagolix and Elagolix may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rifabutin may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rifabutin may cause a minor interaction that can limit clinical effects when taken with Bexarotene and Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide
Rifabutin (Compound) resembles Rifaximin (Compound) and Rifaximin may cause a moderate interaction that could exacerbate diseases when taken with Enzalutamide |
DB00307 | DB01263 | 1,101 | 859 | [
"DDInter202",
"DDInter1494"
] | Bexarotene | Posaconazole | Bexarotene (Targretin) is an antineoplastic agent indicated by the FDA for Cutaneous T cell lymphoma. It has been used off-label for lung cancer, breast cancer, and Kaposi's sarcoma. | Posaconazole is a triazole antifungal drug that is used to treat invasive infections by Candida species and Aspergillus species in severely immunocompromised patients. | Minor | 0 | [
[
[
1101,
23,
859
]
],
[
[
1101,
6,
8374
],
[
8374,
45,
859
]
],
[
[
1101,
21,
29102
],
[
29102,
60,
859
]
],
[
[
1101,
24,
482
],
[
482,
24,
859
]
],
[
[
1101,
24,
850
],
[
850,
63,
859
]
],
[
[
1101,
25,
303
],
[
303,
24,
859
]
],
[
[
1101,
23,
760
],
[
760,
63,
859
]
],
[
[
1101,
23,
1419
],
[
1419,
24,
859
]
],
[
[
1101,
25,
1151
],
[
1151,
63,
859
]
],
[
[
1101,
62,
600
],
[
600,
24,
859
]
]
] | [
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} (Compound) causes {v} (Side Effect)",
"Kidney function abnormal"
],
[
"Kidney function abnormal",
"{u} (Side Effect) is caused by {v} (Compound)",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Medroxyprogesterone acetate"
],
[
"Medroxyprogesterone acetate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Imatinib"
],
[
"Imatinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
],
[
[
"Bexarotene",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Posaconazole"
]
]
] | Bexarotene (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Posaconazole (Compound)
Bexarotene (Compound) causes Kidney function abnormal (Side Effect) and Kidney function abnormal (Side Effect) is caused by Posaconazole (Compound)
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may cause a moderate interaction that could exacerbate diseases when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may lead to a major life threatening interaction when taken with Medroxyprogesterone acetate and Medroxyprogesterone acetate may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Cobicistat and Cobicistat may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Imatinib and Imatinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may lead to a major life threatening interaction when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole
Bexarotene may cause a minor interaction that can limit clinical effects when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Posaconazole |
DB00595 | DB14730 | 1,545 | 1,412 | [
"DDInter1374",
"DDInter264"
] | Oxytetracycline | Calaspargase pegol | A tetracycline analog isolated from the actinomycete streptomyces rimosus and used in a wide variety of clinical conditions. | Asparaginase is an important agent used to treat acute lymphoblastic leukemia (ALL) . Asparagine is incorporated into most proteins, and the synthesis of proteins is stopped when asparagine is absent, which inhibits RNA and DNA synthesis, resulting in a halt in cellular proliferation. This forms the basis of asparaginase treatment in ALL , , . Calaspargase pegol, also known as _asparlas_, is an asparagine specific enzyme which is indicated as a part of a multi-agent chemotherapy regimen for the treatment of ALL . The asparagine specific enzyme is derived from Escherichia coli, as a conjugate of L-asparaginase (L-asparagine amidohydrolase) and monomethoxypolyethylene glycol (mPEG) with a succinimidyl carbonate (SC) linker to create a stable molecule which increases the half-life and decreases the dosing frequency [FDA label], . Calaspargase pegol, by _Shire_ pharmaceuticals, was approved by the FDA on December 20, 2018 for acute lymphoblastic anemia (ALL) . | Moderate | 1 | [
[
[
1545,
24,
1412
]
],
[
[
1545,
64,
640
],
[
640,
24,
1412
]
],
[
[
1545,
24,
126
],
[
126,
24,
1412
]
],
[
[
1545,
40,
1572
],
[
1572,
24,
1412
]
],
[
[
1545,
63,
663
],
[
663,
24,
1412
]
],
[
[
1545,
25,
1517
],
[
1517,
24,
1412
]
],
[
[
1545,
64,
640
],
[
640,
63,
322
],
[
322,
24,
1412
]
],
[
[
1545,
24,
126
],
[
126,
25,
792
],
[
792,
24,
1412
]
],
[
[
1545,
40,
1572
],
[
1572,
64,
640
],
[
640,
24,
1412
]
],
[
[
1545,
63,
663
],
[
663,
24,
250
],
[
250,
24,
1412
]
]
] | [
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Isotretinoin"
],
[
"Isotretinoin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Epirubicin"
],
[
"Epirubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} (Compound) resembles {v} (Compound)",
"Demeclocycline"
],
[
"Demeclocycline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Acitretin"
],
[
"Acitretin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
],
[
[
"Oxytetracycline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methotrexate"
],
[
"Methotrexate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Blinatumomab"
],
[
"Blinatumomab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Calaspargase pegol"
]
]
] | Oxytetracycline may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may lead to a major life threatening interaction when taken with Isotretinoin and Isotretinoin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Epirubicin and Epirubicin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin may lead to a major life threatening interaction when taken with Rivaroxaban and Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline (Compound) resembles Demeclocycline (Compound) and Demeclocycline may lead to a major life threatening interaction when taken with Acitretin and Acitretin may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Oxytetracycline may cause a moderate interaction that could exacerbate diseases when taken with Methotrexate and Methotrexate may cause a moderate interaction that could exacerbate diseases when taken with Blinatumomab and Blinatumomab may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol |
DB09472 | DB12332 | 1,383 | 1,619 | [
"DDInter1693",
"DDInter1626"
] | Sodium sulfate | Rucaparib | Sodium Sulfate Anhydrous is the anhydrous, sodium salt form of sulfuric acid. Sodium sulfate anhydrous disassociates in water to provide sodium ions and sulfate ions. Sodium ion is the principal cation of the extracellular fluid and plays a large part in the therapy of fluid and electrolyte disturbances. Sodium sulfate anhydrous is an electrolyte replenisher and is used in isosmotic solutions so that administration does not disturb normal electrolyte balance and does not lead to absorption or excretion of water and ions. | Rucaparib is an anticancer drug and poly (ADP-ribose) polymerase (PARP) inhibitor. PARP is an enzyme that plays an essential role in DNA repair. Rucaparib is proposed to work in several PARP-dependent and PARP-independent mechanisms of action; however, it causes a unique effect of synthetic lethality. By targeting the genetically-mutated cancer cells that lack a DNA repair mechanism, rucaparib causes cancer cell death and reduces tumour growth.[A18745,A31354] Rucaparib was granted FDA Breakthrough Therapy designation in April 2015 and accelerated approval in December 2016. The drug was later approved by the European Commission in May 2018. It is currently used to treat recurrent ovarian and prostate cancer in adults.[L42155,L42185] | Moderate | 1 | [
[
[
1383,
24,
1619
]
],
[
[
1383,
63,
222
],
[
222,
23,
1619
]
],
[
[
1383,
63,
154
],
[
154,
24,
1619
]
],
[
[
1383,
24,
823
],
[
823,
24,
1619
]
],
[
[
1383,
64,
1181
],
[
1181,
24,
1619
]
],
[
[
1383,
24,
180
],
[
180,
63,
1619
]
],
[
[
1383,
64,
1166
],
[
1166,
25,
1619
]
],
[
[
1383,
63,
876
],
[
876,
25,
1619
]
],
[
[
1383,
24,
351
],
[
351,
25,
1619
]
],
[
[
1383,
24,
982
],
[
982,
64,
1619
]
]
] | [
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lurasidone"
],
[
"Lurasidone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triclabendazole"
],
[
"Triclabendazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Terfenadine"
],
[
"Terfenadine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oliceridine"
],
[
"Oliceridine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tizanidine"
],
[
"Tizanidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
],
[
[
"Sodium sulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Rucaparib"
]
]
] | Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine and Sibutramine may cause a minor interaction that can limit clinical effects when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Lurasidone and Lurasidone may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Triclabendazole and Triclabendazole may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sodium sulfate may lead to a major life threatening interaction when taken with Terfenadine and Terfenadine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Oliceridine and Oliceridine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib
Sodium sulfate may lead to a major life threatening interaction when taken with Dolasetron and Dolasetron may lead to a major life threatening interaction when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Tizanidine and Tizanidine may lead to a major life threatening interaction when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Rucaparib
Sodium sulfate may cause a moderate interaction that could exacerbate diseases when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Rucaparib |
DB01177 | DB05273 | 77 | 507 | [
"DDInter904",
"DDInter1638"
] | Idarubicin | Samarium (153Sm) lexidronam | An orally administered anthracycline antineoplastic. The compound has shown activity against breast cancer, lymphomas and leukemias, together with the potential for reduced cardiac toxicity. | Samarium Sm 153 lexidronam is a radioactive medication used to treat pain caused by cancer that has spread to the bone. It is a radiopharmaceutical. Radiopharmaceuticals are radioactive agents that may be used to diagnose some diseases by studying the function of the body's organs or to treat certain diseases.Samarium Sm 153 lexidronam is used to help relieve the bone pain that may occur with certain kinds of cancer. The radioactive samarium is taken up in the bone cancer area and gives off radiation that helps provide relief of pain. | Major | 2 | [
[
[
77,
25,
507
]
],
[
[
77,
63,
789
],
[
789,
24,
507
]
],
[
[
77,
24,
248
],
[
248,
24,
507
]
],
[
[
77,
24,
270
],
[
270,
63,
507
]
],
[
[
77,
63,
970
],
[
970,
25,
507
]
],
[
[
77,
25,
39
],
[
39,
64,
507
]
],
[
[
77,
24,
1468
],
[
1468,
64,
507
]
],
[
[
77,
64,
1064
],
[
1064,
25,
507
]
],
[
[
77,
24,
1532
],
[
1532,
25,
507
]
],
[
[
77,
25,
478
],
[
478,
25,
507
]
]
] | [
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Foscarnet"
],
[
"Foscarnet",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ocrelizumab"
],
[
"Ocrelizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ponatinib"
],
[
"Ponatinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cladribine"
],
[
"Cladribine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
],
[
[
"Idarubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Samarium (153Sm) lexidronam"
]
]
] | Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Foscarnet and Foscarnet may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Valganciclovir and Valganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ocrelizumab and Ocrelizumab may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Fluorouracil and Fluorouracil may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Idarubicin may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib and Ponatinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Idarubicin may lead to a major life threatening interaction when taken with Cladribine and Cladribine may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Ifosfamide and Ifosfamide may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam
Idarubicin may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may lead to a major life threatening interaction when taken with Samarium (153Sm) lexidronam |
DB00014 | DB13139 | 521 | 1,032 | [
"DDInter839",
"DDInter1063"
] | Goserelin | Levosalbutamol | Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal. | Levosalbutamol, or levalbuterol, is a short-acting β2 adrenergic receptor agonist used in the treatment of asthma and chronic obstructive pulmonary disease (COPD). [Salbutamol] has been marketed as a racemic mixture, although beta2-agonist activity resides almost exclusively in the (R)-enantiomer. The enantioselective disposition of salbutamol and the possibility that (S)-salbutamol has adverse effects have led to the development of an enantiomerically pure (R)-salbutamol formulation known as levosalbutamol (levalbuterol). | Moderate | 1 | [
[
[
521,
24,
1032
]
],
[
[
521,
25,
1618
],
[
1618,
24,
1032
]
],
[
[
521,
24,
124
],
[
124,
24,
1032
]
],
[
[
521,
25,
982
],
[
982,
63,
1032
]
],
[
[
521,
1,
774
],
[
774,
24,
1032
]
],
[
[
521,
25,
351
],
[
351,
25,
1032
]
],
[
[
521,
25,
1618
],
[
1618,
63,
1220
],
[
1220,
23,
1032
]
],
[
[
521,
24,
124
],
[
124,
64,
1220
],
[
1220,
23,
1032
]
],
[
[
521,
25,
982
],
[
982,
64,
1618
],
[
1618,
24,
1032
]
],
[
[
521,
24,
1133
],
[
1133,
25,
1618
],
[
1618,
24,
1032
]
]
] | [
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} (Compound) resembles {v} (Compound)",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ribociclib"
],
[
"Ribociclib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glasdegib"
],
[
"Glasdegib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivosidenib"
],
[
"Ivosidenib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
],
[
[
"Goserelin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Granisetron"
],
[
"Granisetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cabozantinib"
],
[
"Cabozantinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
]
]
] | Goserelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Goserelin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Goserelin (Compound) resembles Degarelix (Compound) and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Goserelin may lead to a major life threatening interaction when taken with Ribociclib and Ribociclib may lead to a major life threatening interaction when taken with Levosalbutamol
Goserelin may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Glasdegib and Glasdegib may lead to a major life threatening interaction when taken with Dexamethasone and Dexamethasone may cause a minor interaction that can limit clinical effects when taken with Levosalbutamol
Goserelin may lead to a major life threatening interaction when taken with Ivosidenib and Ivosidenib may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol
Goserelin may cause a moderate interaction that could exacerbate diseases when taken with Granisetron and Granisetron may lead to a major life threatening interaction when taken with Cabozantinib and Cabozantinib may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol |
DB04948 | DB06616 | 1,084 | 594 | [
"DDInter1083",
"DDInter224"
] | Lofexidine | Bosutinib | Lofexidine is a non-opioid centrally acting alpha2-adrenergic receptor agonist that was first approved for the treatment of opioid withdrawal in the United Kingdom in 1992. It was first studied for use as an antihypertensive in 1980, but its researched was stopped as it was found less effective for the treatment of hypertension than clonidine. Lofexidine was then repurposed for the treatment of opioid withdrawal, as it was seen to be more economical and have fewer side effects than clonidine. Lofexidine was developed by US Woldmeds LLC and it was approved by the FDA on May 16, 2018. | Bosutinib is a 7-alkoxy-3-quinolinecarbonitrile that functions as a potent, dual SRC and ABL tyrosine kinase inhibitor indicated for chronic myelogenous leukemia (CML), specifically Philadelphia chromosome-positive (Ph+) CML. Philadelphia chromosome is a hallmark of CML due to the reciprocal translocation t(9;22)(q34;q11), resulting in a BCR-ABL fusion protein.[A6902,A261796,A261801] The first BCR-ABL inhibitor, [imatinib], was introduced over a decade ago as a breakthrough in CML management; however, emerging resistance to [imatinib] poses challenges in achieving remission. Second-generation BCR-ABL inhibitors like bosutinib inhibit most resistance-conferring BCR-ABL mutations except V299L and T315, thus providing more therapeutic options for patients.[A6901,A17961] Bosutinib was first approved by the FDA in 2012 for the treatment of adult chronic, accelerated, or blast-phase Ph+ CML with resistance or intolerance to prior therapy. On September 26, 2023, bosutinib was also approved by the FDA for the treatment of pediatric CML that is newly diagnosed or resistant/intolerant to prior therapy. This approval was based on favorable results obtained from the open-label, randomized, multicenter trial BFORE that showed a significant improvement in major molecular response, defined as a ≤0.1% BCR ABL ratio on an international scale, with bosutinib treatment. | Moderate | 1 | [
[
[
1084,
24,
594
]
],
[
[
1084,
62,
112
],
[
112,
23,
594
]
],
[
[
1084,
63,
1559
],
[
1559,
24,
594
]
],
[
[
1084,
24,
1374
],
[
1374,
24,
594
]
],
[
[
1084,
24,
774
],
[
774,
63,
594
]
],
[
[
1084,
64,
478
],
[
478,
24,
594
]
],
[
[
1084,
25,
985
],
[
985,
64,
594
]
],
[
[
1084,
64,
1493
],
[
1493,
25,
594
]
],
[
[
1084,
25,
39
],
[
39,
25,
594
]
],
[
[
1084,
24,
913
],
[
913,
64,
594
]
]
] | [
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Metronidazole"
],
[
"Metronidazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Famotidine"
],
[
"Famotidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Abiraterone"
],
[
"Abiraterone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Degarelix"
],
[
"Degarelix",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Nilotinib"
],
[
"Nilotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
],
[
[
"Lofexidine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apalutamide"
],
[
"Apalutamide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Bosutinib"
]
]
] | Lofexidine may cause a minor interaction that can limit clinical effects when taken with Metronidazole and Metronidazole may cause a minor interaction that can limit clinical effects when taken with Bosutinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Famotidine and Famotidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Abiraterone and Abiraterone may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Degarelix and Degarelix may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lofexidine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Lofexidine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may lead to a major life threatening interaction when taken with Bosutinib
Lofexidine may lead to a major life threatening interaction when taken with Halofantrine and Halofantrine may lead to a major life threatening interaction when taken with Bosutinib
Lofexidine may lead to a major life threatening interaction when taken with Panobinostat and Panobinostat may lead to a major life threatening interaction when taken with Bosutinib
Lofexidine may cause a moderate interaction that could exacerbate diseases when taken with Apalutamide and Apalutamide may lead to a major life threatening interaction when taken with Bosutinib |
DB01004 | DB11760 | 563 | 119 | [
"DDInter806",
"DDInter1742"
] | Ganciclovir | Talazoparib | An acyclovir analog that is a potent inhibitor of the Herpesvirus family including cytomegalovirus. Ganciclovir is used to treat complications from AIDS-associated cytomegalovirus infections. | Talazoparib is an inhibitor of mammalian polyadenosine 5’-diphosphoribose polymerases (PARPs), enzymes responsible for regulating essential cellular functions, such as DNA transcription and DNA repair. Developed by Pfizer, talazoparib was first approved by the FDA in October 2018 and by the EMA in June 2019. It was approved by Health Canada in September 2020. Talazoparib is currently used in the treatment of BRCA-mutated breast cancer and HRR-mutated prostate cancer.[L47236, L47301, L47306] | Moderate | 1 | [
[
[
563,
24,
119
]
],
[
[
563,
63,
599
],
[
599,
24,
119
]
],
[
[
563,
24,
985
],
[
985,
24,
119
]
],
[
[
563,
1,
248
],
[
248,
24,
119
]
],
[
[
563,
24,
1619
],
[
1619,
63,
119
]
],
[
[
563,
24,
507
],
[
507,
25,
119
]
],
[
[
563,
25,
1292
],
[
1292,
25,
119
]
],
[
[
563,
64,
581
],
[
581,
25,
119
]
],
[
[
563,
24,
676
],
[
676,
64,
119
]
],
[
[
563,
63,
599
],
[
599,
24,
66
],
[
66,
24,
119
]
]
] | [
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Osimertinib"
],
[
"Osimertinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} (Compound) resembles {v} (Compound)",
"Valganciclovir"
],
[
"Valganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Rucaparib"
],
[
"Rucaparib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Samarium (153Sm) lexidronam"
],
[
"Samarium (153Sm) lexidronam",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Deferiprone"
],
[
"Deferiprone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Infliximab"
],
[
"Infliximab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Talazoparib"
]
],
[
[
"Ganciclovir",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alemtuzumab"
],
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Talazoparib"
]
]
] | Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ganciclovir (Compound) resembles Valganciclovir (Compound) and Val
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Samarium (153Sm) lexidronam and Samarium (153Sm) lexidronam may lead to a major life threatening interaction when taken with Talazoparib
Ganciclovir may lead to a major life threatening interaction when taken with Deferiprone and Deferiprone may lead to a major life threatening interaction when taken with Talazoparib
Ganciclovir may lead to a major life threatening interaction when taken with Infliximab and Infliximab may lead to a major life threatening interaction when taken with Talazoparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Talazoparib
Ganciclovir may cause a moderate interaction that could exacerbate diseases when taken with Alemtuzumab and Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Talazoparib |
DB00030 | DB01105 | 1,685 | 222 | [
"DDInter934",
"DDInter1665"
] | Insulin human | Sibutramine | Human Insulin, also known as Regular Insulin, is a short-acting form of insulin used for the treatment of hyperglycemia caused by Type 1 and Type 2 Diabetes. Human insulin is produced by recombinant DNA technology and is identical to endogenously produced insulin. Typically prescribed for the management of diabetes mellitus, insulin is a peptide hormone produced by beta cells of the pancreas that promotes glucose metabolism. Insulin is released from the pancreas following a meal to promote the uptake of glucose from the blood into internal organs and tissues such as the liver, fat cells, and skeletal muscle. Absorption of glucose into cells allows for its transformation into glycogen or fat for storage. Insulin also inhibits hepatic glucose production, enhances protein synthesis, and inhibits lipolysis and proteolysis among many other functions. Insulin is an important treatment in the management of Type 1 Diabetes (T1D) which is caused by an autoimmune reaction that destroys | Sibutramine (trade name Meridia in the USA, Reductil in Europe and other countries), usually as sibutramide hydrochloride monohydrate, is an orally administered agent for the treatment of obesity. It is a centrally acting stimulant chemically related to amphetamines thus it is classified as a Schedule IV controlled substance in the United States. In October 2010, Sibutramine was withdrawn from Canadian and U.S. markets due to concerns that the drug increases the risk of heart attack and stroke in patients with a history of heart disease. | Moderate | 1 | [
[
[
1685,
24,
222
]
],
[
[
1685,
24,
215
],
[
215,
23,
222
]
],
[
[
1685,
24,
984
],
[
984,
62,
222
]
],
[
[
1685,
24,
1680
],
[
1680,
24,
222
]
],
[
[
1685,
24,
549
],
[
549,
63,
222
]
],
[
[
1685,
24,
73
],
[
73,
25,
222
]
],
[
[
1685,
24,
1529
],
[
1529,
64,
222
]
],
[
[
1685,
24,
215
],
[
215,
6,
8374
],
[
8374,
45,
222
]
],
[
[
1685,
24,
1680
],
[
1680,
21,
29209
],
[
29209,
60,
222
]
],
[
[
1685,
24,
1241
],
[
1241,
64,
384
],
[
384,
62,
222
]
]
] | [
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Danazol"
],
[
"Danazol",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Indinavir"
],
[
"Indinavir",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sibutramine"
]
],
[
[
"Insulin human",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Brexpiprazole"
],
[
"Brexpiprazole",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
]
]
] | Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Danazol and Danazol may cause a minor interaction that can limit clinical effects when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Dapagliflozin and Dapagliflozin may cause a moderate interaction that could exacerbate diseases when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Metamfetamine and Metamfetamine may lead to a major life threatening interaction when taken with Sibutramine
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Indinavir and Indinavir (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sibutramine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Etacrynic acid and Etacrynic acid (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Sibutramine (Compound)
Insulin human may cause a moderate interaction that could exacerbate diseases when taken with Brexpiprazole and Brexpiprazole may lead to a major life threatening interaction when taken with Idelalisib and Idelalisib may cause a minor interaction that can limit clinical effects when taken with Sibutramine |
DB00222 | DB00959 | 245 | 1,486 | [
"DDInter825",
"DDInter1191"
] | Glimepiride | Methylprednisolone | First introduced in 1995, glimepiride is a member of the second-generation sulfonylurea (SU) drug class used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control. Type 2 diabetes is a metabolic disorder with increasing prevalences worldwide; it is characterized by insulin resistance in accordance with progressive β cell failure and long-term microvascular and macrovascular complications that lead to co-morbidities and mortalities. Sulfonylureas are one of the insulin secretagogues widely used for the management of type 2 diabetes to lower blood glucose levels. The main effect of SUs is thought to be effective when residual pancreatic β-cells are present, as they work by stimulating the release of insulin from the pancreatic beta cells and they are also thought to exert extra-pancreatic effects, such as increasing the insulin-mediated peripheral glucose uptake. Glimepiride works by stimulating the secretion of insulin granules from | Methylprednisolone is a [prednisolone] derivative glucocorticoid with higher potency than [prednisone]. It was first described in the literature in the late 1950s.[A188811,A188814] Methylprednisolone was granted FDA approval on 24 October 1957. In the outbreak of COVID-19, low dose methylprednisolone-based therapy was successful in treating COVID-19-associated pneumonia in one patient with long-term immunosuppression. The efficacy of methylprednisolone in novel coronavirus pneumonia is being investigated further in clinical trials. | Moderate | 1 | [
[
[
245,
24,
1486
]
],
[
[
245,
24,
175
],
[
175,
40,
1486
]
],
[
[
245,
24,
167
],
[
167,
1,
1486
]
],
[
[
245,
21,
28714
],
[
28714,
60,
1486
]
],
[
[
245,
24,
1072
],
[
1072,
23,
1486
]
],
[
[
245,
24,
115
],
[
115,
62,
1486
]
],
[
[
245,
24,
494
],
[
494,
24,
1486
]
],
[
[
245,
24,
890
],
[
890,
63,
1486
]
],
[
[
245,
64,
600
],
[
600,
24,
1486
]
],
[
[
245,
63,
1560
],
[
1560,
24,
1486
]
]
] | [
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Triamcinolone"
],
[
"Triamcinolone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydrocortisone"
],
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} (Compound) causes {v} (Side Effect)",
"Asthenia"
],
[
"Asthenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoniazid"
],
[
"Isoniazid",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Aluminum hydroxide"
],
[
"Aluminum hydroxide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Mestranol"
],
[
"Mestranol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
],
[
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pegaspargase"
],
[
"Pegaspargase",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
]
]
] | Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Triamcinolone and Triamcinolone (Compound) resembles Methylprednisolone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydrocortisone and Hydrocortisone (Compound) resembles Methylprednisolone (Compound)
Glimepiride (Compound) causes Asthenia (Side Effect) and Asthenia (Side Effect) is caused by Methylprednisolone (Compound)
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Isoniazid and Isoniazid may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Aluminum hydroxide and Aluminum hydroxide may cause a minor interaction that can limit clinical effects when taken with Methylprednisolone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Disopyramide and Disopyramide may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Mestranol and Mestranol may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Glimepiride may lead to a major life threatening interaction when taken with Fluconazole and Fluconazole may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone
Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Pegaspargase and Pegaspargase may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone |
DB01001 | DB09241 | 688 | 1,629 | [
"DDInter1632",
"DDInter1186"
] | Salbutamol | Methylene blue | Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, | Methylene blue is an oxidation-reduction agent. The intravenous form of methylene blue is approved by the FDA for the treatment of pediatric and adult patients with acquired methemoglobinemia. Historically, it has been widely used in Africa to treat malaria, but now it disappeared when chloroquine (CQ) and other drugs entered the market. Its use as an urinary tract antiseptic has also been investigated. Methylthioninium chloride (INN, or methylene blue, proposed trade name Rember) is an investigational drug being developed by the University of Aberdeen and TauRx Therapeutics that has been shown in early clinical trials to be an inhibitor of Tau protein aggregation. The drug is of potential interest for the treatment of patients with Alzheimer's disease. | Moderate | 1 | [
[
[
688,
24,
1629
]
],
[
[
688,
63,
1052
],
[
1052,
24,
1629
]
],
[
[
688,
24,
1148
],
[
1148,
24,
1629
]
],
[
[
688,
24,
1032
],
[
1032,
63,
1629
]
],
[
[
688,
63,
73
],
[
73,
25,
1629
]
],
[
[
688,
24,
93
],
[
93,
25,
1629
]
],
[
[
688,
24,
1293
],
[
1293,
64,
1629
]
],
[
[
688,
64,
290
],
[
290,
25,
1629
]
],
[
[
688,
24,
1090
],
[
1090,
37,
1629
]
],
[
[
688,
63,
1052
],
[
1052,
24,
1148
],
[
1148,
24,
1629
]
]
] | [
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Levosalbutamol"
],
[
"Levosalbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Phentermine"
],
[
"Phentermine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Valbenazine"
],
[
"Valbenazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tetryzoline"
],
[
"Tetryzoline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Methylene blue"
]
],
[
[
"Salbutamol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ritodrine"
],
[
"Ritodrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
],
[
"Isoprenaline",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylene blue"
]
]
] | Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Levosalbutamol and Levo
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Phentermine and Phentermine may lead to a major life threatening interaction when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Dextroamphetamine and Dextroamphetamine may lead to a major life threatening interaction when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Valbenazine and Valbenazine may lead to a major life threatening interaction when taken with Methylene blue
Salbutamol may lead to a major life threatening interaction when taken with Cocaine and Cocaine may lead to a major life threatening interaction when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Tetryzoline and Tetryzoline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue and Tetryzoline may lead to a major life threatening interaction when taken with Methylene blue
Salbutamol may cause a moderate interaction that could exacerbate diseases when taken with Ritodrine and Ritodrine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline and Isoprenaline may cause a moderate interaction that could exacerbate diseases when taken with Methylene blue |
DB00041 | DB00965 | 1,648 | 1,258 | [
"DDInter38",
"DDInter693"
] | Aldesleukin | Ethiodized oil | Aldesleukin, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) Aldesleukin is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125. | Ethiodized oil is used by injection as a radio-opaque contrast agent. The composition of the oil is comprised of iodine combined with ethyl esters of fatty acids of poppyseed oil. And although these esters are primarily as ethyl monoiodostearate and ethyl diiodostearate, the actual, specific structure is unknown. | Moderate | 1 | [
[
[
1648,
24,
1258
]
],
[
[
1648,
24,
1486
],
[
1486,
24,
116
],
[
116,
63,
1258
]
],
[
[
1648,
24,
278
],
[
278,
63,
116
],
[
116,
63,
1258
]
],
[
[
1648,
25,
497
],
[
497,
24,
116
],
[
116,
63,
1258
]
]
] | [
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethiodized oil"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethiodized oil"
]
],
[
[
"Aldesleukin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iopodic acid"
],
[
"Iopodic acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethiodized oil"
]
],
[
[
"Aldesleukin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iohexol"
],
[
"Iohexol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Iodide I-131"
],
[
"Iodide I-131",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ethiodized oil"
]
]
] | Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Methylprednisolone and Methylprednisolone may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Ethiodized oil
Aldesleukin may cause a moderate interaction that could exacerbate diseases when taken with Iopodic acid and Iopodic acid may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Ethiodized oil
Aldesleukin may lead to a major life threatening interaction when taken with Iohexol and Iohexol may cause a moderate interaction that could exacerbate diseases when taken with Iodide I-131 and Iodide I-131 may cause a moderate interaction that could exacerbate diseases when taken with Ethiodized oil |
DB00420 | DB01611 | 508 | 1,487 | [
"DDInter1532",
"DDInter893"
] | Promazine | Hydroxychloroquine | A phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. It is currently not approved for use in the United States. | Hydroxychloroquine is a racemic mixture consisting of an R and S enantiomer. Hydroxychloroquine is an aminoquinoline like [chloroquine]. It is a commonly prescribed medication in the treatment of uncomplicated malaria, rheumatoid arthritis, chronic discoid lupus erythematosus, and systemic lupus erythematosus. Hydroxychloroquine is also used for the prophylaxis of malaria in regions where chloroquine resistance is unlikely. It was developed during World War II as a derivative of [quinacrine] with less severe side effects. Chloroquine and hydroxychloroquine are both being investigated for the treatment of SARS-CoV-2. **The FDA emergency use authorization for hydroxychloroquine and [chloroquine] in the treatment of COVID-19 was revoked on 15 June 2020.** Hydroxychloroquine was granted FDA approval on 18 April 1955. A recent study reported a fatality in the group being treated with hydroxychloroquine for COVID-19. | Major | 2 | [
[
[
508,
25,
1487
]
],
[
[
508,
24,
1520
],
[
1520,
25,
1487
]
],
[
[
508,
63,
245
],
[
245,
24,
1487
]
],
[
[
508,
23,
1283
],
[
1283,
24,
1487
]
],
[
[
508,
24,
286
],
[
286,
63,
1487
]
],
[
[
508,
24,
473
],
[
473,
24,
1487
]
],
[
[
508,
1,
1335
],
[
1335,
24,
1487
]
],
[
[
508,
23,
460
],
[
460,
63,
1487
]
],
[
[
508,
40,
21
],
[
21,
25,
1487
]
],
[
[
508,
63,
1494
],
[
1494,
25,
1487
]
]
] | [
[
[
"Promazine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium oxide"
],
[
"Magnesium oxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Magnesium hydroxide"
],
[
"Magnesium hydroxide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Repaglinide"
],
[
"Repaglinide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Oxcarbazepine"
],
[
"Oxcarbazepine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Magnesium carbonate"
],
[
"Magnesium carbonate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Amitriptyline"
],
[
"Amitriptyline",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
],
[
[
"Promazine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Palonosetron"
],
[
"Palonosetron",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Hydroxychloroquine"
]
]
] | Promazine may cause a moderate interaction that could exacerbate diseases when taken with Primaquine and Primaquine may lead to a major life threatening interaction when taken with Hydroxychloroquine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine may cause a minor interaction that can limit clinical effects when taken with Magnesium oxide and Magnesium oxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Magnesium hydroxide and Magnesium hydroxide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Repaglinide and Repaglinide may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine (Compound) resembles Oxcarbazepine (Compound) and Oxcarbazepine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine may cause a minor interaction that can limit clinical effects when taken with Magnesium carbonate and Magnesium carbonate may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine
Promazine (Compound) resembles Amitriptyline (Compound) and Amitriptyline may lead to a major life threatening interaction when taken with Hydroxychloroquine
Promazine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron and Palonosetron may lead to a major life threatening interaction when taken with Hydroxychloroquine |
DB00184 | DB01156 | 763 | 593 | [
"DDInter1290",
"DDInter252"
] | Nicotine | Bupropion | Nicotine is highly toxic alkaloid. It is the prototypical agonist at nicotinic cholinergic receptors where it dramatically stimulates neurons and ultimately blocks synaptic transmission. Nicotine is also important medically because of its presence in tobacco smoke. | Bupropion (also known as the brand name product Wellbutrin®) is a norepinephrine/dopamine-reuptake inhibitor (NDRI) used most commonly for the management of Major Depressive Disorder (MDD), Seasonal Affective Disorder (SAD), and as an aid for smoking cessation. Bupropion exerts its pharmacological effects by weakly inhibiting the enzymes involved in the uptake of the neurotransmitters norepinephrine and dopamine from the synaptic cleft, therefore prolonging their duration of action within the neuronal synapse and the downstream effects of these neurotransmitters. More specifically, bupropion binds to the norepinephrine transporter (NET) and the dopamine transporter (DAT).[A6399,A178810] Bupropion was originally classified as an "atypical" antidepressant because it does not exert the same effects as the classical antidepressants such as Monoamine Oxidase Inhibitors (MAOIs), Tricyclic Antidepressants (TCAs), or Selective Serotonin Reuptake Inhibitors (SSRIs). While it has comparable effectiveness to typical first-line options for the treatment of depression such as SSRIs,[A178798,A178804] bupropion is a unique option for the treatment of MDD as it lacks any clinically relevant serotonergic effects, typical of other mood medications, or any effects on histamine or adrenaline receptors.[A6399,A178840] Lack of activity at these receptors results in a more tolerable side effect profile; bupropion is less likely to cause sexual side effects, sedation, or weight gain as compared to SSRIs or TCAs, for example.[A178804,A178807] When used as an aid to smoking cessation, bupropion is thought to confer its anti-craving and anti-withdrawal effects by inhibiting dopamine reuptake, which is thought to be involved in the reward pathways associated with nicotine, and through the antagonism of the nicotinic acetylcholinergic receptor.[A178825,A1966,A16508] A Cochrane Review of meta-analyses of available treatment modalities for smoking cessation found that abstinence rates approximately doubled when bupropion was used as compared to placebo, and was found to have similar rates of smoking cessation as [nicotine] replacement therapy (NRT). Bupropion is sometimes used as an add-on agent to first-line treatments of depression such as selective serotonin reuptake inhibitor (SSRI) medications when there is a treatment-failure or only partial response. Bupropion is also used off-label for the management of Attention/Deficit-Hyperactivity Disorder (ADHD) in adults with comorbid bipolar depression to avoid mood destabilization caused by typical stimulant medications used for the treatment of ADHD. When used in combination with [naltrexone] in the marketed product ContraveⓇ for chronic weight management, the two components are thought to have effects on areas of the brain involved in the regulation of food intake. This includes the hypothalamus, which is involved in appetite regulation, and the mesolimbic dopamine circuit, which is involved in reward pathways. Studies have shown that the combined activity of bupropion and [naltrexone] increase the firing rate of hypothalamic pro-opiomelanocortin (POMC) neurons and blockade of opioid receptor-mediated POMC auto-inhibition, which are associated with a reduction in food intake and increased energy expenditure.[L6562,A179038,A179050] The combination of naltrexone and bupropion was shown to result in a statistically significant weight loss, with a mean change in body weight of -6.3% compared to -1.3% for placebo. | Moderate | 1 | [
[
[
763,
24,
593
]
],
[
[
763,
6,
3486
],
[
3486,
45,
593
]
],
[
[
763,
18,
10375
],
[
10375,
57,
593
]
],
[
[
763,
21,
29220
],
[
29220,
60,
593
]
],
[
[
763,
23,
752
],
[
752,
23,
593
]
],
[
[
763,
24,
1033
],
[
1033,
63,
593
]
],
[
[
763,
6,
3486
],
[
3486,
45,
752
],
[
752,
23,
593
]
],
[
[
763,
6,
8374
],
[
8374,
45,
256
],
[
256,
62,
593
]
],
[
[
763,
6,
6365
],
[
6365,
48,
11585
],
[
11585,
44,
593
]
],
[
[
763,
6,
8717
],
[
8717,
45,
188
],
[
188,
24,
593
]
]
] | [
[
[
"Nicotine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) downregulates {v} (Gene)",
"RPS4Y1"
],
[
"RPS4Y1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain upper"
],
[
"Abdominal pain upper",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Alpelisib"
],
[
"Alpelisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Cimetidine"
],
[
"Cimetidine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Prasugrel"
],
[
"Prasugrel",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) binds {v} (Gene)",
"CYP2E1"
],
[
"CYP2E1",
"{u} (Gene) is associated with {v} (Disease)",
"obesity"
],
[
"obesity",
"{u} (Disease) is treated by {v} (Compound)",
"Bupropion"
]
],
[
[
"Nicotine",
"{u} (Compound) binds {v} (Gene)",
"CYP2A6"
],
[
"CYP2A6",
"{u} (Gene) is bound by {v} (Compound)",
"Nevirapine"
],
[
"Nevirapine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bupropion"
]
]
] | Nicotine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Bupropion (Compound)
Nicotine (Compound) downregulates RPS4Y1 (Gene) and RPS4Y1 (Gene) is downregulated by Bupropion (Compound)
Nicotine (Compound) causes Abdominal pain upper (Side Effect) and Abdominal pain upper (Side Effect) is caused by Bupropion (Compound)
Nicotine may cause a minor interaction that can limit clinical effects when taken with Cimetidine and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Nicotine may cause a moderate interaction that could exacerbate diseases when taken with Alpelisib and Alpelisib may cause a moderate interaction that could exacerbate diseases when taken with Bupropion
Nicotine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Bupropion
Nicotine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Prasugrel (Compound) and Prasugrel may cause a minor interaction that can limit clinical effects when taken with Bupropion
Nicotine (Compound) binds CYP2E1 (Gene) and CYP2E1 (Gene) is associated with obesity (Disease) and obesity (Disease) is treated by Bupropion (Compound)
Nicotine (Compound) binds CYP2A6 (Gene) and CYP2A6 (Gene) is bound by Nevirapine (Compound) and Nevirapine may cause a moderate interaction that could exacerbate diseases when taken with Bupropion |
DB00087 | DB13985 | 599 | 546 | [
"DDInter41",
"DDInter1108"
] | Alemtuzumab | Lutetium Lu 177 dotatate | Alemtuzumab is a humanized monoclonal antibody specific to lymphocyte antigens. It is a recombinant DNA-derived humanized monoclonal antibody (Campath-1H) that is directed against the 21-28 kD cell surface glycoprotein, CD52. The Campath-1H antibody is an IgG1 kappa with the human variable framework and constant regions, and complementarity-determining regions from a murine (rat) monoclonal antibody (Campath-1G). Alemtuzumab is produced in mammalian cell (Chinese hamster ovary) suspension culture in a medium containing neomycin. Alemtuzumab was approved by the FDA in 2001. It is marketed as LEMTRADA for multiple sclerosis (MS) treatment and CAMPTAH for B-cell chronic lymphocytic leukemia (B-CLL). The dose of alemtuzumab used for B-CLL is | A 177Lu-labeled somatostatin analog peptide, Lutetium Lu 177 dotatate belongs to an emerging form of treatments called Peptide Receptor Radionuclide Therapy (PRRT), which involves targeting tumours with molecules carrying radioactive particles that bind to specific receptors expressed by the tumour. Lutetium Lu 177 dotatate may also be referred to as 177Lu-DOTA-Tyr3-octreotate. Compared to the alternative somatostatin analogue DOTA-Tyr3-octreotide (dotatoc), Lutetium Lu 177 dotatate displays higher uptake of radioactivity in tumors and better residence times . In terms of biodistribution, Lutetium Lu 177 dotatate demonstrated a lower whole-body retention, indicating potentially lower risk for bone marrow toxicity . The presence of a radioligand allows monitoring of treatment response post therapy and prior to next fraction of the dose delivery which may be clinically beneficial in estimating the intensity of lesion uptakes or deciding the dose for subsequent administrations . Lutetium Lu 177 dotatate was approved by the FDA as Lutathera in January 2018 for intravenous injection. It is a first radiopharmaceutical agent to be approved for gastroenteropancreatic neuroendocrine tumors (GEP-NETs) and is indicated for adult patients with somatostatin receptor-positive GEP-NETs . Targeting pancreas and other parts of the gastrointestinal tract such as the intestines and colon, neuroendocrine tumors may commonly metastasize to metastasize to the mesentery, peritoneum, and liver . Patients with GEP-NETs have limited second-line treatment options after the metastasis of tumors and inadequate therapeutic response from first-line therapies. In a clinical trial involving patients with advanced somatostatin receptor-positive GEP-NET, the treatment of Lutetium Lu 177 dotatate in combination with octreotide resulted in longer progression-free survival compared to patients receiving octreotide alone and there was evidence of an overall survival benefit . | Moderate | 1 | [
[
[
599,
24,
546
]
],
[
[
599,
24,
66
],
[
66,
24,
546
]
],
[
[
599,
63,
1184
],
[
1184,
24,
546
]
],
[
[
599,
63,
1057
],
[
1057,
25,
546
]
],
[
[
599,
25,
1377
],
[
1377,
25,
546
]
],
[
[
599,
24,
629
],
[
629,
25,
546
]
],
[
[
599,
25,
676
],
[
676,
64,
546
]
],
[
[
599,
24,
66
],
[
66,
24,
1683
],
[
1683,
24,
546
]
],
[
[
599,
24,
1683
],
[
1683,
63,
66
],
[
66,
24,
546
]
],
[
[
599,
63,
1184
],
[
1184,
24,
66
],
[
66,
24,
546
]
]
] | [
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Etanercept"
],
[
"Etanercept",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Upadacitinib"
],
[
"Upadacitinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Ustekinumab"
],
[
"Ustekinumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
],
[
[
"Alemtuzumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Anakinra"
],
[
"Anakinra",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Efalizumab"
],
[
"Efalizumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Lutetium Lu 177 dotatate"
]
]
] | Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Etanercept and Etanercept may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Alemtuzumab may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Sirolimus and Sirolimus may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Alemtuzumab may lead to a major life threatening interaction when taken with Upadacitinib and Upadacitinib may lead to a major life threatening interaction when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Ustekinumab and Ustekinumab may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate
Alemtuzumab may cause a moderate interaction that could exacerbate diseases when taken with Anakinra and Anakinra may cause a moderate interaction that could exacerbate diseases when taken with Efalizumab and Efalizumab may cause a moderate interaction that could exacerbate diseases when taken with Lutetium Lu 177 dotatate |
DB00774 | DB01124 | 1,577 | 1,411 | [
"DDInter889",
"DDInter1828"
] | Hydroflumethiazide | Tolbutamide | A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822) | Tolbutamide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It is structurally similar to acetohexamide, chlorpropamide and tolazamide and belongs to the sulfonylurea class of insulin secretagogues, which act by stimulating β cells of the pancreas to release insulin. Sulfonylureas increase both basal insulin secretion and meal-stimulated insulin release. Medications in this class differ in their dose, rate of absorption, duration of action, route of elimination and binding site on their target pancreatic β cell receptor. Sulfonylureas also increase peripheral glucose utilization, decrease hepatic gluconeogenesis and may increase the number and sensitivity of insulin receptors. Sulfonylureas are associated with weight gain, though less so than insulin. Due to their mechanism of action, sulfonylureas may cause hypoglycemia and require consistent food intake to decrease this risk. The risk of hypoglycemia is increased in elderly, debilitated and malnourished individuals. Tolbutamide appears to be metabolized in the liver. Tolbutamide and its metabolites are excreted in urine (75-85%) and feces. | Moderate | 1 | [
[
[
1577,
24,
1411
]
],
[
[
1577,
24,
959
],
[
959,
40,
1411
]
],
[
[
1577,
63,
245
],
[
245,
40,
1411
]
],
[
[
1577,
7,
19948
],
[
19948,
46,
1411
]
],
[
[
1577,
18,
2423
],
[
2423,
57,
1411
]
],
[
[
1577,
21,
28828
],
[
28828,
60,
1411
]
],
[
[
1577,
63,
660
],
[
660,
23,
1411
]
],
[
[
1577,
24,
1296
],
[
1296,
63,
1411
]
],
[
[
1577,
62,
126
],
[
126,
24,
1411
]
],
[
[
1577,
63,
1274
],
[
1274,
24,
1411
]
]
] | [
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glipizide"
],
[
"Glipizide",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} (Compound) resembles {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) upregulates {v} (Gene)",
"CNPY3"
],
[
"CNPY3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) downregulates {v} (Gene)",
"PSMD2"
],
[
"PSMD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Photosensitivity reaction"
],
[
"Photosensitivity reaction",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Insulin degludec"
],
[
"Insulin degludec",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
],
[
[
"Hydroflumethiazide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tolbutamide"
]
]
] | Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Glipizide and Glipizide (Compound) resembles Tolbutamide (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Glimepiride and Glimepiride (Compound) resembles Tolbutamide (Compound)
Hydroflumethiazide (Compound) upregulates CNPY3 (Gene) and CNPY3 (Gene) is upregulated by Tolbutamide (Compound)
Hydroflumethiazide (Compound) downregulates PSMD2 (Gene) and PSMD2 (Gene) is downregulated by Tolbutamide (Compound)
Hydroflumethiazide (Compound) causes Photosensitivity reaction (Side Effect) and Photosensitivity reaction (Side Effect) is caused by Tolbutamide (Compound)
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Esomeprazole and Esomeprazole may cause a minor interaction that can limit clinical effects when taken with Tolbutamide
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Insulin degludec and Insulin degludec may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Hydroflumethiazide may cause a minor interaction that can limit clinical effects when taken with Warfarin and Warfarin may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide
Hydroflumethiazide may cause a moderate interaction that could exacerbate diseases when taken with Flurbiprofen and Flurbiprofen may cause a moderate interaction that could exacerbate diseases when taken with Tolbutamide |
DB05578 | DB06603 | 330 | 39 | [
"DDInter1566",
"DDInter1387"
] | Ramucirumab | Panobinostat | Ramucirumab is a human monoclonal antibody (IgG1) against vascular endothelial growth factor receptor 2 (VEGFR2), a type II trans-membrane tyrosine kinase receptor expressed on endothelial cells. By binding to VEGFR2, ramucirumab prevents binding of its ligands (VEGF-A, VEGF-C, and VEGF-D), thereby preventing VEGF-stimulated receptor phosphorylation and downstream ligand-induced proliferation, permeability, and migration of human endothelial cells. VEGFR stimulation also mediates downstream signalling required for angiogenesis and is postulated to be heavily involved in cancer progression, making it a highly likely drug target. In contrast to other agents directed against VEGFR-2, ramucirumab binds a specific epitope on the extracellular domain of VEGFR-2, thereby blocking all VEGF ligands from binding to it. Ramucir | Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market. | Major | 2 | [
[
[
330,
25,
39
]
],
[
[
330,
24,
282
],
[
282,
63,
39
]
],
[
[
330,
25,
578
],
[
578,
63,
39
]
],
[
[
330,
63,
383
],
[
383,
24,
39
]
],
[
[
330,
64,
4
],
[
4,
24,
39
]
],
[
[
330,
25,
503
],
[
503,
64,
39
]
],
[
[
330,
63,
1237
],
[
1237,
25,
39
]
],
[
[
330,
64,
914
],
[
914,
25,
39
]
],
[
[
330,
25,
1046
],
[
1046,
25,
39
]
],
[
[
330,
24,
1427
],
[
1427,
64,
39
]
]
] | [
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Nepafenac"
],
[
"Nepafenac",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ticagrelor"
],
[
"Ticagrelor",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pentosan polysulfate"
],
[
"Pentosan polysulfate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Zanubrutinib"
],
[
"Zanubrutinib",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Diflunisal"
],
[
"Diflunisal",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Caplacizumab"
],
[
"Caplacizumab",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
],
[
[
"Ramucirumab",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Vortioxetine"
],
[
"Vortioxetine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Panobinostat"
]
]
] | Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Nepafenac and Nepafenac may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ramucirumab may lead to a major life threatening interaction when taken with Ticagrelor and Ticagrelor may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Pentosan polysulfate and Pentosan polysulfate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ramucirumab may lead to a major life threatening interaction when taken with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may cause a moderate interaction that could exacerbate diseases when taken with Panobinostat
Ramucirumab may lead to a major life threatening interaction when taken with Zanubrutinib and Zanubrutinib may lead to a major life threatening interaction when taken with Panobinostat
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Clomipramine and Clomipramine may lead to a major life threatening interaction when taken with Panobinostat
Ramucirumab may lead to a major life threatening interaction when taken with Diflunisal and Diflunisal may lead to a major life threatening interaction when taken with Panobinostat
Ramucirumab may lead to a major life threatening interaction when taken with Caplacizumab and Caplacizumab may lead to a major life threatening interaction when taken with Panobinostat
Ramucirumab may cause a moderate interaction that could exacerbate diseases when taken with Vortioxetine and Vortioxetine may lead to a major life threatening interaction when taken with Panobinostat |
DB00741 | DB01400 | 167 | 1,372 | [
"DDInter885",
"DDInter1279"
] | Hydrocortisone | Neostigmine | Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952. | A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike physostigmine, does not cross the blood-brain barrier. | Moderate | 1 | [
[
[
167,
24,
1372
]
],
[
[
167,
63,
751
],
[
751,
40,
1372
]
],
[
[
167,
24,
61
],
[
61,
24,
1372
]
],
[
[
167,
6,
4973
],
[
4973,
45,
1372
]
],
[
[
167,
21,
29549
],
[
29549,
60,
1372
]
],
[
[
167,
1,
1220
],
[
1220,
24,
1372
]
],
[
[
167,
24,
1662
],
[
1662,
63,
1372
]
],
[
[
167,
25,
1011
],
[
1011,
63,
1372
]
],
[
[
167,
25,
770
],
[
770,
24,
1372
]
],
[
[
167,
40,
870
],
[
870,
24,
1372
]
]
] | [
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Pyridostigmine"
],
[
"Pyridostigmine",
"{u} (Compound) resembles {v} (Compound)",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Edrophonium"
],
[
"Edrophonium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Osteoarthritis"
],
[
"Osteoarthritis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Dexamethasone"
],
[
"Dexamethasone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Picosulfuric acid"
],
[
"Picosulfuric acid",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Neostigmine"
]
]
] | Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Pyridostigmine and Pyridostigmine (Compound) resembles Neostigmine (Compound)
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Edrophonium and Edrophonium may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Hydrocortisone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Neostigmine (Compound)
Hydrocortisone (Compound) causes Osteoarthritis (Side Effect) and Osteoarthritis (Side Effect) is caused by Neostigmine (Compound)
Hydrocortisone (Compound) resembles Dexamethasone (Compound) and Dexamethasone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Hydrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Picosulfuric acid and Picosulfuric acid may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Hydrocortisone may lead to a major life threatening interaction when taken with Fingolimod and Fingolimod may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Hydrocortisone may lead to a major life threatening interaction when taken with Thalidomide and Thalidomide may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine
Hydrocortisone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may cause a moderate interaction that could exacerbate diseases when taken with Neostigmine |
DB01362 | DB06204 | 497 | 768 | [
"DDInter960",
"DDInter1746"
] | Iohexol | Tapentadol | Iohexol is an effective non-ionic, water-soluble contrast agent which is used in myelography, arthrography, nephroangiography, arteriography, and other radiographic procedures. Its low systemic toxicity is the combined result of low chemotoxicity and low osmolality. | Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake.[A260721, A36596] Tapentadol was first approved by the FDA on November 20, 2008. The extended-release formulation of tapentadol was also approved by the FDA on August 26, 2011. Used in the management of pain, tapentadol is typically reserved for patients who have limited alternative treatment options. | Major | 2 | [
[
[
497,
25,
768
]
],
[
[
497,
21,
28692
],
[
28692,
60,
768
]
],
[
[
497,
64,
1532
],
[
1532,
24,
768
]
],
[
[
497,
25,
22
],
[
22,
24,
768
]
],
[
[
497,
25,
407
],
[
407,
63,
768
]
],
[
[
497,
64,
222
],
[
222,
25,
768
]
],
[
[
497,
25,
247
],
[
247,
76,
768
]
],
[
[
497,
21,
28692
],
[
28692,
60,
189
],
[
189,
40,
768
]
],
[
[
497,
21,
29081
],
[
29081,
60,
1347
],
[
1347,
24,
768
]
],
[
[
497,
64,
1532
],
[
1532,
6,
10215
],
[
10215,
45,
768
]
]
] | [
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ephedrine"
],
[
"Ephedrine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Opium"
],
[
"Opium",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Iobenguane"
],
[
"Iobenguane",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v} and {u} may lead to a major life threatening interaction when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rivastigmine"
],
[
"Rivastigmine",
"{u} (Compound) resembles {v} (Compound)",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} (Compound) causes {v} (Side Effect)",
"Angioedema"
],
[
"Angioedema",
"{u} (Side Effect) is caused by {v} (Compound)",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tapentadol"
]
],
[
[
"Iohexol",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Tapentadol"
]
]
] | Iohexol (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Tapentadol (Compound)
Iohexol may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Iohexol may lead to a major life threatening interaction when taken with Ephedrine and Ephedrine may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Iohexol may lead to a major life threatening interaction when taken with Opium and Opium may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Iohexol may lead to a major life threatening interaction when taken with Sibutramine and Sibutramine may lead to a major life threatening interaction when taken with Tapentadol
Iohexol may lead to a major life threatening interaction when taken with Iobenguane and Iobenguane may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol and Iobenguane may lead to a major life threatening interaction when taken with Tapentadol
Iohexol (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Rivastigmine (Compound) and Rivastigmine (Compound) resembles Tapentadol (Compound)
Iohexol (Compound) causes Angioedema (Side Effect) and Angioedema (Side Effect) is caused by Clopidogrel (Compound) and Clopidogrel may cause a moderate interaction that could exacerbate diseases when taken with Tapentadol
Iohexol may lead to a major life threatening interaction when taken with Ifosfamide and Ifosfamide (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Tapentadol (Compound) |
DB00705 | DB05773 | 441 | 1,047 | [
"DDInter496",
"DDInter1848"
] | Delavirdine | Trastuzumab emtansine | A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1. | Trastuzumab emtansine, formerly called Trastuzumab-DM1 (T-DM1) is a first-in-class HER2 antibody drug conjugate (ADC) comprised of Genentech's trastuzumab antibody linked to ImmunoGen's cell-killing agent, DM1. T-DM1 combines two strategies-- anti-HER2 activity and targeted intracellular delivery of the potent anti-microtubule agent, DM1 (a maytansine derivative)--to produce cell cycle arrest and apoptosis. Trastuzumab emtansine is marketed under the brand name Kadcyla and is indicated for use in HER2-positive, metastatic breast cancer patients who have already used taxane and/or trastuzumab for metastatic disease or had their cancer recur within 6 months of adjuvant treatment. The FDA label has two precautions. First that trastuzumab emtansine and trastuzumab cannot be interchanged. Second that there is a black box warning of serious side effects such as hepatotoxicity, embryo-fetal toxicity, and cardiac toxicity. | Moderate | 1 | [
[
[
441,
24,
1047
]
],
[
[
441,
24,
310
],
[
310,
63,
1047
]
],
[
[
441,
64,
467
],
[
467,
24,
1047
]
],
[
[
441,
25,
1593
],
[
1593,
63,
1047
]
],
[
[
441,
63,
168
],
[
168,
24,
1047
]
],
[
[
441,
62,
63
],
[
63,
24,
1047
]
],
[
[
441,
23,
222
],
[
222,
24,
1047
]
],
[
[
441,
24,
1487
],
[
1487,
24,
1047
]
],
[
[
441,
25,
973
],
[
973,
24,
1047
]
],
[
[
441,
24,
1409
],
[
1409,
64,
1047
]
]
] | [
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Teniposide"
],
[
"Teniposide",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a minor interaction that can limit clinical effects when taken with {v}",
"Sibutramine"
],
[
"Sibutramine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Hydroxychloroquine"
],
[
"Hydroxychloroquine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Trastuzumab emtansine"
]
],
[
[
"Delavirdine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Apixaban"
],
[
"Apixaban",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Trastuzumab emtansine"
]
]
] | Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Cabazitaxel and Cabazitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may lead to a major life threatening interaction when taken with Simvastatin and Simvastatin may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may lead to a major life threatening interaction when taken with Crizotinib and Crizotinib may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Bortezomib and Bortezomib may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Teniposide and Teniposide may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may cause a minor interaction that can limit clinical effects when taken with Sibutramine and Sibutramine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Hydroxychloroquine and Hydroxychloroquine may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may lead to a major life threatening interaction when taken with Paclitaxel and Paclitaxel may cause a moderate interaction that could exacerbate diseases when taken with Trastuzumab emtansine
Delavirdine may cause a moderate interaction that could exacerbate diseases when taken with Apixaban and Apixaban may lead to a major life threatening interaction when taken with Trastuzumab emtansine |
DB00791 | DB15066 | 132 | 445 | [
"DDInter1902",
"DDInter821"
] | Uracil mustard | Givosiran | Nitrogen mustard derivative of uracil. It is a alkylating antineoplastic agent that is used in lymphatic malignancies, and causes mainly gastrointestinal and bone marrow damage. | Givosiran is a small interfering RNA (siRNA) directed towards 5-aminolevulinic acid synthase, a critical enzyme in the heme biosynthesis pathway. It is manufactured by Alnylam Pharmaceuticals and was first approved for use in the United States in November 2019 for the treatment of adults with acute hepatic porphyria, a genetic disorder in which the overproduction of toxic heme intermediates leads to neuro-, nephro-, and gastrotoxicity. Givosiran represents an important step forward in the treatment of acute hepatic porphyria as it is the first approved pharmacotherapy for the prevention of acute attacks - previous strategies involved non-therapeutic measures (e.g. trigger avoidance), intravenous [hemin] for the treatment of attacks, and liver transplantation in refractory cases. Givosiran is the second-ever FDA-approved member of the siRNA drug class (the first being [patisiran]), a new class of drugs promising an important and exciting step forward in the treatment of genetic disorders. | Moderate | 1 | [
[
[
132,
24,
445
]
],
[
[
132,
63,
1287
],
[
1287,
24,
445
]
],
[
[
132,
24,
384
],
[
384,
24,
445
]
],
[
[
132,
25,
1377
],
[
1377,
25,
445
]
],
[
[
132,
63,
1287
],
[
1287,
63,
1555
],
[
1555,
24,
445
]
],
[
[
132,
24,
384
],
[
384,
63,
1555
],
[
1555,
24,
445
]
],
[
[
132,
25,
1377
],
[
1377,
64,
1555
],
[
1555,
24,
445
]
],
[
[
132,
63,
1287
],
[
1287,
24,
1272
],
[
1272,
24,
445
]
],
[
[
132,
25,
1377
],
[
1377,
25,
850
],
[
850,
24,
445
]
],
[
[
132,
1,
970
],
[
970,
63,
482
],
[
482,
24,
445
]
]
] | [
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Oxaliplatin"
],
[
"Oxaliplatin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Flucytosine"
],
[
"Flucytosine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Brentuximab vedotin"
],
[
"Brentuximab vedotin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
],
[
[
"Uracil mustard",
"{u} (Compound) resembles {v} (Compound)",
"Fluorouracil"
],
[
"Fluorouracil",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tioguanine"
],
[
"Tioguanine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Givosiran"
]
]
] | Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Givosiran
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Idelalisib and Idelalisib may cause a moderate interaction that could exacerbate diseases when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Oxaliplatin and Oxaliplatin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may cause a moderate interaction that could exacerbate diseases when taken with Amphotericin B and Amphotericin B may cause a moderate interaction that could exacerbate diseases when taken with Flucytosine and Flucytosine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide may lead to a major life threatening interaction when taken with Brentuximab vedotin and Brentuximab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Givosiran
Uracil mustard (Compound) resembles Fluorouracil (Compound) and Fluorouracil may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine may cause a moderate interaction that could exacerbate diseases when taken with Givosiran |
DB00694 | DB01064 | 51 | 1,148 | [
"DDInter485",
"DDInter987"
] | Daunorubicin | Isoprenaline | A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of leukemia and other neoplasms. | Isoprenaline is a non-selective beta adrenergic receptor agonist indicated to treat heart block, Adams-Stokes attacks, bronchospasm in anesthesia, cadiac arrest, hypovolemic shocks, septic shock, hypoperfusion, congestive hear failure, and cardiogenic shock.[A15638,L33160] Isoprenaline research in the 1940s found that this isopropyl analog of epinephrine dilated the bronchi, as well as raising the heart rate and cardiac output, without vasoconstriction.[A233724,A233729] The US patent from 1943 states that this compound had a wider therapeutic index and a stronger action than [adrenaline]. Isoprenaline was granted FDA approval on 19 February 1948. | Moderate | 1 | [
[
[
51,
24,
1148
]
],
[
[
51,
24,
480
],
[
480,
24,
1148
]
],
[
[
51,
6,
9842
],
[
9842,
45,
1148
]
],
[
[
51,
18,
5178
],
[
5178,
46,
1148
]
],
[
[
51,
18,
6461
],
[
6461,
57,
1148
]
],
[
[
51,
21,
28717
],
[
28717,
60,
1148
]
],
[
[
51,
63,
534
],
[
534,
24,
1148
]
],
[
[
51,
24,
1151
],
[
1151,
63,
1148
]
],
[
[
51,
25,
880
],
[
880,
63,
1148
]
],
[
[
51,
35,
77
],
[
77,
63,
1148
]
]
] | [
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Formoterol"
],
[
"Formoterol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} (Compound) binds {v} (Gene)",
"CYP1A1"
],
[
"CYP1A1",
"{u} (Gene) is bound by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"XBP1"
],
[
"XBP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} (Compound) downregulates {v} (Gene)",
"DDX10"
],
[
"DDX10",
"{u} (Gene) is downregulated by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} (Compound) causes {v} (Side Effect)",
"Flushing"
],
[
"Flushing",
"{u} (Side Effect) is caused by {v} (Compound)",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Tramadol"
],
[
"Tramadol",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} may lead to a major life threatening interaction when taken with {v}",
"Ivabradine"
],
[
"Ivabradine",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
],
[
[
"Daunorubicin",
"{u} (Compound) resembles {v} (Compound) and {u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Idarubicin"
],
[
"Idarubicin",
"{u} may cause a moderate interaction that could exacerbate diseases when taken with {v}",
"Isoprenaline"
]
]
] | Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Formoterol and Formoterol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Daunorubicin (Compound) binds CYP1A1 (Gene) and CYP1A1 (Gene) is bound by Isoprenaline (Compound)
Daunorubicin (Compound) downregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Isoprenaline (Compound)
Daunorubicin (Compound) downregulates DDX10 (Gene) and DDX10 (Gene) is downregulated by Isoprenaline (Compound)
Daunorubicin (Compound) causes Flushing (Side Effect) and Flushing (Side Effect) is caused by Isoprenaline (Compound)
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Tramadol and Tramadol may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Sunitinib and Sunitinib may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Daunorubicin may lead to a major life threatening interaction when taken with Ivabradine and Ivabradine may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline
Daunorubicin (Compound) resembles Idarubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Idarubicin and Idarubicin may cause a moderate interaction that could exacerbate diseases when taken with Isoprenaline |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.